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ABSTRACT 
Von Willebrand factor (VWF) is a large multimeric plasma glycoprotein essential to 
normal haemostasis. A major determinant of plasma VWF levels is ABO blood group 
with levels in group 0 individuals 25-30% less than non-group 0 individuals. Previous 
reports have suggested that ABO(H) blood group sugars, presented on the N-linked 
glycan chains of VWF, modulate susceptibility to proteolysis by ADAMTS13. To 
extend this hypothesis, plasma samples were collected from individuals with the rare 
Bombay blood group that do not present H-antigen structures. Absence of H-antigen 
from Bombay VWF was demonstrated by H on VWF ELISA and western blot analysis. 
VWF: Ag measurement demonstrated that VWF: Ag levels in Bombay individuals were 
significantly lower (median = 0.69 IU/ml) than in control groups A, B and AB. 
(p<0.05). Susceptibility of purified HMW-VWF fractions to cleavage by plasma 
derived and recombinant ADAMTS13 was assessed using VWF: CB and VWF 
multimer gels and demonstrated that Bombay VWF was cleaved significantly faster 
than 0 or AB VWF. Increasing urea concentration (0.5 to 2M) increased the cleavage 
rate for each blood group, but eliminated the differences between groups, implying that 
reduction in the number of terminal sugars on VWF N-linked glycans increases 
susceptibility of globular VWF to ADAMTS13 proteolysis. Interestingly two N-linked 
glycan sites are present within the A2 domain (NI515 and N1574) close to the 
ADAMTS13 cleavage site (Y1605MI606). A -55kDa tryptic fragment of VWF was 
isolated by ion-exchange chromatography. N-terminal and mass spectroscopy analysis 
demonstrated that the fragment comprised VWF residues 1493-1877, incorporating the 
ADAMTS13 cleavage site and sites N1515 and N1574. PNGase F digestion showed 
that both predicted N-linked sites were occupied and western blotting with anti-H lectin 
demonstrated that both are likely to present complex sugar structures capped with blood 
group sugars. Sequence analysis of the VWF A2 domain from 59 species showed that 
both sites are highly conserved, indicating their importance. The techniques developed 
to analyse ABO and Bombay VWF were then applied to artificially modified VWF. 
Neuraminidase and PNGase F digestion of purified VWF was performed to produce 
glycan modified VWF. Removal of VWF sialic acid did not affect multimeric structure 
or collagen binding but decreased susceptibility to ADAMTS13 proteolysis. Digestion 
with PNGase F (PNG-VWF) resulted in the removal of >90% VWF N-linked glycans, 
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and increased susceptibility to ADAMTS13 proteolysis and also allowed proteolysis in 
the absence of urea. PNG-VWF also bound ADAMTS 13 with -4-fold increased affinity 
and was able to bind ADAMTS13 when in a globular conformation. To examine the 
effect of specific glycan chains, the two A2 domain glycans, N1515 and N1574 were 
mutated to glutamic acid residues and expressed in HEK293T cells. Mutation of the 
sites did not affect secretion of the molecule or formation of Weibel-Palade bodies and 
the multimeric structure and affinity for collagen was not altered. N1515Q was 
proteolysed by ADAMTS13 at a similar rate to wtVWF, but N1574Q was cleaved 
significantly faster and was also cleaved in the absence of urea. Furthermore, N1574Q 
bound ADAMTS13 with -2-fold increased affinity compared to wild type VWF. 
Together these results demonstrate that the glycan moiety of VWF plays an important 
role in modulating the interaction of VWF with ADAMTS13. Specifically, 
glycosylation at N1574Q protects the molecule from ADAMTS13 proteolysis. The 
effect of glycan modification and mutation on susceptibility to ADAMTS13 cleavage 
and ADAMTS13 binding can be used to construct a model in which glycans limit 
ADAMTS13 cleavage of VWF by a combination of steric effects and local and long 
range conformational effects. 
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CHAPTER1 
1. INTRODUCTION 
1.1 VON WILLEBRAND FACTOR 
Von Willebrand Factor (VWF) is a large multimeric plasma glycoprotein essential to 
normal haemostasis. Firstly; VWF acts as the carrier molecule for pro-coagulant Factor 
VIII (FVIII), extending its half life within the circulation by protecting it from 
proteolytic degradation by proteases such as activated protein C. ' Secondly, VWF 
supports platelet adhesion to thrombogenic surfaces at sites of vascular injury. 2 
1.2.1 VWF Tissue Distribution and Sites of Synthesises 
VWF is found in plasma, endothelial cells (EC), megakaryocytes and the subendothelial 
matrix. In-vivo biosynthesis of VWF is limited to EC and megakaryocytes. 3 In EC, 
VWF is either constitutively secreted or stored in Weibel-Palade bodies and 
megakaryocyte VWF is stored in the a-granules of its platelet progeny. 4 The majority of 
circulating VWF is derived from the endothelium. In a porcine model with hereditary 
VWF deficiency, total body irradiation and subsequent transplantation of normal bone 
marrow restores a normal platelet count, but does not re-establish the plasma VWF 
pool. 5 Evidence also suggests that expression of VWF may vary between vascular beds. 
Immunohistochemistry performed on porcine blood vessels showed that VWF was 
consistently present in venous EC, with the exception of the pulmonary vein, but was 
absent from the majority of arterial EC, except the distal abdominal aorta, the vasa 
vasorum of the thoracic aorta and the pulmonary artey. 6 Analysis of VWF expression in 
mice using quantitative RT-PCR and in-situ hybridisation analysis, demonstrated that 
VWF mRNA levels were highest in EC derived from the spleen, aorta, lung and spleen, 
with the lowest levels in the liver, gut and kidney. It was also again demonstrated that 
VWF expression was higher in venous EC than arterial EC. 7 
1.2.2 VWF Gene Structure 
The VWF gene is located distally on the short arm of chromosome 12 (12pl3.2) and 
spans -180kb of genomic DNA. After transcription the mRNA product is spliced to 52 
8 
exons. Exon I represents a 5' untranslated sequence, 9 exons 2-18 encode a signal and 
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propeptide sequence and exons 19-52 encode for the mature VWF subunit. 8 A non- 
processed VWF pseudogene is located on chromosome 22 (22ql 1) which is -29kb in 
length, spanning exons 23-34 of the functional VWF gene and has 97% sequence 
homology. 10,11 The VWF pseudogene contains multiple stop codons, indicating that it is 
not a functional human gene. 10 
1.2.3 Transcriptional Regulation of the VWF Gene 
Regulation of VWF gene expression has been investigated using the promoter sequence 
linked to a reporter gene. 12 The promoter sequence comprised of base pairs -487 to 
+247 (numbered relative to the transcription start site) was sufficient to mediate 
endothelial specific expression. of the reporter gene. Deletion analysis demonstrated that 
a 112bp fragment: -90 to +22, contained core promoter activity. 
12,13 As well as the 
transcription start site, this region also contains a TATA box at position 30 and a 
CCAAT box located 8bp downstream of the TATA box. Deletion analysis also 
demonstrated a strong silencer sequence upstream of the core promoter at base pairs - 
487 to -312 that is activated by an NF-I protein that was shown by DNase footprint 
analysis to interact with nucleotides -440 to -470.14 
The effect of the silencer sequence is counteracted by transcription factors of the GATA 
family, that bind to a positive regulatory sequence in exon one, at base pairs +150 to 
+247. This positive regulatory element is therefore responsible for overcoming the 
effect of the silencer region and also confers EC specificity on the core promoter. 12 
DNA sequence analysis of the positive regulatory sequence predicted a GATA binding 
site at +222 and also an SPI binding site at +180. Mutation of the SPI site had no effect 
on transcriptional activity, but mutation of the GATA site resulted in significant 
reduction of reporter gene expression, demonstrating the positive regulatory sequence 
with an intact GATA binding site is required to active VWF gene expression in EC. 12 
Finally another negatively regulatory element has been located in the region -89 to 
+244, that is able to bind the Oct-] transcriptional repressor. 13 
1.3 VWF SYNTHESIS AND PROCESSING 
Following translation of the VWF mRNA, pre-pro-VWF is synthesised, comprised of a 
21 amino acid N-terminal signal peptide, a 741 amino acid pro-peptide and a 2050 
amino acid mature protein. Pre-pro-VWF undergoes extensive post-translational 
modifications as it passes through the endoplasmic reticulum (ER) to either be stored or 
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secreted. 15 VWF is also unique in that it undergoes two distinct polymerisation steps in 
separate organelles; dimers of VWF are formed in the ER and multimerisation occurs in 
the Golgi or post-Golgi network. 
1.3.1 N-finked Glycosylation 
The signal peptide of the primary VWF translation product directs the protein to the 
rough endoplasmic reticulurn (RER) where the signal peptide is cleaved and initial N- 
linked glycosylation occurs, resulting in the addition of high-mannose sugar structures 
to a predicted 16 asparagine residues; twelve in the mature subunit and four in the pro- 
peptide. 16 N-linked glycosylation is essential for dimerisation of VWF, since treatment 
of endothelial. cells with Tunicamycin, an antibiotic that prevents N-linked 
glycosylation17, results in the accumulation of pro-VWF monomers in the ER. 18 The N- 
linked glycans of VWF are discussed in further detail in section 1.15.2. 
1.3.2 Dimerisation 
Dimerisation of VWF monomers also occurs in the ER through the formation of 
intersubunit disulphide bonds between cysteine residues located in the C-terminal 
region of each mature VWF monomer. 19,20 Studies have demonstrated that monomeric 
VWF is retained in the ER by binding to ER regulatory proteins, such as BiP, and is 
subsequently degraded. 18,21 
1.3.3 N-linked Glycan Processing 
Following dimerisation, VWF is transported to the Golgi apparatus for modification of 
the N-linked glycan chains. Mannose residues are trimmed and there is addition of 
galactose and terminal sialic acid residues, producing complex glycan structures. 22 
Interestingly, further carbohydrate processing of VWF may occur in the trans-Golgi 
network (TGN) where the A, B and H blood group glycosyltransferases are present. It 
has been demonstrated that the N-linked glycans of VWF present the ABO(H) blood 
group antigens. 23 
1.3.4 0-linked Glycosylation 
There is further addition of carbohydrate structures in the Golgi with the attachment of a 
predicted ten 0-linked glycan chains to serine and threonine residues. 16 At present there 
24 
is no experimental evidence to suggest that the O-linked glycans, present the ABO(H) 
blood group sugars. 
1.3.5 Sulphation 
Sulphation of VWF takes place in the TGN. A study by Carew demonstrated that one of 
the N-terminal N-linked glycans is sulphated as are N-linked glycans present in the 
propeptide. 24 Furthermore, inhibition of sulphation does not affect VWF 
multimerisation, storage or stability. 24 
1.3.6 Multimerisation 
Multimerisation of pro-VWF dimers occurs in the TGN by the formation of 
intermolecular disulphide bonds between cysteine residues located at the N-terminal 
ends of adjacent molecules. 20,25 Multimerisation of VWF is dependent on the presence 
of calcium and an acidic pH (-6.0), conditions typical of the TGN. Treatment of 
HUVEC's with ammonium chloride causes increased pH within acidic organelles and 
results in the secretion of un-multimerised VWF dimers and treatment with chelating 
agents such as EDTA also inhibit multimerisation. 18,26 Furthermore the presence of the 
propeptide is essential for multimerisation. 21 Recombinant expression of VWF with the 
propeptide sequence deleted results in the secretion of VWF dimers. 27 Co-transfection 
of cells with sequences encoding for the VWF propeptide, and VWF with the 
propeptide sequence deleted, result in the secretion of fully multimerised VWF, 
demonstrating that the propeptide does not need to be a continuous part of the VWF 
structure. 21 The propeptide contains vicinal cysteine motifs similar to motifs found at 
the active site of protein disulphide isomerise (PDls), suggesting that the propeptide 
may have intermolecular PDI-like enzyme activity involved in the formation of 
disulphide bonds required for multimerisation. 28 
25 
1.3.7 Propeptide Cleavage 
Cleavage of the propeptide takes place in the TGN and is mediated by the enzyme 
furin, 29 with cleavage occurring at the C-terminal end of the RSKR sequence. Pro-VWF 
is cleaved in-vitro when it is co-transfected with furin, but not with other 
endoproteases. 30 After furin cleavage, the propeptide remains non-covalently associated 
with VWF. 29 The propeptide remains associated to VWF until it is secreted with mature 
VWF in equimolar amounts, but is found in the circulation at an -10 fold lower 
concentration due to its shorter hal f-lif . 
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Figure 1.1 Dimerisation and multimerisation of VWF 
Within the ER, VWF dimers are formed by intersubunit disulphide bonds between 
cysteine residues located in the C-ten-ninal region of each mature VWF monomer. 
Multimerisation of pro-VWF dimers occurs in the post-Golgi by the formation of 
intermolecular disulphide bonds between cysteine residues located at the N-terminal 
ends of adjacent molecules. Following multi meri sation, the propeptide is cleaved by 
furin, and remains non-covalently associated with VWF. 
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1.4 VWF STORAGE AND SECRETION 
The mature VWF product maybe either constitutively secreted or stored in Weibel- 
Palade bodies in EC. Megakaryocyte VWF is stored in the a-granules of the platelet 
progeny and is released upon platelet activation. 34 The majority of VWF synthesised by 
EC is constitutively secreted (-95%) and is comprised of low to medium molecular 
weight VWF multimers. 35 The remaining VWF stored in Weibel-Palade (WP) bodies is 
comprised of the highest molecular weight and most biologically active multimers. 
36 
VWF circulates in plasma at a concentration of -10gg/ml with a half-life of -12 
hours. 31,37 
1.4.1 Weibel-Palade Bodies 
WP bodies are EC specific, rod shaped, membrane bound organelles, which, 
demonstrated by electron microscopy, are electron dense rod like structures 0.1 to 
0.2ptni in diameter and up to 4gm in length which store VW in longitudinally arranged 
tubular structures 150A in diameter. 38,39 Electron microscopy studies have demonstrated 
that the WP bodies most likely originate from the TGN. 40,41 As well as VWF, a number 
of other proteins have been shown to co-localise with VWF in WP bodies: Factor VIII, 
P-Selectin, Endothelin, CD36/lamp3, Interlukin-8, al, 3-Fucosyltransferase VI, Tissue- 
type plasminogen activator and angiopoietin-2.42-52 The exact mechanism governing the 
targeting of VWF to WP bodies is relatively unknown, however evidence suggests that 
it is VWF itself which is the major factor involved in WP body formation. EC of mice 
and pigs deficient in VWF are devoid of WP bodies, 53,54 furthermore, in vitro 
transfection of VWF cDNA into cell lines that do not normally express VWF, results in 
the formation of VWF containing storage granules that share morphology very similar 
to WP bodieS. 41,55-57 The exact structural aspects of VWF that lead to the genesis of WP 
bodies are unknown. One hypothesis suggests that multimerisation of VWF in the TGN 
is a prerequisite for WP body formation, since only cells that can synthesise multimeric 
VWF form WP-like storage granules. In addition, cells transfected with VWF cDNA 
containing mutations that result in defective multimerisation are devoid of WP-like 
structures. 41,55'58 However, contrary to this a number of studies have shown that 
multimerisation is not required for VvT formation and VWF storage. 28,57 v)&T 
expressed with the C domains deleted so that dimerisation could not occur, still formed 
storage granules. 57 Also, in a recent study, three mutations, Cysl225Gly, Cys788Arg 
and Arg273Trp, that cause multimerisation defects, were all shown to form WP-like 
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structures when transfected into HEK293T cells, 56 although changes were observed in 
the length of time required to form the storage structures and in the length and number 
of WP-like bodies formed. 56 
There is also some conflicting evidence as to whether cleavage of the propeptide is 
required for WP body formation. In AtT-20 or RIN 5F cells, an intact furin cleavage site 
was required for storage of VWF . 
59 However, in monkey kidney CV-1 cells expression 
of a VWF mutant that lacks the propeptide cleavage site but is able to form covalently 
linked polymers, resulted in the formation of Weibel-Palade body-like vesicles4l and 
this has also been observed in other subsequent studies. 60 
There is strong evidence however, that the propeptide is essential for WP body 
formation. VWF expressed lacking the propeptide was shown not to form WP-like 
structures, 61 however, expression of the propeptide alone was sufficient for the 
formation of storage granules. 61 If the propeptide was co-expressed with propeptide 
deleted VWF, then storage granules were observed. The propeptide is also able to direct 
non-related VWF proteins to storage granules. Expression of a chimeric construct, with 
the VWF propeptide and C3a protein demonstrated that the presence of the propeptide 
re-routed a normally constitutively secreted protein to the regulated storage pathway. 62 
1.4.2 Regulated Secretion 
VWF and associated WP body proteins are released in response to a number of agonists. 
In all cases the secretion of the WP body contents involves the translocation of the WP 
bodies from the cytoplasm towards the plasma membrane and the fusion of these 
vesicles with the plasma membrane. 
Thrombin, histamine, fibrin, complement components C5a and C5b-9, oxidative stress 
and leukotrienes have been shown to induce VWF release by mediating a rise in the 
concentration of cytosolic free Ca2+ ([Ca2+]). 63"70 Regulated secretion of VWF can also 
be induced by secretagogues, such as epinephrine, adenosine or the vasopressin 
71,73 analogue DDAVP (1-deamino-8-D-arginine vasopressin). DDAVP is used in the 
72 clinical treatment of VWD and several other bleeding disorders. Physical activity and 
other acute stresses raise plasma VWF levels; evidence suggests that this is mediated by 
74 epinephrine induced EC secretion. Finally other factors such as shear stress or hypoxia 
75,76 have also been shown to induce EC to secrete the store of VWF. 
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Figure 1.2 Post translational modification of VWF 
Following translation the signal peptide directs VWF to the ER where the signal peptide 
is cleaved and initial N-linked glycosylation occurs and C-terminal dimers are formed. 
The molecule passes to the Golgi where there is further carbohydrate processing, the 
addition of O-linked carbohydrates and sulphation of N-terminal N-linked glycans. 
Further carbohydrate processing may take place in the TGN with the addition of ABO 
blood group sugars to N-linked glycan chains. Also in the TGN, VWF multimers are 
formed by intermolecular disulphide bonds between N-terminal cysteines of adjacent 
molecules. Cleavage of the propeptide occurs, and the VWF molecule is either 
constitutively secreted into the circulation or stored within the cell. 
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1.5 VWF STRUCTURE AND FUNCTION 
Mature VWF multimers are made of a variable number of VWF monomeric subunits. 
Monomeric mature VWF is comprised of 2050 amino acids with a molecular weight of 
-250kDa each. Fully multimerised VWF may consist of >20 monomer subunits with a 
molecular weight exceeding 200OOkDa, making it the largest known soluble globular 
protein, and it is the largest VWF multimers that are the most biologically active in 
mediating VVYT's adhesive function. 77 The multimeric nature of VWF can be visualised 
using agarose get electrophoresis under non-reducing conditions. 78 Purified VWF 
visualised under the electron microscope appears as either as a loosely coiled mass of 
VWF multimers with an apparent diameter of 200-300mn or elongated filamentous 
structures, 2-3nm in diameter and up to 1300nrn in length. 79 Using atomic force 
microscopy (AFM) it was shown that the elongated structures are "uncoiled" VVvT 
multimers . 
80 The elongated (uncoiled) VWF structures were obtained by exposing the 
molecule to shear stress; with 35dyn/cm2 being the critical shear stress needed to cause 
VWF to change confirmation to an extended structure exposing intra-molecular 
domains. 80 This level of shear stress is within physiological levels found in the arterial 
circulation .81 As will be discussed later, this conformational change in VWF is essential 
for various functional aspects of the molecule; for example the interaction with GPlba 
and exposure of the cleavage site for the VWF cleaving protease. To mimic the 
unravelling effect of shear stress on VWF in vitro, denaturants such as urea and 
guanidine HC1 or modulators such as the antibiotic, ristocetin or the snake venom, 
botrocetin may used. 
Each pro-VWF monomer is comprised of four types of homologous repeating domains. 
There are four D domains, a truncated D domain, three A domains, three B domains and 
two C domains and a CK domain arranged in the order: 
NH2-DI-D2-D'-D3-Al-A2-A3-D4-BI-B2-B3-Cl-C2-CK-COOH 
The DI and D2 domains represent the propeptide and are removed from the mature 
molecule as previously discussed. Each mature subunit contains a large number of 
cysteine residues (169 out of 2050 (-8%)) and in the secreted protein there are no free 
sulphydryl groups, suggesting that all cysteine residues not forming intermolecular 
disulphide bridges are paired in intramolecular disulphide bonds. 16,19,20 
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Figure 1.3 Domain structure of VWF 
VWF is comprised of four homologous repeating domains: four D domains, a truncated 
D' domain, three A domains, three B domains, two C domains and a cysteine knot 
domain (CSK). VWF dimers are formed by intramolecular disulphide bonds at the C- 
terminus and multimers form by intramolecular disulphide bonds at the N-terminus. 
Shown on the figure are the binding site for various ligands and the ADAMTS13 
cleavage site within the A2 domain. 
31 
1.6 THE D DOMAINS 
The DI and D2 domains comprise residues 34-746 and represent the VWF propeptide. 
The truncated D' and D3 domains comprise residues769-1242 and represent the N- 
terminal portion of the mature VWF monomer. Each D domain is comprised of 
approximately 360 residues (the truncated D' domain is 97 amino acids long) and are 
rich in cysteine residues. (DI - 9.1%, D2 - 8.9%, D' - 17%, D3 - 9.6% and D4 - 
82 8.8%). There is significant sequence homology between the D domains and the 
position of the majority of the cysteine residues is conserved, suggesting that they have 
a similar tertiary structure. An RGD consensus integrin binding sequence is located at 
residues 698-701 in the D2 domain which may be implicated in cell attachment. 82 
As previously discussed the propeptide (D I -D2) is required for multimerisation of VWF 
and direction to VWF storage granules. 61 The propeptides of several hormones and 
enzymes have been demonstrated to aid the correct folding of the mature protein acting 
83,84 as molecular chaperones. Studies have shown that the propeptides of the hormones: 
subtilisin, preprosomatostatin, lactase-phlorizin hydrolase and prouroguanylin assist in 
protein folding and stabilisation prior to protein maturation . 
85-89 Analogous to this, the 
VWF propeptide functions as an intramolecular chaperone folding VWF into the correct 
orientation necessary for proper intermolecular disulphide bond formation. 90 
Furthermore, evidence suggests that the VWF propeptide needs to be intact for 
multimerisation to occur. Deletion of either the DI or D2 domain results in the 
production of un-multimerised VWF dimers. 91 Moreover, studies on a number of 
naturally occurring mutations in the VWF propeptide, (Tyr87Ser, 90 Arg273Trp, 
92 
93 94 Asn528Ser,, Gly550Arg, Cys623T65 and 625insGIY95) show that although the 
mutations do not occur in close proximity to any functional areas, they all result in 
aberrant multimerisation. 90 
The D' and D3 domains comprise the N-terminal portion of the mature VWF subunit 
and contain the sites for multimerisation, and the FVIII and P-Selectin binding sites. 
Both the D' and D3 domains are required for multimerisation to occur. A study by 
Voorberg et al demonstrated that recombinant VWF produced with deletion of either 
the D' or D3 or both domains, did not form multimers. 25 In addition this study showed 
that a VWF construct composed of only the Dl-D2-D'-D3 domains was able to form 
intermolecular disulphide bonds, further highlighting that multimerisation is 
independent from dimerisation. 25 
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Digestion of plasma VWF with V8-protease and trypsin generates a dimeric fragment 
spanning residues 1036-1491 with the flanking regions being monomeric . 
96 This 
demonstrated that all the intersubunit disulphide bonds must occur within these 
residues. Thus the D3 domain contains the cysteine residues necessary for multimer 
formation. In a study by Azuma et al a smaller VWF fragment was isolated spanning 
residues 1212-1491. Individual mutation of cysteine residues 1222,1225 and 1227 to 
alanine prevented polymerisation of a recombinant VWF fragment spanning residues 
1204-1493.97 However, a study by Dong et al showed that mutation of these residues in 
full length VWF (FL-VWF) did not affect processing, multimerisation or secretion of 
VWF, suggesting that intersubunit disulphide bonding differs between FL-VWF and 
truncated VVvT. 98 Furthermore this study showed that Cysl 142 was essential for 
multimerisation. Mutation to alanine resulted in the secretion of VWF dimers only. 98 
Other studies have implicated CysI130, Cys1149, Cysl157 and Cys1234 as important 
cysteine residues required for multimerisation. 99,100 
Although the D' domain does not contain cysteine residues involved in intersubunit 
disulphide bond formation, mutations occurring in the D' domain have an adverse effect 
on VWF multimerisation. For example the naturally occurring C788R mutation causes 
the formation of only low molecular weight multimers, 101 as does the C804F 
mutation. 102 This suggests that although the D' domain does not directly participate in 
intersubunit disulphide bonding, correct folding of the D' domain is essential for 
multimerisation to occur, thus it may have a molecular chaperone type role comparable 
to that of the propeptide. 
1.6.1 Factor VIII Binding 
As mentioned previously, VWF acts as the carrier molecule for FVIII- This is essential 
to the survival of FVIII in the circulation, 103 prolonging its half-life from 2 to 12 
hours, 103 stabilising the FVIII molecule and protecting it from inactivation by protein 
cIO4,105 and preventing activation and inactivation by Factor Xa. 106,107 Furthermore, 
VWF also acts a cofactor for thrombin catalyzed cleavage of the FVIII light chain. 108 
FVIII circulates with VWF in a non-covalently associated complex, (99% VWF: I% 
FVIII. ) FVIII binds to VWF with a KD of 200-400pM109, but the affinity of FVIII for 
VWF is decreased when VWF is bound to collagen (KD 5nM). 110 All sizes of VWF 
multimers bind FVIII with the same affinity. "' The formation of the VWF: FVIII 
complex has a rapid association rate (K.,, = 5.9 x 106 M"s-1), this rapid formation of the 
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complex prevents the interaction of FVIII with other ligands. 112 The binding site for 
FVIII is located in the D' and D3 domains, (residues 769-1242), 13 " 14 with a possible 
critical role for resides 841-859.1 15-117 
1.6.2 P-Selectin Binding 
The YD3 domains of VWF have also been shown to participate in binding to 
P-Selectin. A study by Padilla et al demonstrated that newly secreted ultralarge VWF 
multimers are anchored to EC by P-Selectin. CHO cells expressing P-Selectin were able 
to anchor VWF molecules to their surface under flow conditions, visualised by the 
appearance of string like structures able to support platelet adhesion! 18 Using a cellular 
based system, it was confirmed that P-Selectin is dependent on VWF for recruitment to 
WP bodies, and was shown that P-Selectin interacts with VWF via the VW D'D3 
domains. 119 
1.7 A1A2A3 DOMAINS 
VWF contains 3 homologous A domains that span residues 1260-1874, (Al domain 
1260-1453, A2 domain 1498-1668, A3 domain 1691-1874. ) 120 The three domains share 
approximately 30% homology. The Al and A3 domains both contain an intramolecular 
disulphide bond that forms loops of approximately 187 residues (Figure 1.3). The A2 
domain lacks this conserved cysteine loop. The crystal structures for both the Al and 
A3 domains have been resolved. 121,122 A domains are also found in other proteins, 
including immune system leukocyte integrins LFA-1 and Mac-1, components of the 
complement system, Factor 2B and component C and cell adhesion molecules, in all 
these molecules, A domains play a role in mediating interactions with specific 
ligands. 123 
The Al domain of VWF contains binding sites for the platelet receptor GPIba, 96 
heparin, 124 sulphatides, 125,126 minor binding sites for collagen types I and III and a 
binding site for collagen type VI. The A2 domain contains the cleavage site for the 
VWF cleaving protease ADAMTS 13, the linker region between AI and A2 is involved 
in leukocyte binding127 and the A3 domain contains the major collagen binding site. 
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Figure 1.4 VWF A domains 
Both the Al and A3 domain contain an intramolecular disulphide bond between 
cysteine residues, leading to the formation of a loop of 187 amino acids. The 
ADAMTS 13 cleavage site (Y I 605-M 1606) is located in the middle of A2 domain. 
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1.7.1 Platelet GPIba 
The Al domain contains the binding site for GPlba, 96 which is a component of the 
platelet GPlb-IX-V complex. 128 To mimic this interaction in vitro VWF needs to be 
treated with modulator such as ristocetin or botrocetin to allow binding to platelets. 
The location of the Al domain as the site of interaction with GPIba was initially 
demonstrated using a 52/48kDa fragment of VWF generated by trypsin digestion 
spanning residues 1212-1491 that was able to inhibit ristocetin induced platelet 
aggregation. 96 Additionally, a similar fragment expressed in E. coli (residues 1208- 
1496), was able to also inhibit platelet aggregation and also competed with the binding 
to platelets of an anti-GPlba monoclonal antibody known to inhibit VWF binding. 
129 
Finally, an Al domain deleted VWF mutant was unable to mediate ristocetin induced 
platelet aggregation. 130 Although the specific residues involved in the interaction with 
GPlba are unknown, a study using E. coli expressed Al domain demonstrated that the 
VWF GPlba binding domain contained multiple interaction sites and the residues 
between the Al domain intramolecular bond, (Cysl272-Cysl458) were important in the 
interaction. 13 1 Furthermore a study using synthetic VWF peptides showed that residues 
Aspl277-Glul3O5 represented a major site of adherence to GPlb. 132 Specific mutations; 
R1287S, G1324S, H1326T, T1357S/EI359A, Q1367R and S1370R133 and also 
Glul260Ala and Arg1274AIa, 134 all reduced recombinant VWF Al domain- 
ristocetin/botrocetin induced binding to platelets. To assess binding kinetics of the 
VWF: GPIba interaction, a recombinant fragment of GPIba has been expressed 
spanning the first 289 residues of GPlba. Recombinant VWF Al domain binds to this 
fragment with a KD of 3.3 ýtM. 13 5 Using Surface Plasmon Resonance, full length VWF 
has been shown to bind to rGPlba with a KD of 30nM. 136 Finally, a recent study has 
suggested that the D'D3 domains shield the Al domain, modulating its interaction with 
GPlb-IX-V. Recombinant VWF lacking the D'D3 domains was more effective at 
binding platelets and isolated D'D3 region could inhibit the interaction of DD3 deleted 
VWF with GPlba. 137 Furthermore, it was demonstrated that the D'D3 region was in 
close proximity to the Al domain in soluble VWF but not when VWF was 
immobilized. 137 
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1.7.2 Heparin 
The VWF Al domain has also been shown to contain a heparin binding site, indicating 
that VWF may interact with matrix heparin-like glycosaminoglycan. 138 An initial study 
demonstrated that the 52/48kDa tryptic fragment of VWF was able to inhibit the 
binding of FL-VWF to heparin and was also able to bind heparin itself. 124,139 Binding to 
heparin was dramatically decreased if Al domain deleted VWF. 130 A recent study has 
demonstrated that residues Lys1362 and Arg1395 and clusters 1332-1336 and 1405- 
1408 are essential residues for heparin binding with in the Al domain. 140 
1.7.3 Collagen Binding 
Collagen is the main component of the extracellular matrix capable of binding VWF- 
The major types of collagen involved in this interaction are types I and III. Collagen 
type III is present in the sub-endothelium and is exposed after limited injury insult to the 
endothelium, whereas collagen type I is located deeper in the vessel wall so is only 
exposed after extensive injury. Both the Al and A3 domains contain collagen binding 
sites. Initial studies with the tryptic 48/52kDa Al domain VWF fragment demonstrated 
that this portion of the VWF molecule could inhibit binding of FL-VWF to collagen, 
suggesting this fragment contained a collagen binding site. 141 Similar studies using 
trypsin and V8 protease generated fragments demonstrated that two distinct domains of 
VWF could interact with collagen types I and 111'142 and the region 1674-2128 
contained a binding site for type III collagen. 143 It has also been established that the 
propeptide contains a collagen binding site, however since the propeptide is removed 
during multimer assembly this is unlikely to be significant. 144 Further studies using 
purified recombinant Al domain failed to demonstrate any binding to collagen, 129,145,146 
and deletion of the Al domain failed to prevent VWF interacting with collagen types I 
and 111.130 These results indicated that whilst a collagen binding site may be present 
within the Al domain, it is only a minor binding site and the results obtained with the 
trYptic fragments of VWF may be explained by contamination by full length VWF 
material after purification of the fragments. Evidence that the major collagen binding 
site was located in the A3 was obtained by a study showing that recombinant A3 
domain could inhibit binding of multimeric VWF to collagen and could bind collagen 
with a KD of -2-3gM, 147 and a further study using an A3 domain deleted VWF mutant 
showed abolished binding to type III collagen. 148 
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Mutagenic studies of the VVYT A3 domain demonstrated that residues Asp1742, 
Ser1783 and His1786 are essential for collagen binding and mutation of residues 
IleI738, Thr1740, Va11760, Glul764, Arg1726 and Arg1779 decreases collagen 
binding at least 10 fold, suggesting that these residues are important. 149,150 These 
residues define a flat hydrophobic region at the front face of the A3 domain that 
represent the collagen binding site. 150,15 1 Recently, the VWF binding sequence in type 
152 III collagen has been shown to be RGQOGVMGF (where 0 is hydroxproline). 
A recent study however has proposed a model in which both domains support adhesion 
to collagen in a synergistic fashion. Using both SPR and a plate based collagen binding 
assay, Morales et al showed that recombinant Al (rAI) domain bound to both types I 
and III collagen with higher affinity than recombinant A3 domain and furthermore 
collagen bound rAI was able to support platelet adhesion under flow conditions. 
Examination of the binding kinetics obtained by SPR showed that the Al protein has 
lower association and dissociation rates and Al domain was also less effective at 
inhibiting the binding of multimeric VWF to collagen. The authors results proposed that 
the major binding site for collagen is located in the A3 domain, and this mediates a fast 
association to decelerate the rapid flowing VWF. Binding to collagen via the A3 
domain causes a conformational change that exposes a cryptic collagen binding site in 
the Al domain that adds to the overall affinity of VWF for collagen. 153 This conclusion 
is supported by evidence that mutations in the Al domain, G1324S 1 53 and R1308L' 54 
cause impaired collagen binding by affecting the conformation of the Al domain. 153,154 
The multimeric nature of VWF is important in determining the affinity for collagen, 155 
with the highest molecular weight multimers have more collagen binding sites and 
156 therefore bind to collagen with the highest affinity, KD 1-7nM . Based on the crystal 
structure of the A3 domain the interaction of the A3 domain collagen is achieved 
through interactions between negatively charged residues on the A3 domain and 
positively charged residues on collagen. The absence of a pronounced binding groove 
precludes a large van der Waals surface interaction between the A3 domain and 
collagen and is consistent with the low affinity for collagen of a single A3 domain and 
the requirement for multimeric VWF for tight association with collagen. 122 
Finally, the Al domain has been shown to contain the binding site for collagen type VI 
which is abundant in the arterial subendothelium. 157,158 
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1.7.4 A2 Domain 
The VWF A2 domain harbours the cleavage site for the VWF cleaving protease, 
ADAMTS13 . 
159 Recombinant VWF with the A2 domain deleted is not cleaved by 
ADAMTS13 . 
160 As will be ftirther discussed, ADAMTS13 cleaves the Tyr1605- 
Met1606 bond in the A2 domain, regulating VWF multimeric size, and thus VWF 
functional activity. Although the crystal structure of the VWF A2 domain has not yet 
been resolved a homology model has been proposed where the Tyrl605-Metl6O6 bond 
is buried within the domain. 161 For ADAMTS13 cleavage of VWF to occur the VWF 
molecule must adopt an unfolded conformation to expose the cleavage site. This occurs 
in vivo under shear stress conditions 162 and may be replicated in vitro by the use of 
denaturants. 161 Without the use of in vitro denaturants cleavage does not occur. 161 
1.8 D4 AND B DOMAINS 
The D4 and B 1-3 domains form the region of the VWF monomer in-between the A3 
domain and the CI domain. Little investigation has focused on this portion of the VWF 
molecule, as such, no functional role has been determined for either the D4 or B 
domains. Expression of rVWF with the D4 domain deleted had no effect on VWF 
multimeric structure and did not alter binding of VWF to type III collagen, 156 and 
recombinant D4 domain was also unable to inhibit VWF binding to type VI collagen. 157 
Further investigation is needed to ascertain the role of these domains. 
1.9 THE C DOMAINS AND THE CYSTEINE KNOT 
The C domains and the cysteine knot (CK) domain are located at the C terminal end of 
the VWF monomer. The Cl and C2 domains span residues 2255-2645 and have 
sequence homology to cysteine rich domains found in thrombospondin and alpha- 
procollagen types I and 111.163 The Cl domain contains the RGDS (Arg-Gly-Asp-Ser) 
sequence required for binding to the platelet GP1Ib1l1a receptor and also to the HUVEC 
vitronectin receptor. 164 
The CK domain spans the final 90 C-terminal residues of VWF from 2724-2813 and 
contains the cysteine residues involved in the formation of VWF dimers. The CK 
domain is homologous with the cysteine knot family of proteins and the VWF CK 
domain is particularly similar to the CK domains found in several epithelial mucins and 
Norrie disease protein (norrin) that form oligomers through C-terminal CK domains. 165- 
167 The CK domains are characterised by 6 conserved cysteine residues, with disulfide 
39 
bonding occurring between cysteines 2 and 5 and between cysteines 3 and 6 and this 
defines a ring that is penetrated by a disulfide bond between cysteines I and 4, with 
additional un-conserved cysteine residues that differ between CK domains, mediating 
dimerisation. 168 Analysis of the VWF CK domain demonstrated that it contains the 6 
conserved cysteine residues; Cys2724-Cys2774 (bond 1-4), Cys2750-2804 (bond 2-5) 
and Cys2754-Cys2806 (bond 3-6). Mutation of two of the un-conserved cysteine 
residues in the VWF CK domain, C2771 and C2773, prevented dimerisation, indicating 
these cysteine residues are necessary for dimerisation of VWF . 
19,169 Furthermore 
molecular modelling based on transforming growth factor P, suggested that these two 
residues were pivotal in forming inter-molecular disulphide bonds to form VW 
dimers. 19 
1.10 VWF FUNCTION IN COAGULATION 
Haemostasis is a regulated response to maintaining blood flow within the vascular 
system; preventing blood loss at sites of vessel injury but at the same time maintaining 
blood fluidity. 
At sites of vascular injury three events occur to prevent blood loss: 
1) Vasoconstriction to reduce blood flow, 2) Formation of the primary platelet plug - 
this is a rapid process that limits blood loss but is unstable and 3) Stabilisation of the 
platelet plug - this occurs via the coagulation cascade which culminates in the 
generation of thrombin; this in turn converts soluble fibrinogen to fibrin, which 
enmeshes the initial platelet aggregation and converts the primary platelet plug to a firm 
stable hemostatic plug. Platelets themselves are disc shaped, anucleated blood cells, 
derived from megakaryocytes. Upon insult to the endotheliurn platelets adhere either 
directly to the endothelium, under low shear stress conditions or via the interaction with 
VWF, under high shear stress conditions. 
1.10.1 Blood Vessel and Blood Flow Dynamics 170 
In a blood vessel, red blood cells represent the majority of the circulating mass and as 
such they occupy most of the lumen, forcing white blood cells and platelets to the sides 
of the vessel. 17 1 Assuming blood follows the properties of a Newtonian fluid, the 
velocity profile of blood will be parabolic. Therefore, the velocity of the blood flow 
through the vessel will be maximal in the centre and will decrease towards the vessel 
wall. The fluid in the blood vessel can be thought of as being in different layers called 
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planes or laminae, moving at different velocities. The difference in velocity between the 
layers creates the shearing flow, i. e. the sliding motion between two adjacent laminae. 
Shear stress is the tangential force per unit area of contact between the laminae and is 
expressed in Pascal (Pa) using the International System of Units or dyn/cm2 in the CGS 
system. (I Pa = 10 dyn/cm2) 
Shear rate is the rate of change in velocity between laminae with respect to the distance 
from the axis of the vessel. It is expressed in velocity divided by distance, in units of §" - 
In Newtonian fluids there is a linear relationship between shear stress and shear rate. 
Maximal shear rate occurs at the sides of the vessel, while minimal shear rate occurs at 
the centre of the vessel. 
Platelets and the vessel wall can be viewed as two juxtaposed surfaces. The platelets are 
in the fluid phase while the vessel wall is stationary. In order for bonds to form between 
platelets and vessel wall, the two need to be I Onm or less apart from each other. When a 
platelet is in close enough proximity for a bond to occur, it must do so before the 
distance between itself and the vessel wall is increased. Thus, the initial interaction 
requires a fast on-rate. The interaction between platelet and vessel wall also needs to 
withstand the force (drag) applied to it by the moving fluid. The higher the shear forces, 
the higher the drag. The shear forces have an effect on the platelet bonds formed with 
the vessel wall; the interaction is subjected to torque, where the fluid flow and the 
spherical nature of the platelets produce a rotating motion; where bonds at the front of 
the platelet/vessel interaction are compressed and bonds at the rear are subjected to 
tensile stress. 
At sites of vascular injury VWF is essential to the initiation of platelet adhesion and 
therefore subsequent haemostatic plug formation, since it is able to resist the 
haemodynamic forces and provide a rapid link between the extracellular matrix and 
platelets. 
1.11 VWF AND PRIMARY PLATELET PLUG FORMATION 
1.11.1 Platelet Adhesion 
Upon vascular insult, VWF acts to mediate platelet adhesion to the subendothelium and 
platelet-platelet aggregation. 172 VWF is especially important for these processes under 
conditions of high shear stress and rapid blood flow; such conditions are found in 
arterioles and stenosed arteries. 173 After exposure of the subendothelium, VWF is able 
to interact with the exposed subendothelial matrix proteins, principally collagen via the 
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A3 domain, anchoring it to the subendothelium and as discussed this may induce a 
conformational change allowing interaction of the Al domain with collagen as well. 
Furthermore, HMW-VVYT multimers (that are the most biologically active) are released 
from the VVT bodies in EC, in the basolateral direction, and are bound to the 
subendothelium before reaching the circulation. 174 Depending on the vascular segment 
involved in the process, the subendothelial matrix may contain sufficient endogenous 
VW to support platelet adhesion alone. 175,176 Indeed analysis of different collagen 
preparations showed that fibrillar collagen contained a substantial quantity of VWF that 
could enhance platelet aggregatory responses. 177 However, when no endogenous VWF 
is present the process of platelet adhesion is not affected. Vascular beds that do not 
contain endogenous VWF can support platelet adhesion6 and this is also demonstrated 
by experiments on pigs with VWD that do not secrete VWF into the blood stream or the 
subendothelial matrix. Infusion of VWF concentrate into the pigs corrected the plasma 
defect and returned haemostasis to normal, even though there was an absence of 
endogenous VWF. 178 Thus plasma VWF is able support platelet aggregation regardless 
of the presence of endogenous VWF. 
The shear forces that are encountered cause VWF to undergo a conformation change 
resulting, as discussed, in the un-coiling of the molecule into its elongated 
confirmation. 80 This exposes the binding site for GPIba and provides the initial point of 
interaction between VWF and platelets. 173 The binding of platelet GPIba to VWF has an 
extremely fast association rate so that platelets may be tethered even at very high flow 
rates. 173 Above a threshold value of wall shear stress rate of -1000 per second, the 
interaction of VWF with GPIba is the only interaction that can initiate adhesion. 170 The 
interaction also has a fast dissociation rate and as such cannot provide irreversible 
platelet adhesion. However, the interaction serves to arrest the movement of the platelet 
and using video microscopy, platelets are observed to move slowly along the 
immobilised VWF in the direction of the floW. 173 This movement along VWF after the 
interaction with GPIba is associated with platelet activation! 79 Intracellular signals are 
generated that in turn activate protein kinases that cause platelet activation. Upon 
activation the shape of the platelet changes to become more spherical and extrude long 
pseudopods that enhance interaction with adjacent platelets. A release reaction occurs 
resulting in the secretion of ADP, serotonin, fibrinogen, lysosomal enzymes, 
P-thromboglobulin, heparin neutralising factor and also platelet VWF. The platelet 
membrane also exposes more negatively charged phospholipids to provide an optimal 
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surface for binding of other coagulation factors. The activation of platelets also leads to 
activation of platelet receptor GPIlbIlIa (integrin aIIA) and P-Selectin on the platelet 
surface. GPlIbIlIa interacts with the RGDS sequence in the VWF CI domain, forming 
an irreversible bond that arrests the platelet's movement and stabilises the GPIba 
interaction and thus mediates platelet adhesion. 180,181 
Under conditions of low shear stress platelets are able to interact directly with the 
exposed subendothelial matrix. Recently the dimeric form of platelet receptor GPVI has 
been shown to bind directly to fibrous collagen present in the subendothelium, 182,183 
stimulating platelet adhesion and activation. 184 The platelet collagen receptor, GPIalIa 
(integrin a2PI) is also able to directly interact with collagen 185 and there is evidence that 
platelet glycoprotein V (part of the GPlb-V-IX receptor) also plays a role in adhesion to 
collagen. 186 
1.11.2 Platelet Aggregation 
Once platelets have adhered to the site of vascular injury further platelets are recruited 
to the site to form the primary platelet plug. This is mediated by VWF interacting with 
GPlba and GPIIbllIa in the same way as described above and fibrinogen interacting 
with GPlIbIlla. Platelets can also bind, via GPlba, to P-Selectin on activated 
platelets. 187 At low wall shear stress rate of -100 per second, as commonly found in the 
venous circulation, 171 fibrinogen interacting with GPlIbllla forms the predominant link 
between aggregated platelets, 188 although VWF competes with fibrinogen for 
GPIIbllla. 189 At high shear rates however, fibrinogen alone is unable to support platelet 
aggregation and VWF is required to further the formation of the platelet aggregate. 190-192 
Platelet VWF can also be involved in the formation of the platelet plug. However, since 
it is released from the a-granules of activated platelets it is unlikely to be involved in the 
initial adhesion of platelets to the site of vascular injury. Platelet VWF has been shown 
to mediate platelet aggregation at high shear stress and therefore is involved in the 
extension of the platelet aggregate after the initial adhesion of platelets to the exposed 
subendothelium. 192 
1.11.3 VWF Self-Association 
Evidence from recent studies has suggested that VWF is also able to self-associate 
under flow conditions during platelet adhesion. In a study by Savage et al (200 1)193 
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platelets perfused over immobilised recombinant VWF lacking the Al domain, failed to 
tether to the surface. However they adhered if they were perfused over the Al domain 
deleted VWF with soluble VWF. Likewise, perfused platelets failed to interact with 
collagen bound recombinant A3 domain, but adhered if they were perfused with soluble 
VWF. 193 These observations suggest that self-assembly of VWF multimers occurs at 
sites of vascular injury and this may aid the formation of the platelet plug. 193 A further 
study also demonstrated that VWF in suspension was able to self-associate in the 
presence of high shear stress. 194 Finally, the self assembly of VWF was investigated 
using a static plate binding assay that demonstrated the interaction between immobilised 
and soluble VWF involved multiple domains. 195 
1.12 VON WILLEBRAND DISEASE 
Von Willebrand Disease (VWD) is the most common human congenital bleeding 
disorder, affecting 1% of the population. The disease was first identified by Dr Eric Von 
Willebrand in 1924 in families from the Aland islands who had a bleeding tendency 
distinct from haemophilia and other forms of bleeding diathesis. 
VWD results from either a qualitative or quantitative deficiency in VWF, caused by 
mutations at the VWF locus. Symptoms vary according to severity of the disease and 
include epistaxis, gingival bleeding, menorrhagia, prolonged bleeding from trivial 
wounds, skin bruises and haernatomas and gastrointestinal bleeding in more severe 
cases. Severe deficiency of VWF or abnormalities in its interaction with FVIII, causes a 
secondary moderate deficiency of FV111, with typical haemophilia symptoms such as 
haemarthrosis and deep tissue bleeding. 
VWD is a heterogeneous disorder, classified into three major categories. Type I VWD 
refers to a partial quantitative deficiency. Type 2 VWD refers to qualitative deficiency 
and type 3 VWD results from a total VWF deficiency. 
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Type 1 VWD is the most common VWD deficiency (70% of all VWD patients). By 
definition its is a quantitative deficiency, caused by mutations that impair VWF 
synthesis and/or secretion, but normal VWF function and multimer distribution are 
retained. However an increasing body of evidence suggests that more detailed analysis 
of VWF from patients with type I VWD shows subtle abnormalities in multimer 
composition and distribution. This is more consistent with the dominant-negative effect 
of many type I VWD associated mutations. Type I VWD can be inherited as a 
dominant or recessive trait, depending on the specific mutation and on the variable 
penetrance. 
Type 3 VWD is characterised by total absence or minimal detectable VWF protein in 
plasma. It is a recessive disorder resulting from mutation of both copies of the VWF 
gene. Heterozygotes for these mutations are normally unaffected and do not present 
with a type I or type 3 VWD phenotype. The distinction between the two forms is made 
from a clinical point of view, since type 3 VWD have more severe symptoms. 
Type 2 VWD is characterised by normal or reduced plasma VWF antigen, with 
disproportionate loss of certain functions. It includes a series of subtypes (2A, 213,2M, 
2N). Inheritance is dominant, with the exception of type 2N and a rare variant of type 
2A. 
Tyj2e 2A VWD is the most common qualitative deficiency. It is associated with the 
absence of large and intermediate molecular weight VWF multimers (Fig 1.6), which 
are the most effective in haemostatic activity. Type 2A VWD is usually transmitted as a 
dominant disorder caused by single amino acid substitution usually within the Al and 
A2 domains. Two distinct molecular mechanisms are involved in causing the type 2A 
VWD phenotype and the corresponding causative mutations are designated group I and 
group II. Group I mutations are associated with impaired assembly and secretion of 
normal VWF multimers. It is assumed that only the larger multimers carrying these 
mutations are retained in the endoplasmic reticulum, since they have incorporated a 
large number of mutant subunits interfering with processing and secretion process. 
Group II mutations are associated with normal processing and secretion of VWF 
multimers. Loss of large and intermediate molecular weight multimers then occurs in 
plasma, due to increased susceptibility to proteolysis by ADAMTS13. Molecular 
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modelling of the A2 domain suggests that these mutations may change the conformation 
of the molecule, and thereby leading to an unfolded domain more susceptible to 
proteolytic cleavage. A distinct set of mutations within the propeptide also cause a 
recessive form of type 2A VWD by impairing multimer assembly in the Golgi. The 
basis for the recessive clinical phenotype is not completely understood. 
Type 2B VWQ is characterised by increased affinity of VWF for platelet GPIba- 
Different point mutations have been identified all clustered in the region of the Al 
domain, which contains the GPIba binding site. Paradoxically, this abnormality does 
not lead to thrombosis but to a bleeding phenotype. This can be explained by the 
presence of increased clearance of both VWF and platelets, leading to absence of 
haemostatically effective high molecular weight multimers in plasma and intermittent 
thrombocytopenia. 
Type 2M VWD is characterised by normal VWF multimers distribution but decreased 
platelet adhesion. Mutations associated with this particular phenotype have been 
identified in GPIba binding site in Al domain and they cause a disruption of this 
interaction 
TMe 2N VWD shows preserved platelet-dependent functions and normal VWF 
multimeric pattern, but decreased FVIII binding and subsequently low FVIII levels due 
to enhanced clearance. All the mutations described are located in the region of VWF 
containing FVIII binding site (i. e. D'D3). The phenotype is autosomal recessive, since 
FVIII binding to VWF is not dependent on VWF multimeric size. Furthermore, VWF is 
physiologically in excess compared to FVIII and thus the amount of VWF synthesized 
by a single allele is sufficient to bind all the circulating FVIII. 
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Figure 1.5 Distribution of VWF multimers in VWD 
Multimer analysis of a patient with type I VWD shows a non-nal multimer distribution 
compared to normal plasma (NP). Patients with type 2A VWD and type 2B VWD 
present an abnormal multimer profile with the absence of high and medium molecular 
weight multimers. (Figure reproduced from Sadler 1988) 2 
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1.13 REGULATION OF VWF FUNCTION 
As already discussed, VWF is secreted as a series of multimers, ranging in size from 
dimers of 500kDa up to ultra large multimers, in excess of 200OOkDa, and it is the 
largest multimers that have the highest affinity for GPIba and collagen and are thus the 
most biologically active. 196 As a result of this the multimeric size of VWF needs to be 
carefully regulated prevent abnormal thrombus formation. This is achieved in plasma by 
the VWF cleaving protease ADAMTS13, (A Ilisintegrin And Metalloproteinase with 
ThromboSPondin type-1 repeats. ) 
1.13.1 ADAMTS13 
ADAMTS13 is a Zn2+/Ca2+ dependent metalloprotease that belongs to the 19 member 
ADAMTS enzyme family. Functions of other ADAMTS family members include; 
development of the genitourinary system - ADAMTSI'197 assembly of collagen fibrils 
- ADAMTS2,198 procollagen II N-proteinase activity - ADAMST3,199 cleavage of 
proteoglycans of cartilage - ADAMTS4 and 5.200,201 
The human ADAMTS13 gene is located on chromosome 9 (9q34), spanning 37kb of 
genomic DNA and encodes for 29 exons. The transcription mRNA product is -5kb and 
encodes for a 1472 amino acid protein. 202 The apparent mass of ADAMTS13 is 
-190kDa compared with a calculated molecular weight of 145kDa; this difference is 
most likely due to glycosylation, with ADAMTS13 containing 10 potential N-linked 
203 glycosylation sites. The primary site of synthesis is in the liver, with a number of 
studies reporting most active expression in hepatic stellate cells. 202-207 However a recent 
study detected ADAMTS13 in both arterial and venous endothelial cells by 
immunofluorescence staining, and RT-PCR analysis confirmed that ADAMTS13 was 
synthesised in these cellS. 208 ADAMTS13 is secreted constitutively in to the blood as an 
active protease and has a plasma concentration of -1-2[ig/ml (5-IOnM) with a half-life 
209,210 of 2-3 days. 
ADAMTS13 is a multi domain protein consisting of a signal peptide, a propeptide, a 
metalloprotease domain, a disintegrin domain a thrombospondin type-I motif (TSR), a 
cysteine-rich domain, a spacer domain, seven additional TSRs and two CUB 
203 domains. 
The metalloprotease domain contains the active enzymatic site and its activity is 
dependent on the presence of Zn2+ and Ca2+ ions and therefore is inhibited by divalent 
chelating agents such as EDTA. 159A molecular model based on homology with 
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adamalysin 11 suggests that three histidine residues; His244,228 and 234, coordinate the 
catalytic Zn 2+ ion at the active site . 
21 1A potential calcium binding site, conserved in 
most ADAMTS13 family members, is predicted to lie on the opposite side to the 
catalytic domain and may involve residues Glu83, Asp173, Cys281 and Asp284- 203 
Figure 1.6 Domain structure of ADAMTS13 
ADAMTS13 is a multi domain protein containing a metalloprotease domain (MP), a 
disintegrin domain (Dis) a thrombospondin type- I motif (TSR), a cysteine-rich domain, 
a spacer domain, seven additional TSR's. Interestingly ADAMTS13 is the only 
ADAMTS family member to posses two CUB domains, located at the C-terminal end of 
the protein, 
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1.13.2 ADAMTS13 Interaction with VWF 
As previously discussed, ADAMTS13 is responsible for the cleavage of VWF at the 
Y1605-MI606 bond in the VWF A2 domain, generating 176kDa and 140kDa fragments 
found in the circulation212 and thus regulates VWF multimeric size. Cleavage of VWF 
by ADAMTS13 is responsible for the characteristic triplet structure observed in 
multimeric analysis of VWF. Molecular models of the A2 domain suggest that the 
Y1605-MI606 bond is buried within the domain 161,213 and this is supported by the 
observation that cleavage of VWF requires shear stress to alter the confirmation of the 
molecule into its elongated configuration. This may be mimicked in vitro by the use of 
urea, guanidine HCl or ristocetin. Cleavage of VWF in vitro using denaturants may 
require long incubation times, 196 whereas cleavage of VWF under flow conditions 
occurs in minutes. 
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To investigate the interaction of ADAMTS 13 with VWF, a number of studies have 
employed the use of short recombinant substrates to avoid the use of denaturants or the 
need for shear stress. Kokame et al demonstrated that the shortest VWF fragment that 
could be cleaved by ADAMTS13 was a 73 amino acid fragment (VWF73) spanning 
215 residues 1596-1668 of the A2 domain. Other studies have used VWF 115 substrate, 
spanning residues 1554-1668 of the A2 domain. 216 Both these short substrates do not 
require urea for cleavage, indicating the structure is pen-nissive to ADAMTS13 
cleavage. 
Whilst the A2 domain contains the ADAMTS13 cleavage site, evidence suggests that 
the primary binding site for ADAMTS 13 lies in the A3 domain. A study by Dong et al 
showed that under flow conditions and by the use of SPR that ADAMTS 13 bound with 
217 the greatest affinity to recombinant A3 domain, compared to Al or A2 domains. 
However in a subsequent study, the presence of the A3 domain had no effect on the rate 
of proteolysiS218 and this was further supported by a study using a VWF fragment 
spanning residues 1554-1874, (designated VWFI15-A3), for which the rate of 
proteolysis was shown to be similar to the VWF 115 substrate spanning residues 1554- 
1668, indicating that the presence of the A3 domain had no effect on the rate of 
216 proteolysis by ADAMTS13 . The latter study also determined a specificity constant 
(y. cat/K M) of _8 X 104 M-1 s"' which was close to the apparent &g/K. value obtained for 
full length multimeric VWF of -3.4 x 104 M-1 S"1.219 
It has also been demonstrated that binding of VWF to GPIba enhances ADAMTS13 
cleavage of VWF. Recombinant VWF A2A3 was cleaved -10 fold faster than 
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recombinant AlA2A3, indicating that Al domain inhibited cleavage, but this inhibition 
can be relieved by binding of the Al domain to GPlba or heparin. 218 
The domains of ADAMTS 13 are also important in the interaction with VWF. The 
spacer domain is essential for activity. Truncations of ADAMTS 13 up to the 
metalloprotease domain, the disintegrin domain and the cysteine rich domain were 
220-222 
unable to bind (or bound with low affinity) or cleave FL-VWF or VWF73 . 
However addition of the spacer domain restored protease activity, indicating that it is 
essential for ADAMTS 13 aCtiVity? 20-222 Using a plate binding assay, it was 
demonstrated that ADAMTS13 truncated up to the first thrombospondin repeat bound 
VWF with a Kd 206nM; addition of the spacer domain increased the affinity to Kd 
26nM which was comparable to the affinity of wild type ADAMTS13 for VWF, (Kd 
14nM . 
)222 Similar results were also obtained with the VWF73 substrate. 220 It was also 
shown that individual domains of ADAMTS13 could bind to VWF73; Disintegrin 
domain - KD = 489nM, first TSR - KD = 136riN4, Cysteine rich domain - KD = l2lnM 
and Spacer domain - KD = 108nM. 
223 This suggests that all the proximal C-terminal 
domains act in cooperation to confer an efficient recognition of the substrate. 
Conflicting data exists as to the function of the CUB domains (Complement 
components Clr/Cls, Uegf (sea urchin fibropellins) and Bone morphogenic proteinl. ) 
These domains are not present in other ADAMTS family members, but they are present 
in other proteins involved in developmental processes (embryogenesis, organogenesis, 
innervation), suggesting they can have a role in protein-protein interactions. 224 
1.13.3 VWF Cleavage by Thrombospondin-1 
As well as cleavage by ADAMTS13, VWF multimer size is also regulated to some 
degree by a protein disulphide bond reductase, identified as thrombospondin-I (TSP- 
1. )225 A study by Xie et al showed that incubation of VWF with purified TSP-1 resulted 
in the formation of thiol dependent complexes of VWF and TSP-I, and the generation 
of free thiols in VWF, furthermore the multimeric size of VWF was reduced. Also, an 
inverse relationship was demonstrated between the plasma molar ratio of VWF/TSP-1 
and VWF multimeric size. 225 Moreover, the administration of TSP-1 to mice resulted in 
a reduction of VWF multimeric size. 225 A subsequent study demonstrated, that 
surprisingly, the average VWF multimer size was reduced in TSP- I null mice. 226 TSP- I 
has been shown to interact with the VWF A3 domain,, 225,226 and as previously discussed 
the A3 domain may harbour the primary binding site for ADAMST 13 . 
217 This suggests 
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that TSP-1 may compete with ADAMTS13 for binding to VWF and inhibit to some 
degree ADAMST13 proteolysis. This study also showed that TSP-1 is stored in the a- 
granules of platelets and is able to reduce platelet VWF multimer size upon platelet 
lysis or activation. This was unable to occur in the TSP-I null mice, and resulted in 
increased collagen and platelet binding. This implies that TSP-I controls plasma 
derived and platelet derived VWF in different ways and the action of TSP-I maybe 
more relevant to platelet derived VWF. 226 
1.14 GLYCOSYLATION 
The process of glycosylation involves the attachment of mono, oligo or polysaccharides 
to proteins or lipids and occurs as a post-translational modification. Glycosylation is 
known to affect protein folding, localization and trafficking, protein solubility, 
antigenicity, biological activity and half-life, as well as cell-to-cell interactions. 227-229 
The majority of glycan structures fall into three groups: those attached to lipids and 
those attached to proteins via a nitrogen atom (N-linked) or an oxygen atom (0-linked). 
1.14.1 N-linked Glycosylation 
N-linked glycosylation is the best understood glycosylation pathway and results from 
the attachment of glycan chains to the amide nitrogens of asparagine side chains. For N- 
linked glycosylation to occur the asparagine residue has to be part of the sequence; Asn- 
Xaa-Ser/Thr, where Xaa can be any amino acid except proline'230 and there is some 
limited evidence that Thr at position 3 is increases the chance that the site will be 
occupied. 231 There are also exceptional cases where N-linked glycosylation can occur at 
the sequence Asn-Xaa-Cys. 232 There are three types of N-linked glycan; high-mannose, 
hybrid and complex, that all contain a common core, but differ in the terminal 
elaborations extending from the basic structure. 
1.14.1.1 N-linked glycan synthesis 
The synthesis of N-linked glycan may be divided into three stages: 1) formation of a 
lipid-linked precursor oligosaccharide, 2) en bloc transfer of the precursor to the protein 
of peptide and 3) processing of the oligosaccharide. 22 
Generation of the glycan begins with the synthesis of a GlC3ManqGlcNAC2 Structure 
attached via a pyrophosphate linkage to a lipid dolichol. This initially occurs on the 
cytoplasmic side of the ER with the enzyme, UDP-GlcNAc - dolichol phosphate N- 
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acetylglucosamine- I -phosphate transferase, attaching a GIcNAc residue from a UDP- 
GIcNAc nucleotide donor to the lipid linked dolichol. Further dolichylpyrophosphate 
enzymes catalyse the attachment of a second GlcNAc residue and five mannose residues 
from GDP-Man donors, forming a Man5GIcNAC2 structure. 233,234 The structure is 
translocated across the ER membrane and becomes inaccessible to cytoplasmic 
enzymes. Once translocated, four subsequent mannose residues are attached followed 
by three glucose residues, with the sugars donated from dolichol linked 
monosaccharides on the ER membrane. 22 The next stage in N-glycan synthesis involves 
the transfer of the G1C3Man9G1cNAC2 structure to the nascent polypeptide chain. This 
occurs in the lumen of the ER and is catalysed by the enzyme, 
oligosaccharyltransferase, that transfers the glycan to the asparagine residue, with the 
energy for the reaction being derived from the cleavage of the phosphate-glycan 
bond. 235,236 
After transfer to the nascent peptide chain, synthesis of the glycan is completed by a 
series of processing steps that involves the removal and addition of sugar residues. 
Initially the three glucose residues are removed within the ER by Glucosidase I, which 
removes the terminal al-2 linked glucose residue, then Glucosidase Il which removes 
the two inner al-3 linked glucose residues. 237 As will be discussed, removal of the 
glucose residues allows the newly formed glycoprotein to enter the calnexin- 
calreticulin cycle which ensures that the protein is folded correctly and is then 
transported to the Golgi body for further carbohydrate processing. As the glycoprotein 
leaves the ER, ER Mannosidase I removes a mannose residue, then following 
transportation to the Golgi, Golgi Mannosidases IA, IB and IC remove some or all of 
the four al-2 linked mannose residues from the glycan chain. Glycans that undergo no 
finiher processing are termed high-mannose structures. 22 Further construction of hybrid 
and complex structures occurs by the addition of a G1cNAc residue by GlcNAc 
transferase I, in the medial region of the Golgi body, then removal of two mannose 
residues by Mannosidase II and the addition of a further GlcNAc residue by G1cNAc 
transferase II. At this stage, the glycan is of the most abundant bi-antennary type, 
however other distinct GlcNAc transferases can initiate further branching to form less 
common tri and tetra-antennary structures. The glycan structure can then be further 
elaborated in the trans-Golgi network by the addition of galactose residues by 
galactosyltransferases and terminal sialic acid residues by sialyltransferases. 22 
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1.14.1.2 Effect of N-linked glycans on protein folding 
As mentioned, removal of glucose residues from the N-linked glycan allows the 
glycoprotein to enter the calnexin-calreticulin cycle. Calnexin (membrane-bound) and 
calreticulin (soluble) are homologous ER lectins that bind transiently to virtually all 
newly synthesized monoglucosylated glycoproteins. 238,239 Once two of the glucose 
residues have been removed by Glucosidase I and II, the newly synthesised 
glycoprotein can bind to either calnexin or calreticulin. 240,241 Calnexin and calreticulin 
are then able to complex with the thiol oxidoreductase, ERp57.242 Transient disulphide 
bonds are formed between the glycoprotein and ERpS7 and these serve as intermediates 
in oxidation and isomerization reactions and lead to the formation of correctly paired 
disulfide bonds within the glycoprotein. 243 Once the protein is correctly folded 
Glucosidase 11 removes the remaining glucose residue and the glycoprotein dissociates 
from calnexin or calreticulin. The high mannose glycan structure may then bind to 
mannose specific lectins such as ERGIC-53 and VIP36 for transport to the Golgi . 
244 If 
the protein is misfolded, the glycan chains are re-glucosylated by an ER 
glucosyltransferase, (Uridine diphosphate (UDP)-glucose: glycoprotein 
glucosyltransferase), and re-binds to either calnexin or calreticulin; the process is 
repeated until the protein is correctly folded or degraded. 
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Figurel. 7 N-linked glycan processing 
Following synthesis of the lipid-linked precursor oligosaccharide within the ER, the 
enzyme oligosaccharyltransferase transfers the Dolichol linked GIC3Man, )GIcNAC2 
structure to the nascent polypeptide chain and further carbohydrate processing occurs 
through a series of steps that add and remove sugar residues. Within the ER, 
glucosidases I& 11 and ER mannosidase removes terminal glucose and mannose 
residues. Within the cis-Golgi and medial Golgi further mannose residues are removed 
and GIcNAc residues added to the glycan chain. The glycan is completed by addition of 
galactose and sialic acid residues within the trans-Golgi network. The example shown 
in this figure represents the synthesis of a complex N-linked glycan. Alternative 
pathways of digestion and sugar addition result in the fori-nation of other glycan 
structures such as high mannose or hybrid structures. 
55 
1.14.2 O-linked Glycosylation 
O-linked glycosylation is perhaps less understood than the N-linked pathway. However 
significant progress has been made in understanding the function that O-linked confer 
on proteins. Unlike N-linked glycosylation there is no consensus sequence for the 
addition of an O-linked chain to a protein, the only requirement is the presence of a 
SerfIbr residue. A number of general rules, however, aid the prediction of which 
Ser/Thr residues will be glycosylated: 1) Initial of 0-linked glycosylation takes place in 
the Golgi, as such only exposed Ser/Tlir residues will be glycosylated. 2) Mucin-type 0- 
glycosylation occurs mostly on P-turns of the secondary structure and on other regions 
with an extended conformation. 3) O-linked glycosylation normally occurs in regions of 
low hydrophobicity. 4) Large amino acids are not normally found in the vicinity of 0- 
linked glycans. 245,246 
1.14.2.1 Synthesis of 0-linked glycans 
The most common type of O-linked glycans contain an initial GaINAc residue attached 
to the Ser/Thr residues and are called mucin type glycans. Synthesis of mucin type 
glycan begins in the Golgi, where the enzyme UDP-GaINAc: polypeptide N-Acetyl- 
galactosaminyltransferase (GaINAc-T) facilitates the addition of a GaINAc residue to 
the Ser/Thr residue. 247 In total nine mammalian GaINAc-T have been identified, 
although some specificity has been demonstrated, most cell types express multiple 
GaINAc-T. 248,249 Galactosyltransferse enzymes can then attach a Gal residue to the 
GaINAc forming the core I structure. The core I structure can then be modified by the 
addition of further sugar residues to form other core structures, with eight core 
structures identified so far. 250 Most commonly, the core I structure may be either 
terminated by the addition of two sialic residues, or the enzyme UDP-GIcNAc: Galpl- 
3GalNAca1-R-PI-6GlcNAc transferase (core 2 GlcNAc-T) attaches a GlcNAc residue 
to core I to form the core 2 structure. 25 1 After the synthesis of a core 2 structure, a Pl- 
4Gal-T acts to produce a Pl-6 linked lactosamine that can be extended into 
polylactosamine by Pl-3GlcNAc-T and PI-4Gal-T, or the structure can be terminated 
250 by the addition of sialic acid residues. 
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1.15 GLYCAN STRUCTURE OF VWF 
As discussed, VWF undergoes extensive post translational modifications resulting in the 
addition of a potential 16 N-linked glycan chains and 10 0-linked glycans chains, so 
that the total carbohydrate component of VWF accounts for -15% of its total molecular 
weight. 16 Analysis of the carbohydrate component of VWF demonstrated both the 
presence of mannose and GaINAc residues in VWF, indicating that both 0 and N- 
linked glycan chains were incorporated in to the molecule '252 
253 with N-linked glycan 
accounting for 70% of the carbohydrate component and 0-linked glycans accounting 
for 30%. 254 The carbohydrate composition of VWF can be seen in table I below. 
Sugar Residue % total protein weight 
Sialic acid 3.7 
Galactose 2.4 
N-Acetylglucosamine 4.0 
Mannose 3.2 
Fucose 1.0 
N-Acetylgalactosamine 0.7 
Table 1.1 Carbohydrate composition of VWF 
Carbohydrate accounts for 15% of the total molecular weight of VWF and the presence 
of both mannose and GaINAc residues confirms that VWF undergoes both N- and 0- 
linked glycosylation. (Reproduced from Sodetz et a0253 
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1.15.1 0-linked Glycosylation of VWF 
VWF contains 10 predicted sites of O-linked glycosylation; 1248,1255,1256,1263, 
1468,1477,1486,1487,1679 and 2298. Eight of these are clustered in two groups of 
four between the Al and A2 domains. Many soluble glycoproteins contains clusters of 
O-linked glycans at hinge or linker regions between folded domains. 255 The specific 
function of this is unknown, but evidence suggests it gives rigidity to flexible regi ons of 
the protein. 256 The structure of a major VWF O-linked glycan has been determined to be 
a tetrasaccharide containing two sialic acid residues, a Gal residue and a GaINac residue 
(Figure 1.8). As described above this represents a disialyted core I structure and 
represents >70% of VWF O-linked glycans. 257 
NeuAc(a2-3)-Gal(01-3),. -. 
GaINac(al-3)-Ser/Thr 
NeuAc(a2-6)1'ý 
Figure 1.8 Major structure of the 0-linked glycans of VWF 
VWF is predicted to contain 10 O-linked glycan sites, with the major O-linked glycan 
shown to be a disialyted core I structure. This structure is also known as the t-antigen. 
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1.15.2 N-linked Glycosylation of VWF 
VWF is predicted to be N-linked glycosylated at 4 sites within the propeptide: N99, 
N156, N211 and N666 and at 12 sites within the mature subunit: N857, NI 147, N1231, 
N1515, N1574, N2223, N2290, N2357, N2400, N2546, N2585, N2790.16 
In a number of initial studies glycan structures were isolated and sequenced. Samor et al 
(198; ) characterised a major N-linked glycan and proposed a bi-antennary, 
monosialylated glycan of the N-acetyllactosaminic type. Further work by Debeire et al 
(1983) confirmed the observation of this glycan structure and showed that the primary 
structure contained single polylactosamine extensions and also contained an al-6 linked 
Fucose residue. Furthermore this glycan structure accounted for 60% of the total N- 
258 linked structures released from VWF. 
NeuAc(a2-6)-Gd(Ol-4)-GIcNac(ol-2)-Man(al-3) 
Man(ol-4)-&IcNac(ol-4)-GlcNac(ol-4ýN 
Gal (01-4)-Gl cNac(p 1-2yMan(al-6) 
I (al-6) 
Fuc 
Figure 1.9 Primary glycan structure of a major N-linked glycan isolated from 
VWF 
The major N-linked glycan presented on VWF is a bi-antennary, monosialylated glycan 
with a single polylactosamine extensions and an al-6 linked fucose. This glycan 
structure was predicted to account for 60% of the N-linked glycan. (reproduced from 
Debeire et a0258 
59 
A later study by Samor et al also reported a monosialyated, monofucosylated, tetra- 
antennary structured glycan with single polylactosamine extensions. 259 
Man(al-3) 
NeuAc(a2-6)-Gal(pl-4)-GicNac(PI-2), 'ý \ Man(DI-4ýýcNac(Ol-4)-C4cýkc(Ol-4)-N I (al-6) 
Fuc 
Gcd (PI-4ýCA cýbc(PI-6) 
Mcin(al-6) 
Figure 1.10 Primary structure of a tetraantennary glycan isolated from VWF 
(reproduced from Samor et a0259 
A detailed study of VWF N-linked glycans was performed by Matsui, Titani and 
Mizuochi. (1992). 23 N-linked glycans were released from VWF by hydrazionolysis and 
purified by lectin affinity chromatography and the glycans sequenced by sequential 
exoglycosidase digestion in con unction with methylation analysis. They confirmed that 
the major type of N-linked glycan presented by VWF was the bi-antennary type 
(78.2%). Of these bi-antennary glycans, 70% did not have a bisecting GlcNAc residue. 
Mono-antennary structure comprised 0.4% of the total N-linked structures, tri-antennary 
12.3% and tetra-antennary 2.3%. Furthermore a small number (0.8%) high mannose 
structures were observed. 23 An interesting and significant finding was that a number of 
23 the N-linked chains presented the ABO(H) blood group sugars. This had also been 
reported in 1979 by SodetZ, 253 but the observation had not been supported by later 
studies. 254,258 Further study using blood group sugar specific antibodies and lectins 
confirmed that the VWF does indeed present ABO blood group sugars. Interestingly in 
the same study, a-2-macroglobulin and FVIII were also shown to present the blood 
group SUgarS. 260 
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Figure 1.11 VWF glycosylation sites 
From the primary amino acid sequence and early work by Titani et al, VWF is 
predicted to contain 10 O-linked glycosylation sites and 16 N-linked sites. Of the N- 
linked sites, four occur in the propeptide (131-132) and the remaining twelve are spread 
throughout the molecule. Eight of the O-linked sites are predicted to be clustered 
around the Al domain flanking regions. 
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1.16 FUNCTION OF VWF GLYCANS 
A number of studies have been performed on VWF glycans, mostly using 
exoglycosidases to remove specific glycan residues. Most have focused on the effect of 
removing terminal sialic acid residues with neuraminidase to produce asialo VWF 
(AsWVF), removal of terminal galactose residues with P-galactosidases to produce 
agalactoVWF (AgVWF), or digestion with both neuraminidase and galactosidase to 
produce As/Ag VWF. The results obtained from these studies have sometimes been 
conflicting and the role that glycans play in the structure and function of VWF still 
remains, in part, inconclusive. 
1.16.1 Multimeric Structure 
As mentioned previously, N-linked glycosylation is essential for dimerisation of VWF, 
since treatment of endothelial cells with Tunicamycin results in the accumulation of 
VWF monomers within the cell. It is not known if all the N-linked sites need to be 
occupied for dimerisation/multimerisation to occur or if an individual site(s) are 
required. However, VWF expressed with the A2 domain deleted, thus lacking N-linked 
sites N1515 and N1574, formed normal VWF multimers, suggesting in part that it is 
specific glycan site(s) that are essential to proper multimer formation. Studies using 
exoglycosidases to alter VWF glycan structure have demonstrated removal of sialic acid 
does not affect VWF multimeric structure . 
261-264 However, conflicting results have been 
obtained with regard to the removal of terminal galactose residues. Removal of 
galactose residues from AsVWF was demonstrated to affect multimeric structure, 
causing a loss of high molecular weight multimers and an increase in low molecular 
weight sepecies. 263-265 One of these studies also reported loss of HMW multimers when 
just the terminal galactose residues were removed. 263 However this finding has not been 
confirmed. In contrast to this, a study by Federici et al showed that removal of sialic 
acid and galactose residues did not alter VWF multimeric structure and furthermore 
treatment with neuraminidase, P-galactosidase and endo F, removed 83% of VWF 
carbohydrate and did not affect multimeric structure. 262 
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1.16.2 Platelet Aggregation 
A number of studies have investigated the effect of VWF glycan structure on VWF 
platelet aggregation function with conflicting results. Several studies have suggested 
that AsVWF is able to induce spontaneous platelet aggregation in the absence of 
ristocetin and increases ristocetin mediated aggregation. 266-268 However, other studies 
have obtained results where AsVWF causes a decrease in ristocetin mediated platelet 
aggregation, 269-271 and further studies have observed no effect of AsVWF on ristocetin 
independent or mediated aggregation. 263,272-275 In a study by Lawrence and Gralnick 
wild type and AsVWF preparations were perfused over human umbilical artery 
segments. Compared to wtVWF, AsVWF caused a 69% reduction in platelet binding, 
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demonstrating that under flow conditions (at least in this study) AsVWF had a negative 
effect on VWF platelet binding function. However, a later study by Bastida et al did 
show that AsVWF increased platelet aggregation under flow conditions. 277 The reason 
for the disagreement between these two studies is not clear. More recently, the platelet 
binding function of VWF was assessed using recombinant Al domain produced in 
E. coli, (thus lacking glycosylation) and was compared to Al domain expressed in CHO 
cells that follow glycosylation pathways. The non-glycosylated Al domain bound to 
platelets in a platelet binding assay with slightly higher affinity compared to the 
glycosylated form, apparent KD = 1.4ýtM compared to 4.5 ýLM. 146 The binding site for 
GPlb is located in the Al domain 96 and is flanked by a potential 8 O-linked glycan sites, 
clustered in two groups of four, either side of the Al domain. It is therefore feasible that 
any effect of VWF glycosylation on the interaction with GPIb will be mediated by these 
glycans. In a study by Carew et al (1992), VWF was expressed in Chinese Hamster 
Ovary Cells (CHO) with a reversible defect of O-linked carbohydrate metabolism. Both 
wtVWF and VWF lacking O-linked glycans bound to type I collagen and heparin with 
similar affinity, but O-less VWF was less able to bind to formalin fixed platelets and 
induce ristocetin mediated platelet agglutination. 278 In a study by Schulte et al (2004) 
recombinant Al domain was expressed in COS-7 cells with point mutations to alanine 
of the predicted O-linked glycosylation sites: T1248, S1253, T12559 T1256 and T1468. 
Recombinant Al was also expressed in the presence of an inhibitor of O-linked glycan 
synthesisq ct-N-acetyl-ct-galactosaminide . 
279 O-less Al domain increased platelet 
aggregation, as did S1253A, T1255A and T1468A . 
280 One potential difference for the 
observations in these two mentioned studies is the latter used recombinant Al domain 
and thus has no need to use ristocetin to modulate the interaction with GPIb. 280 
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However, the role that VWF glycans play in its platelet adherence function still remains 
unresolved. 
1.16.3 Protection from Proteolytic Cleavage 
A number of studies have shown that the glycan component of VWF protects against 
proteolytic cleavage. Federici et al demonstrated that As and As/Ag VWF were more 
susceptible to cleavage by plasmin. 262 After incubation with plasmin (32pg/ml) for 4 
hours, wild type VWF had no major loss of HMW multimers, where as AsVWF was 
reduced to medium to LMW multimers and As/Ag VWF was cleaved to dimers and 
monomers. 262 Furthermore a study by Berkowitz et al presented a similar finding where 
As and As/Ag VWF were more susceptible to cleavage by plasmin and also trypsin and 
chymotrypsin . 
26 1 This increased susceptibility to proteolysis may explain why, in the 
studies mentioned above, removal of glycan resides affected multimeric structure, since 
contaminating proteases may have been present in the VWF preparations used. Other 
studies have also demonstrated that the glycan moiety of glycoproteins can protect 
against proteolytic cleavage. Nonglycosylated fibronectin was shown to be more 
susceptible to proteolytic degradation that the glycosylated form. 281 
1.16.4 Collagen Binding 
Little work has been performed on the effects of VWF glycan structure on collagen 
binding. A study by Kessler et al showed that AsVWF bound to type I collagen 
similarly to wild type VWF, and As/AgVWF bound to type I collagen with reduced 
affinity. 265 However, this study also demonstrated a loss of HMW multimers on 
removal of galactose residues. Therefore the reduction in collagen binding function may 
represent a loss of HMW VWF multimers, rather than a direct effect of removing 
galactose residues. 
1.16.5 VWF Clearance 
Although significant progress has been made in defining the biosynthesis and the 
structure and function of VWF, comparatively little is known about the removal of 
VWF from the circulation. Sodetz et al studied the clearance of 1251 labelled human 
VWF (hVWF) in healthy New Zealand white rabbits and showed that VWF was cleared 
in a biphasic pattern, with an initial distribution rate phase of tj/2 = 3hours and an 
elimination phase of tj/2 = l9hours. 269 The biphasic clearance pattern has also been 
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demonstrated in Female Sprague Dawley rats; 282 distribution phase ti/2 = 35mins, 
elimination phase ti/2 = 245mins and also in VWF deficient mice; distribution phase 
ti/2 = 13mins, elimination phase t1/2 =180mins. 283 In the latter study, Lenting et al 
showed that a similar pattern of clearance was observed for both high and low 
molecular weight hVWF preparations, indicating that in the VWF-knockout murine 
model clearance is independent of multimer size. 283 However in a study using Dutch 
Kookier dogs with hereditary VWF deficiency that had undetectable VWF levels, the 
half life for HMW weight VWF was -21hours, but for LMW VWF the half life was 
only 9hours, 284 and moreover in the study using Sprague Dawley rats it was the highest 
molecular weight multimers that were cleared the fastest. 282 These results suggest that 
further work is needed to determine the relationship between VWF multimeric size and 
rate of clearance. As yet, the relationship between ADAMTS13 cleavage of VWF and 
clearance has not been determined. 
In the Lenting et al study using the murine model, the clearance of a number of 
truncated recombinant VWF variants were investigated. The results suggested that a 
major receptor site for clearance was located in the AlA2A3 domains; since clearance 
rates of recombinant AlA2A3 were comparable to FL-VWF . 
283 The D4-CSK domains 
appeared to have a regulatory role by enhancing VWF clearance with deletion of the 
D4-CSK domains reducing the rate of clearance. The D'D3 domains were observed to 
have a negative regulatory role by decreasing the rate clearance, with their deletion 
resulting in -2 fold increased clearance, suggesting that the D'D3 region of VWF has a 
preventive role in VWF clearance. 283 Furthermore this study also demonstrated that 
mutation of Arg1205 in the D3 domain markedly increased clearance, suggesting that 
mutation of Arg1205 abrogated the protective effect of the D'D3 domains. Finally, 
using the same model, Van Schooten et al demonstrated that mutations of cysteine 
residues C 113 0, C 1149 and C2671 resulted in increased clearance. 285 
1.16.6 VWF Clearance - Role of Carbohydrate 
The carbohydrate moiety of many plasma glycoproteins has been shown to influence 
116 ur hepatic clearance rates. Removal of terminal sialic residues and subsequent expos e 
of galactose residues has been shown to increase the rate of clearance for a number of 
proteins, such as prothrombin and thyroxine-binding globulin. 187-'90 Removal of sialic 
acid from carbohydrate chains increases clearance via binding to the asialoglycoprotein 
receptor; that recognises newly exposed galactose and GaINac residues. A number of 
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other carbohydrate receptors are also expressed in the liver that recognise, mannose/N- 
acetylglucosamine, fucose and phosphomannoSyi. 286 
Studies using the rabbit model to investigate clearance showed that asialo VWF labelled 
with 1251 was cleared more rapidly from the circulation, having a half life of 5mins 
compared to 240mins for wild type V)W. 269 This was also accompanied by appearance 
of the 1251 VW in the liver, and hepatic clearance was inhibited by simultaneous 
infusion of asialo-a-l-acid glycoprotein that binds the asialoglycoprotein. 269 In Vitro 
analysis of VWF binding to the asialoglycoprotein receptor showed that wild type 
exhibited negligible binding, whereas binding of AsVWF was comparable to binding of 
asialo-a-l-acid glycoprotein. When the terminal galactose residues were removed from 
AsVWF, binding was abolished, demonstrating that terminal GalPl-4GIcNAc is the 
VWF glycan sequenced recognised by the asialoglycoprotein receptor. 270 However, 
other terminal sugars may play a role in VWF clearance, since other asialo 
glycoproteins with terminal sugars other than galactose have been shown to be cleared 
faster than the corresponding wild type protein. 291,292 Furthermore the hepatic 
asialoglycoprotein receptor has been shown to have 60-fold greater affinity for GaINAc 
over galactose. 293 A murine model has also been made where expression of the ST3Gal- 
IV sialyltransferase has been inactivated. This results in decreased sialic acid content on 
VWF 
, and thus increased terminal galactose presentation. In the 
ST3Gal-IV 
sialyltransferase mice, VWF is cleared faster compared to normal mice. 294 This 
demonstrates that sialic acid prevents clearance of VWF. In addition, a subpopulation of 
humans with abnormally low VWF levels were identified that had increased galactose 
exposure on VWF, providing further evidence that exposure of galactose residues result 
in increased VWF clearance. 
A natural murine model has also provided evidence that VWF glycans can play a 
critical role in VWF clearance. The RIIIS/J mouse is an inbred strain that has reduced 
plasma VWF levels of up to 20-fold compared to wild type? 95 The gene responsible for 
this, Mvwf, is an allele of a N-acetylgalactosaminyltransferase, Galgt2. Mvwf is located 
on chromosome 11,296 distant from the murine VWF gene located on chromosome 6.297 
In normal humans and animals expression of Galgt2 is limited to the kidney and 
intestines. In the RIIIS/J mouse gene expression of Galgt2 is switched from the 
intestinal epithelial cells to vascular endothelial cells causing aberrant glycan 
modification of VWF which results in increased GaINAc presentation on VWF 
glycans. 298 This aberrantly glycosylated VWF was shown to be cleared faster from the 
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circulation by the asialoglycoprotein receptor, with a half-life of 25mins compared to 
300mins for wild type murine VWF . 
298 Finally, the O-linked glycans of VWF may also 
play a role in clearance. Using the Female Sprague Dawley rats, VWF deficient of 0- 
linked glycans was shown to be cleared faster than wild type VWF. 282 
1.17 VWF LEVELS IN HUMAN PLASMA 
The average plasma VWF concentration is -10gg/ml (35nM based on a monomer 
molecular weight of 270kDa). The normal distribution of plasma VWF concentration 
across the population shows a wide range with a skewed distribution towards higher 
levels. 299 The normal laboratory range for VWF is 5-15gg/ml. Low levels or deficiency 
of VWF has long been established as a cause of a bleeding tendency known as Von 
Willebrand Disease? Conversely, an accumulating body of evidence suggests that 
elevated VWF levels may represent a risk factor for myocardial infarction and venous 
thromboembolic disease. 300-304 Furthermore a recent study by Bongers et al (2006) 
showed evidence that high levels of VWF increase the risk of first ischemic stroke. 305 
Various genetic and non-genetic factors contribute to the large variation seen in VWF 
levels across the population with a major contributing factor to the variation being ABO 
blood group status. 
1.17.1 Regulatory Defects of VWF Expression 
Three single nucleotide polymorphisms in the 5' promoter region of the VWF gene 
(C/T at -1234; A/G at -1185 and G/A at -1051) have been shown to exert a major 
influence on plasma VWF levels. 306 Individuals with genotype CCAAGG had mean 
VWF levels of 0.96U/ml, compared to mean levels of 0.78U/ml individuals with 
genotype TTGGAA. 
1.17.2 Environmental Influences 
A number of environmental factors can also increase plasma VWF levels. These include 
increasing age, gender (women higher than men), exercise and any cause of the acute 
phase response, e. g. malignancy, infection or inflammation. 300 Chronically elevated 
VWF levels have also been described in a number of vascular disorders including 
severe atherosclerosis and diabetes. 307 
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1.17.3 Ethnic Group 
VWF levels also vary across ethnic groups, with Caucasians having significantly lower 
levels than African-Americans. 300,308-310 Differences in VWF are also observed between 
African-Americans and Indians, with levels significantly higher in Africans. 310 No 
difference in levels is observed between Caucasians and Indians. 310 
1.17.4 Defects of the VWF Gene 
As previously mentioned, individuals with type I VWD have reduced VWF levels and 
individuals with type 3 VWD have virtually complete VWF deficiency as a result of 
mutations at the VWF locus. The most common type 3 mutation is a single cytosine 
deletion at nucleotide 2435 that results in a frame shift in exon 18.311 A full list of all the 
known VWD causing mutations can be found on the ISTH SSC VWF information home 
page at: httj2: //www. vwf. grouj2. shef. ac. uk/ 
1.17.5 Other Quantitative Trait Loci 
As well as the VWF gene, other gene loci can exert ma or quantitative effects on plasma 
VWF levels. The most common of these is the ABO blood group locus on chromosome 
9q34. Individuals of blood 0 have generally 20-30% lower levels of VWF compared to 
non-0 blood groups. 312 Evidence from twin studies has shown that 66% of the total 
variation in plasma VWF levels is genetically determined, and 30% of the total 
variation is explained the ABO blood group effect on VWF levels. 312 
1.18 THE ABO BLOOD GROUP SYSTEM 
The ABO blood group system was first described by Karl Landsteiner in the early 
313 1900's, and it's molecular basis was reported in 1990 by Yamamoto. The antigens of 
the ABO system (A, B, and H) consist of a series of complex glycan chains that differ 
only with respect to their terminal sugar residues, with the terminal sugars representing 
314 the antigenic structure. 
The H (Fuc ccl->2 Gal Pl->4 GlcNAc Dl->) antigen is formed by the addition of a 
fucose residue to the terminal galactose residue of a specific precursor glycan chain 
(Figure 1.12). This reaction is catalysed by a(1,2)-fucosyltransferase (H-transfemse), 
encoded by the FUT 1 locus located on chromosome 19. Addition of this fucose moiety 
to the precursor chain is essential before further addition of the A (GaINAc al->3 [Fuc 
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al-*2] Galp 1-44 G1cNAc Pl->) or B (Gal al->3 [Fuc al->2] Galp 1->4 G1cNAc 
Pl->) determinants can occur. In blood group A and B individuals, different alleles at 
the ABO blood group locus (9q34) encode fo r either a-1,3-N- 
acetylgalactosarninyltransferase (A transferase) transferase or cc-1,3- 
galactosyltransferase (B transferase), respectively. Consequently A and B glycans differ 
only in respect to the terminal carbohydrate moiety expressed (Figure 1.12). AB 
individuals express both the A and B transferases. In group 0 individuals, the 0 allele 
does not encode any functional transferase enzyme so that they continue to express 
terminal H structures only. 
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Figure 1.12 Construction of ABO antigens 
The blood group antigens are formed by the addition of specific sugar residues to a 
precursor glycan chain. al, 2 fucosyltransferase (H transferase) adds a fucose residue in 
an al-2 linkage to the terminal region of the pre-cursor glycan chain forming the H 
antigen. Formation of the H antigen is necessary for further formation of the A and B 
antigens. Individuals of blood A, express a N-acetylgalactosaminyltransferase (A 
transferase) that adds a N-acetylgalactosarnine residue to the H structure. Individuals of 
blood group B express a galactosyltransferase (B transferase) that adds a galactose 
residue to the H structure. Individuals of blood group AB express both A and B 
transferases and convert H structure to both A and B antigens. Individuals with blood 
group 0 only express the H structure. 
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1.18.1 ABO Genotype 
The ABO gene locus has several different alleles responsible for the blood group 
phenotypes A, B and 0. There are six possible genetic combinations, however the 0 
allele is an amorph with no observable expression. Thus a blood group A individual 
may have the genotype AA or AO and likewise a blood group B individual may have 
the genotype BB or BO. Individuals of blood group AB have the genotype AB and 
group 0 individuals have the genotype 00. 
Furthermore a number of A alleles exist, the two most predominant being A' and A2. 
The product of the Aý allele is a transferase enzyme 5-10 times less active than the 
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product of the A' allele. Consequently, individuals with an A2 allele present less A 
antigen than individuals with A, alleles. 
1.18.2 Bombay and Para-Bombay Phenotype 
In human tissues, H antigen can be synthesised by two distinct a-1,2- 
fucosyltransferases. One is the H gene (FUTI)-encoded H enzyme that regulates 
expression of ABH antigens in red blood cells. The other is the Secretor gene (FUT2)- 
encoded Se enzyme that regulates expression of ABH antigens in the gastrointestinal 
tract and secretions. Very rare individuals with the Bombay phenotype are non-secretors 
who also fail to express H transferase (FUT 1). Such people cannot synthesise A or B 
antigenic structures regardless of their ABO blood group genotype, and ABH antigens 
are absent from both their erythrocytes and secretions. Para-Bombay individuals also 
fail to express H transferase, but do express the FUT2 (Secretor) encoded a-1,2- 
fucosyltransferase, so that ABH antigens are present in their secretions but not on their 
erythrocytes. 
1.19 RELATIONSHIP BETWEEN ABO BLOOD GROUP AND PLASMA VWF 
LEVELS 
An effect of ABO blood group on VWF was first demonstrated by Preston et al in 1964 
with the lowest levels observed in individuals of blood group 0,299 and has 
subsequently been confirmed in larger studies3o9,3 12,316-321 with blood group 0 
individuals having generally -30% lower VWF levels than non-group 0 individuals. 
Moreover the largest of these studies, Gill et al (1987), with I 100 normal individuals, 
demonstrated significant difference in VWF levels between non-0 blood groupS. 316 
Levels were highest in AB individuals, followed by group B, group A and lowest levels 
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were observed in group 0 individuals. Shima et al also showed that the ABO effect was 
the same if the measure of VWF was functional rather than antigenic. Furthermore, 
multimer analysis showed that VWF multimer structure did not between blood 
groups. 319 
As well as ABO phenotype having an effect on VWF levels, ABO genotype has also 
been shown to effect VWF levels. As expected lowest VWF levels were observed in 
genotype 00, (Blood group 0) and it was shown that individuals heterozygous for the 0 
allele - genotypes AO and BO, had significantly lower levels of VWF than individuals 
not carrying an 0 allele. 319,320,322 
The mechanism by which ABO blood group has an effect on VWF levels is unknown. 
However linkage analysis suggests that the effect is due to a direct functional effect of 
the ABO locus rather than a linkage disequilibrium. 320 O'Donnell et al suggested that 
H-antigen expression on VWF mediates the ABO effect on plasma VWF levels, with an 
inverse correlation between H antigen on VWF expression and plasma VWF levels. 322 
How H-antigen expression can influence VWF levels is not clear, however as 
demonstrated with the RIIIS/J mouse, the presence of a single glycan moiety can 
influence plasma VWF levels. It is also interesting that levels of platelet VWF, that has 
been shown not to present the ABO antigens, are not affected by ABO blood group. 323 
Furthermore, a study by Bowen showed that ABO blood group altered susceptibility to 
proteolysis by ADAMTS13. Multimer analysis and CBA showed that purified blood 
group 0 with was cleaved faster than non-O blood group VVR. 324 As discussed the 
carbohydrate component of VWF protects against proteolytic cleavage and the glycan 
structure of other proteins has been shown to protect against proteolysis. It is also 
interesting that the ADAMTS13 cleavage site is in the vicinity of two N-linked glycan 
sites; N 1515 and N 1574. How these may affect cleavage is undetermined. 
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1.20 AIMS OF THESIS 
The overall aim of this thesis is to investigate the effect of VWF glycans on the function 
of the VWF molecule with specific attention to the effect the glycans have on the 
interaction with ADAMTS13. Initially this will involve the purification of VWF from 
plasma and FVIII/VWF concentrates and require the development of collagen binding 
and multimer gel assays to assess functional aspects of VWF and to analysis proteolysis 
by ADAMTS13. The first part of the investigation will focus on the role of the blood 
group sugars presented on VWF, in mediating plasma VWF levels and susceptibility to 
ADAMTS13 proteolysis. Specifically, I will examine VWF from individuals with the 
rare Bombay Phenotype and determine the effect this phenotype has on VWF function. 
I plan to then analyse VWF both in silico and experimentally to investigate further the 
glycan structure of the molecule and the occupancy of specific glycan sites and 
presentation of blood group sugars. 
To further the investigation, I will examine the effect of altering other glycan structures 
present on VWF, by enzymatic digestion to removal specific sugar residues or 
structures and develop lectin analysis assays to assess the extent of sugar alteration. 
Furthermore, I will use site directed mutagenesis to mutate specific N-linked 
glycosylation sites and the glycan modified VWF preparations will be analysed for their 
functional activity, with specific attention paid to the effect on the interaction with 
ADAMTS13. 
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CHAPTER 2 
2. MATERIALS AND METHODS 
2.1 PURIFICATION OF BLOOD GROUP SPECIFIC VWF FROM PLASMA 
2.1.1 Cryoprecipitation 
Cryoprecipitation was used to extract VWF from plasma, exploiting the phenomenon 
that various circulating proteins precipitate out of solution at temperatures of 4'C or 
less. Plasma surplus to requirements was obtained from the National Blood Transfusion 
Service. Two units of blood group specific fresh frozen plasma (-300ml per unit) were 
thawed overnight at 40C. Thawed plasma was pooled in a pre-chilled glass beaker and 
slowly stirred and 50% ethanol pre-chilled to 41C was added drop wise to a final 
concentration of 8%v/v. The plasma/ethanol was stirred for 30mins then decanted into 
pre-chilled 250ml centrifuge tubes in an ice bucket. The resulting precipitate was then 
harvested by centrifugation; 3500rpm for 30mins at 41C. The cryo-supernatant was 
decanted off, aliquoted and stored at -800C for later use as a source of ADAMTS 13. The 
VWF rich pellet was resuspended in 10ml of Tris-Citrate (TC) buffer (20mM Tris, 
lOmM sodium citrate, pH 7.4). and centrifuged at 115OOrpm for 30mins at 22"C. The 
supernatant was removed and was further purified by size exclusion chromatography. 
2.1.2 Gel Filtration 
Gel filtration or size exclusion chromatography separates proteins on the basis of size. 
Smaller proteins enter the gel filtration matrix more readily and have a retarded passage 
through the column, where as larger proteins do not enter the gel filtration matrix and 
pass more readily through the column. 
To isolate high molecular weight VWF, a Sepharose 2B-CL gel filtration column 
(Amersham Pharmacia, UK) (600mm, x 26mm, 318.5ml volume) was pre-equilibrated 
overnight with 2 column volumes of Tris-citrate (TC) buffer. The cryoprecipitated 
VWF (-10ml) was applied to the column at a flow rate of 0.7ml/min, then eluted with 
TC buffer at flow rate Iml/min. Fifty two, 5ml fractions were collected (AI-134). VWF 
concentration was determined by VWF antigen ELISA, multimeric composition was 
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analysed by VWF multimer gels and collagen binding assay and purity assessed by 
silver staining. 
2.2 PURIFICATION OF VWF FROM HAEMATE P 
2.2.1 Gel Filtration 
A commercial VWF/FVIII concentrate, Haernate Pe (ZLB Behring, Germany) was used 
to obtain large quantities of VWF. Haernate P0 was resuspended in 10ml of H20 and 
centrifuged at 40OOg for 5mins. This was loaded on to a Sephacryl-400 gel filtration 
column (Amersharn Pharmacia, UK) (600mm. x 26mm, 320ml volume) that had been 
pre-equilibrated with 2 column volumes of Buffer A, (100mM NaCl, 20mM Tris-HCI, 
pH7.4). The column was eluted at a flow rate of Iml/min and flfty-two 5ml fractions 
were collected (Al-E4). Fractions B7-Dl2 were pooled for further purification by 
Heparin-Sepharose affinity chromatography. 
2.2.2 Heparin-Seph arose Affinity Chromatography 
A SK-16 chromatography column (Amersharn Pharmacia, UK) was packed with 30ml 
of Heparin-Sepharose 6 fast flow (Amersharn Pharmacia, UK) according to 
manufacture's instructions. Briefly, the empty SK-16 column was washed with ddH20 
and the bottom outlet tube connected to an AKTA FPLC machine. The column was 
flushed with 20mM Tris-HCI pH 7.4, and then 35ml of Heparin-Sepharose 6 fast flow 
was poured into the column chamber with a smooth continuous motion. The remaining 
column space was filled with 20mM Tris-HCI pH 7.4 and the plunger inserted into the 
top of the column. The Heparin-Sepharose was allowed to settle for I min, before a flow 
rate of 5ml/min was applied to the column for 20mins to ensure the resin was fully 
packed. The plunger was then pushed -5mm into the top of the resin. The final column 
had a volume of 30ml and a maximum flow rate of 3.5ml/min. 
To purify VWF, the column was equilibrated with 2 column volumes of Buffer A, then 
gel filtered fractions B7-DI2 were passed over the column at a flow rate of 0.4ml/min. 
After sample loading was complete, the column was washed with Buffer A until the 
baseline had returned to zero. VWF was eluted from the column with elution buffer 
(300mM NaCl, 20mM Tris-HCI, pH 7.4). Three 10ml fractions were collected and 
dialysed into 20mM Tris-HCI, pH 7.4 overnight at 4'C. VWF concentration was 
determined by VWF antigen ELISA, multimeric composition was analysed by VWF 
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multimer gels and collagen binding assay and purity assessed by Coomassie and silver 
staining. 
2.3 ANALYSIS OF PURIFIED VWF 
2.3.1 VWF: Ag ELISA 
VWF antigen (VWF: Ag) was measured by sandwich enzyme-linked immunosorbent 
assay. MaxiSorp plates (Nunc) were coated with polyclonal anti-VWF antibodies 
(Dako) diluted 11500 in 5OmM carbonate buffer, pH9.6, overnight at room temperature. 
Wells were then washed 3 times with PBS-T [PBS, Tween 20 (0.1% v/v)] and 100ýd of 
test samples applied to the wells at dilutions 1: 10-1: 60. Reference plasma (Technolcone, 
UK) diluted 1: 10-1: 320 was used as a standard. After I hour incubation at room 
temperature wells were washed, and 100[d anti-VWF-HRP (Dako) diluted 1/1000 in 
PBS-T was added to the wells and allowed to incubate for I hour at room temperature. 
After a final 3 washes, 180[d substrate (Sigma colour fast OPD tablets) was added to 
the wells and the reaction stopped with 100gi IM H2SO4 after -2-3mins. Absorbance 
was recorded at 492nm (UV- 1601 spectrophotometer, Shimadzu). A standard curve was 
generated plotting VWF concentration on the x-axis against absorbance on the y-axis. 
VWF concentration was expressed a percentage, with reference plasma diluted 1: 10 
representing 100% VWF. Graphs were plotted in Microsoft Excel and the equation-of- 
the-line and Rý values were calculated using the "add trendline" function. The equation- 
of-the-line was given in the format: 
y =MX+ C 
Where: y is the absorbance value, m is the gradient of the slope, x is %VWF and c is the 
y intercept. 
To calculate the O/oVWF of unknown samples the equation was rearranged to: 
X= (y - C) /M 
Absorbance values (y) of the unknown samples were substituted into the equation and 
returned a O/oVWF value. 100% was taken to equal IU/ml which is -IOgg/ml. Unless 
stated all VWF concentration were expressed in gg/ml. 
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2.3.2 Collagen Binding Assay 
Collagen binding activity (VWF: CB) is recognised as a sensitive measure of high- 
molecular weight VWF (HMW-VWF). The highest molecular weight VWF multimers; 
bind collagen with the greatest affinity. VWF: CB of plasma and purified VWF was 
determined using an ELISA based collagen binding assay. Initially VWF: CB was 
assessed using a commercial ELISA (Technoclone, UK) according to the 
manufacturer's recommendations. However an in-house VWF: CB was developed as 
part of this project. Human type III collagen prepared from the placenta by trypsin 
digestion (Sigma, UK C-4407) was dissolved for 16 hours at 4"C in 200mM acetic acid 
(final concentration of 0.1 mg/ml). Dissolved collagen was aliquoted and stored at -20T 
until use. Aliquots were only used once and never refrozen. To determine optimal 
coating concentrations and coating times, collagen was diluted to 1-15pg/ml in SOmM 
carbonate buffer, pH 9.6 and 100ýd per well, applied to MaxiSorp plates (Nunc) and 
incubated from 24 hours up to 49 days at room temperature. After coating, wells were 
washed 3 times with phosphate buffered saline with 0.1% Tween (PBS-T) and blocked 
with 2%BSA-PBS-T for I hour at room temperature. After blocking, wells were washed 
3 times as before and samples diluted 1: 10 to 1: 240. Reference plasma (Technolcone, 
UK) diluted in the same way was used as standard. 100pi of sample or standard was 
applied to each well. After incubation for 2 hours at room temperature, wells were 
washed 3 times with PBS-T and anti-VWF-HRP antibody was applied to the wells, 
(1/1000 in PBS-T) for I hour. After a final wash step, 180ýd substrate solution (Sigma 
colour fast OPD tablets) was added to the wells, the reaction stopped with lOOP1 IM 
H2SO4 after -5mins, and the absorbance measured at 492nm. Inter and intra 
experimental coefficients of variation were <5%. 
A standard curve was prepared as described for VWF: Ag ELISA plotting %CBA along 
the x-axis (reference plasma diluted 1: 10 = 100% CBA) and absorbance along the y- 
axis. Since the curve began to slightly plateaux at the 1: 10 dilution the curve was 
linearised by taking the Loglo values of the %CBA standards. The equation-of-the-line 
was given in the format: 
y=mx- C 
Where: y is the absorbance value, m is the gradient of the slope, x is the %CBA and c is 
the y intercept. 
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To calculate the %CBA of unknown samples the equation was rearranged to: 
X= (Y + C) /M 
Absorbance values (y) of the unknown samples were substituted into the equation and a 
Loglo value was obtained and converted to %CBA by use of the inverse Log function. 
To demonstrate that the assay was sensitive to VWF multimeric size, plates were 
incubated with purified, high molecular, medium molecular and low molecular weight 
VWF fractions that had been standardised for VWF: Ag. Bound VWF was detected as 
described above. Finally, to ensure that the interaction between VWF and collagen was 
specific, MaxiSorp plates were coated with equivalent amounts of type III collagen, 
type IV collagen and BSA and then incubated with pooled normal plasma diluted as 
described. 
2.3.3 VWF Multimer Analysis 
The multimeric pattern of VWF may be visualised by analysis in agarose gels under 
non-reducing conditions. VWF multimer analysis was performed using a modification 
of previous methods. Low resolution (0.8-1.3%) and high resolution (1.5-2.5%) agarose 
gels (1.5mm diameter) were prepared by dissolving 0.8-2.5g high gelling temperature 
agarose (Seakem) in 100ml of gel buffer [200mM Tris, lOOmM glycine, 0.1% sodium 
dodecyl sulphate (SDS), pH 9.0] and cast using a Bio-Rad mini gel casting system and 
stored at 40C for a minimum of 2 hours and a maximum of 7 days. Samples were 
diluted 1: 10 with sample buffer (10mM Tris, ImM EDTA, 2% SDS, 8M urea, 0.01% 
bromophenol blue, pH 8.0) and incubated for 30mins at 601C. Gels were assembled in a 
Bio-Rad mini-gel electrophoresis tank and running buffer (lOOmM Tris, ISOmM 
glycine, 0.1% SDS, pH 8.4) applied to the tank and cooled at 4T for 30mins. 10pl of 
sample was applied to each well and electrophorised at 60V for 20mins then 35V until 
the tracking dye had reached the end of the gel. After electrophoresis, transfer of protein 
to Hybond nitrocellulose membranes (Amersham Pharmacia, UK) was carried out for 2 
hours at 400mA at 4T. The membranes were then rinsed in PBS-T, and blocked for I 
hour with 5% membrane blocking reagent/PBS-T (Amersharn Pharmacia, UK). Finally, 
the membranes were incubated with anti-VWF-HRP antibody (DAKO) diluted 1/1000 
for I hour. After washing, bound antibody was detected with ECL chemiluminescent kit 
(Amersham Pharmacia, UK) and exposure to Amersham Hyper-Film. 
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2.3.4 H-antigen on VWF ELISA 
Presence and quantification of H antigen on VWF was preformed using a modified 
sandwich ELISA. 96 well plates (Nunc) were coated with rabbit anti-human VWF 
antibody diluted 11500 in 50mM carbonate buffer and incubated overnight. After 
washing 3 times with PBS-T, wells were blocked with 2% BSA for I hour. After a 
further 3 washes plasma or purified VWF samples were added at dilutions 1: 10-1: 240 
and incubated for 2 hours. Pooled group 0 plasma was used as reference. Plates were 
washed then incubated for I hour with biotin conjugated Wex Europaeus Agglutinin I 
(UEA) (Vector labs, UK) diluted 1/1000 in PBS-T. Plates were washed 3 times then 
incubated with streptavidin conjugated HRP (Vector Labs, UK) for 45mins diluted 
1/1000. After a final 3 washes, 180pl substrate (Sigma colour fast OPD tablets) was 
added to the wells and the reaction stopped with 100[d IM H2SO4. Absorbance was 
recorded at 492nm (UV-1601 spectrophotometer, Shimadzu). Concentrations of 
unknown samples were read from the standard curve, the same samples analysed for H- 
antigen were also analysed for VWF: Ag as described, and the amount of H-antigen was 
expressed per unit of VWF. 
2.4 SDS POLYACRYILAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
SDS-PAGE is used to separate proteins on the basis of their molecular weight. 
Treatment with the anionic detergent, sodium dodecyl sulphate (SDS) denatures 
proteins to their primary structure and confers on them a negative charge. Different 
concentrations of NuPAGE Bis-Tris precast polyacryilamide gels (Invitrogen) were 
used to resolve proteins of different molecular weights using this technique. 
Samples to be analysed under non-reducing conditions were diluted with 2X SDS 
loading buffer, (200mM Tris, 8%SDS, 0.4% Bromophenol blue, 50% glycerol). 
Samples to be analysed under reducing conditions were diluted with the same buffer 
containing 4% w/v P-mercaptoethanol. A pre-stained molecular weight protein marker 
(Invitrogen) was run in parallel with all samples. Samples were heated for 15mins at 
95'C, then electrophoresis was carried out in WAGE gels (Invitrogen) at 200V 
constant, until the gel dye had reached the end of the gel (-40mins). Detection of 
proteins was performed by Coomassie staining, silver staining and western blotting. 
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2.4.1 Coomassie Staining 
Non-specific detection of proteins was achieved using SimplyBlueTm SafeStain 
(Invitrogen, UK), that has a detection limit of 7ng total protein. After SDS-PAGE, gels 
were washed 3 times with ddH20for 5mins, then incubated with 25ml SimplyBlueTM 
SafeStain for I hour at room temperature on a shaker. Gels were then washed with 
double distilled H20(ddH20) until the gel was distained. Gels were dried using gel 
Dryer 583 (Bio-Rad, UK) for two hours. 
2.4.2 Silver Staining 
Non-specific detection of proteins was also performed using silver staining which is 
more sensitive than Coomassie staining, with a detection limit of 0.2-0.6ng of protein. 
Silver staining was performed using the PlusOneTm silver stain kit, (Amersham 
Pharmacia, UK) as per manufactures instructions. Briefly, gels were fixed in 40% 
ethanol, then sensitised, before being stained with silver nitrate, and visualisation of 
proteins bands. 
2.4.3 Western Blot 
Detection of specific proteins in an electrophoresed sample was achieved by western 
blot analysis. After electrophoresis, gels were equilibrated in transfer buffer for 15mins. 
Proteins were transferred to nitrocellulose membranes (Amersharn Pharmacia, UK) 
using a Trans-Blot Electrophoretic Transfer Cell (Bio-Rad), in the presence of ice to 
prevent overheating, and under stirring conditions to ensures equal ionic distribution. 
Transfer was carried out for 60mins at IOOV constant. After transfer, non-specific sites 
were blocked with 2.5% membrane blocking reagent (Arnersharn Pharmacia, UK) in 
PBS-T, for either I hour on a shaker at room temperature or overnight at 4'C. After 
rinsing in PBS-T, membranes were incubated for I hour with the relevant primary 
antibody diluted in PBS-T on a shaker at room temperature. Membranes were then 
washed with PBS-T for lxl5mins and 4x5mins, then incubated with secondary 
antibody linked to HRP, diluted in PBS-T for I hour at room temperature on a shaker. 
After washing as before, protein was detected with an ECL chemiluminescent kit 
(Amersharn Pharmacia, UK). Briefly, equal amounts of solutions A and B are applied to 
the membrane for Imin then the membrane is exposed to Hyper-Film (Amersharn 
Pharmacia, UK) and developed. 
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Primary Antibody Concentration Secondary Concentration 
Antibody 
Rabbit polyclonal . 1/1000 N/A N/A 
Anti-VWF-HRP 
(Dako) 
Mouse Anti-myc 115000 Goat Anti-mouse- 1/2000 
(Invitrogen) HRP (Dako) 
Mouse polyclonal 1/4000 Goat Anti-mouse- 1/2000 
Anti-ADAMTS13 HRP (Dako) 
protease domain 
Table 2.1 Primary and secondary antibodies and their concentrations used for 
western blotting 
2.5 EXPRESSION AND PURIFICATION OF ADAMTS13 
2.5.1 Expression of ADAMTS13 
Recombinant ADAMTS13 (rADAMTS13) was prepared from HEK293 cells that had 
been previously stably transfected with the full length ADAMTS13 cDNA, cloned by 
Dr James Rance into the mammalian expression vector peDNA3.1 in frame with a C- 
terminal myc/His tag. Culture of HEK293 cells stably expressing ADAMTS13 was 
performed as described in section 2.15. Cells were cultured in growth media in T175 
flasks (Nunc) and cultures were expanded until -20 T175 flasks were obtained. Growth 
media was removed from the flasks and after washing each flask twice with sterile PBS, 
25ml Optimem conditioned media was added to each flask and incubated for 3 days at 
37"C, 5% C02- Conditioned media was collected and filtered through a 0.5mm. Nalgene 
filter to remove cell debris. The conditioned medium was then concentrated to 50ml 
using the LabscaleTm TFF system (Millipore, UK) with the Pellicon XL lOkDa filter 
(Millipore, UK). 
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2.5.2 Purification of rADAMTS13 
2.5.2.1 Desalting 
Concentrated and filtered serum-free conditioned medium was desalted using a Hi 
Prepým 26/10 desalting column (Amersham. Pharmacia, UK). The desalting column 
allows the separation of high molecular weight species (>5kDa) from low molecular 
species (<I kDa) using the principle of size exclusion chromatography. The column was 
washed with 300ml ddH20, then equilibrated with 100ml of 20mM Tris-HCI, 500mM 
NaCl, 20mM imidazole, pH 7.8. Concentrated and filtered serum-free conditioned 
medium was applied to the column and the early eluted fraction were collected to be 
further purified. 
2.5.2.2 Nickel Affinity Chromatography 
The desalted media was subjected to nickel affinity chromatography using Nickel 
charged columns that bind His-tagged proteins allowing contaminants to be removed. 
Desalted media was passed over a 5ml Ni2' His trap chealting column (Amersham 
Phannacia, UK) in 20mM Tris-HCI, 500mM NaCl, 20mM imidazole, pH 7.8. Once the 
baseline had returned to zero, the column was washed with 20mM Tris-HCI, 30mM 
NaCl, 20mM imidazole, pH 7.8, then eluted with 20mM Tris-HCI, 500mM NaCl, 
500mM imidazole, pH 7.8. Eluted fractions were dialysed into 20mM Tris-HCI (pH 
7.8) using lOkDa molecular weight cut-off dialysis membranes (Pierce, UK). 
Concentration of ADAMTS13 was assessed using the BCA assay and an ADAMTS13 
ELISA (see below), purity was assessed using SDS-PAGE in 4-15% gels as earlier 
described 
2.6 ANALYSIS OF ADAMTS13 CONCENTRATION 
2.6.1 BCA Assay 
The total protein concentration was determined using a BCA total protein assay kit 
(Pierce, UK). This method is based on the ability of proteins to reduce Cuý2 to CU+' 
(cuprous ion) in an alkaline medium. The purple-coloured reaction product is formed by 
the chelation of two molecules of bicinchoninic acid (BCA) with one cuprous ion. The 
colorimetric intensity correlates with the protein concentration. Bovine serum albumin 
(BSA) was used as a standard and a series of dilutions of known concentrations (range 
15-2000[tg/ml) were prepared. Different dilutions (neat, 1: 5,1: 10) of the unknown 
sample were prepared simultaneously. 25pi of each standard or unknown sample were 
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applied in duplicate to the wells of a microtitre plate. 200ýtl of the working reagent were 
added to each well and incubated at 37'C for 30 minutes on a plate shaker. The 
absorbance was measured at 540 nm using a plate reader (iEMS Reader MF, 
Labsystems). The protein concentration of the unknown sample was determined by 
reading from the BSA standard curve. 
2.6.2 ADAMTS13 ELISA 
To more accurately determine the concentration of ADAMTS13 an Enzyme-Linked 
ImmunoSorbent Assay (ELISA) was optimised in our laboratory by Dr James Crawley. 
MaxiSorp plates (Nunc) were coated overnight at 4"C with Rabbit polyclonal anti- 
ADAMTS13 antibody, (depleted of antibodies against the ADAMTS13 TSP24 
domains) diluted to lOgg/ml in 50mM carbonate buffer (pH 9.6). After coating, wells 
were washed 3 times with PBS-T and blocked with PBS-T-2.5%BSA for I hour at room 
temperature. After blocking, wells were washed 3 times as before and 100ýd of test 
samples or Reference plasma (Technolcone) at dilutions 1: 10,1: 20,1: 40,1: 60,1: 120 
and 1: 240 were added to the wells and incubated for 2 hours at room temperature. The 
plate was then washed 3 times with PBS-T and 100gl of rabbit biotinylated anti- 
ADAMTS13 TSP24 diluted to 0.5ptg/ml in PBS-T-I%BSA was applied to the wells 
and incubated for two hours at room temperature. After washing, the wells were 
incubated for I hour with streptavidin-HRP diluted 1/1000 in PBS-T-I%BSA. After a 
final wash step, 180[il substrate (Sigma colour fast OPD tablets) was added to the wells, 
the reaction stopped with 1001A IM H2SO4, and the absorbance measured at 492nm. A 
standard curve was plotted as described for the VWF: Ag ELISA. Reference plasma 
diluted 1: 10 was taken to be 100% ADAMTS 13 with an approximate value of 100% 
I gg/ml. 
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2.7 CLEAVAGE OF FULL-LENGTH VWF BY ADAMTS13 - OVERVIEW 
Cleavage of FL-VWF by ADAMTS13 in vitro requires the presence of urea to 
presumably unfold or uncoil VWF into a confirmation suitable for cleavage, by 
exposing the ADAMTS13 cleavage site in the A2 domain, and also requires the 
presence of C2+ or Ba2+ ions to activate ADAMTS 13. The source of ADAMTS 13 used 
in the assays was either recombinant material (prepared as described in section 2.5) or 
cryo-depleted plasma (prepared from cryoprecipitation of VWF, section 2.1.1). Analysis 
of ADAMTS13 proteolysis of VWF was performed by CBA or VWF multimer gel 
analysis. 
2.7.1 Cleavage by Cryo-Depleted Plasma 
Cryodepleted plasma obtained after the cryoprecipitation of VWF was used as a source 
of ADAMTS13. The concentration of VWF and multimeric composition was 
determined using VWF multimer gels and VWF ELISA as described. ADAMTS13 
concentration was determined by ADAMTS 13 ELISA. 
50ttl of cryodepleted plasma (typical ADAMTS13 concentration of 0.8gg/ml = -4nM) 
was added to 50gl reaction buffer (50mM Tris-HCI, 375mM NaCl, 25mM BaC12) and 
activated for 20mins at 37T. 1001il high molecular weight-VWF (HMW-VWF) was 
then added to a final concentration of 5[ig/ml. Aliquots were taken for the zero time 
point, then 150gl of the reaction mixture was carefully applied to the surface of circular 
dialysis membranes (Millipore VSWP, 25mm) floating on the surface of 50ml dialysis 
buffer (0.5-4M urea in 5mM Tris-HCI, pH 8.0) contained in a 50ml plastic tube and 
incubated at 370C. Aliquots were removed at specific time points and rate of proteolysis 
assessed as described by CBA (section 2.3.2). 
2.7.2 Cleavage by Recombinant ADAMTS13 
Recombinant ADAMTS13 (final reaction concentration of 15nM) was pre-incubated 
with I OmM BaC12 for 15mins at 37"C to activate ADAMTS 13. Activated ADAMTS 13 
was then added to the reaction mixture containing 5mM BaC12,1.5M urea and 20mM 
Tris-HCI, pH 7.8. VWF was added to a final concentration of 5Pg/ml to start the 
reaction. Aliquots were taken for time point zero, and the reaction incubated at 37T 
and aliquots removed at specific time points for analysis of cleavage by CBA and VWF 
multimer gel analysis (sections 2.3.2 and 2.3.3 respectively). 
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2.8 GENERATION OF VWF PROTEOLYTIC FRAGMENTS BY TRYPSIN 
DIGESTION 
Trypsin - Bovine pancreatic type I (Sigma, UK), was dissolved in 200mM sodium 
acetate, 0.02% sodium azide, pH 7.0 to a final concentration of 4080OU/ml, aliquoted 
and stored at -20'C until use. To generate tryptic fragments, VWF was digested with 
trypsin at a final concentration of 2500U/mg VWF. In initial experiments ling of VWF 
was digested for 0-90mins at 37"C. In subsequent experiments, to generate significant 
amounts of VWF tryptic fragments, 10mg of VWF was digested for 30mins at 37"C. 
Reactions were terminated by the addition of I OOmM Aprotinin and I OOmM Soya bean 
trypsin inhibitor (Sigma, UK) and were immediately subjected to initial purification by 
ion-exchange chromatography. 
2.8.1 Ion-Exchange Chromatography 
To separate the tryptic fragments of VWF, the trypsin digest was subjected to ion 
exchange chromatography (IEC), that separates proteins/peptides on the basis of charge. 
The trypsin digestion reactions were passed through a 5ml Hi Trap Q anion exchanger 
column. (Amersham Pharmacia), that had been pre-equilibrated with 10 column 
volumes 20mM Tris-HCI, pH 7.4, at a flow rate of I ml/min. Once baseline had returned 
to zero, a gradient of 0-500mM NaC1 in 20mM Tris-HCI, pH 7.4 over 60mins, flow rate 
Iml/min was applied to elute the column. Eluted fractions were collected then dialysed 
overnight into 20mM Tris-HCI, pH 7.4. Collected, dialysed fractions were analysed by 
SDS-PAGE in 4-12% and 12% gels as previously described (section 2.4). Protein bands 
were detected by Coomassie staining or western blotting followed by probing with anti- 
VWF-HRP (section 2.4.3) or Wex europaeus as described below. 
2.8.2 H-antigen Blot 
Western blotting followed by probing with the H-antigen specific lectin, Ulex 
europaeus was performed essentially as just described (section 2.4.3) but with some 
essential modifications. Following transfer of proteins to nitrocellulose membranes, 
non-specific sites were blocked with 3% membrane blocking buffer (Amersham 
Pharmacia, UK) overnight at 4*C. Biotinylated Ulex europaeus was diluted 1/500 in 
Tris buffered saline (TBS) supplemented with divalent ions (50mM. Tris, 150mM NaCl, 
IMM M902, ImM CaC12. ImM MnC12) and 2% membrane blocking buffer and 
incubated at room temperature for 2 hours on a shaker. Membranes were washed with 
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PBS-0.5% Tween for 2xlOmins, then 7x5mins. Membranes were then incubated with 
streptavidin-HRP (Amersham Pharmacia) diluted 1/1000 in PBS-0.1% Tween and 2% 
membrane blocking buffer. After washing for lxl5mins and 4x5mins with PBS-T, 
membranes were developed as described (Section 2.4.3). 
2.8.3 N-terminal Sequencing 
N-terminal sequencing of VWF tryptic fragments was performed by Alta Biosciences, 
Birmingham. 
2.9 GLYCOSIDASE DIGESTIONS 
Modification of VWF glycan structure was performed using specific glycosidase 
enzymes to remove specific glycan structures or residues from VWF. In all experiments 
VWF was diluted to a final concentration of 100ttg/ml in 20mM Tris-HCl, pH 7-4. 
Neurarninidase (NEB, UK) at a final concentration of 0.5U was used to remove terminal 
a2-3,6,8,9 linked sialic acid residues. P-galactosidase (Calbiochem, UK) at a final 
concentration of 0.5-5U was used to remove terminal galactose residues and PNGase F 
(NEB, UK) at a final concentration of 2U was used to remove whole N-linked glycan 
chains. All digestions were performed overnight at 371C. As a control to compare the 
removal of VWF glycans under non denaturing and denaturing conditions 100gg/ml 
VWF was denatured with 1% P-mercaptoethanol for 20mins at 90'C. NP40 (NEB) was 
added to a final concentration of 10% v/v and the reaction incubated with the 
appropriate glycosidase overnight at 37C. Removal of glycans was assessed using 
SDS-PAGE in 5% gels followed by staining with anti-VWF-HRP to detect the expected 
shift in mobility and by lectin ELISA's to quantify removal of sugars. 
2.10 LECTIN ELISA 
The glycan component of VWF was assessed by sandwich enzyme-linked 
immunosorbent assay using lectins that recognise specific sugars structures. MaxiSOrP 
plates (Nunc) were coated with polyclonal anti-VWF antibodies (Dako) diluted 1/500 in 
0-05M carbonate buffer, overnight at room temperature. After washing 3 times with 
PBS-T, 100pi samples or standards were added to the wells and allowed to incubate for 
I hour at room temperature. After washing, I OOpI of the appropriate biotinylated-lectin 
(Dako) diluted in TBS supplemented with divalent ions (Tris buffered saline, ImM 
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MgC12,, ImM CaC12, I mM MnC12) at dilutions shown in Table 2.2, was added to each 
well and incubated for 2 hours at room temperature. After washing, I OOPI streptavidin- 
HRP (Amershain Pharmacia, UK) diluted 1/1000 in PBS-T was added to the wells and 
incubated for 45mins at room temperature. After a final 3 washes, 180PI substrate 
(Sigma colour fast OPD tablets) was added to the wells and the reaction stopped with 
100pl IM H2SO4. Absorbance was recorded at 492nin (UV-1601 spectrophotometer, 
Shimadzu). Concentrations of unknown samples were read from the standard curve 
prepared using dilutions of pooled normal plasma. In some experiments glycan 
modified was bound directly to the MaxiSorp plate then detected with the appropriate 
lectin. (For binding of VWF directly to the plate refer to section 2.11) 
Lectin Dilution for Dilution for Glycan target 
western blot ELISA 
Elderberry Bark 115000 115000 Terminal sialic acid 
Lectin residues 
(EBL) 
Ricinus Communis 1/1000 1/2000 Terminal galactose 
Agglutinin I residues 
(RCA-1) 
Concanavalin A 1/1000 115000 Complex N-linked 
(ConA) glycans 
Ulex Europaeus 1/2000 1/1000 H-antigen 
Agglutinin I 
able 2.2 Lectins, their targets and dilutions used for western blot and lectin 
ELISA 
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2.11 VWF: ADAMTS13 BINDING ASSAYS 
The binding of ADAMTS13 to VWF was assessed using a plate binding assay. To 
optimise coating conditions, MaxiSorp plates (Nunc), were coated with VWF 0.5- 
15ng/gl diluted in PBS or 50mM carbonate buffer, pH 9.8 and incubated overnight at 
either room temperature or 4"C. 
In subsequent experiments, plates were coated with 100[11 per well of Control VWF 
(Ctrl-VWF) or glycan altered VWF at a final concentration of 5ng/gl and incubated 
overnight at 41C. Unbound VWF was removed and after washing 3 times with PBS-T, 
wells were blocked with PBS-T-2%BSA for I hour at room temperature. After washing, 
the wells were incubated with 100gl of 1-125nM ADAMTS13 diluted in PBS-2%BSA, 
for 2 hours at room temperature with gentle shaking. Wells were then washed and 
incubated for I hour at room temperature with either, anti-ADAMTS13 TSP24 
depleted antibody diluted 115000 in PBS-2%BSA or biotinylated anti-TSP2-4 diluted 
115000 in PBS-2%BSA. Wells were then washed again and incubated with either goat 
anti-rabbit Ig-HRP (1/2000 in PBS-2%BSA) for I hour or Streptavidin-HRP (1/1000 in 
PBS-T) for 45mins at room temperature. After a final wash step, 180gl substrate (Sigma 
colour fast OPD tablets) was added to the wells, the reaction stopped with 100gl IM 
H2SO4, and the absorbance measured at 492nm. 
The absorbance values were plotted against the ADAMTS13 concentration, using 
Graph Pad Prism 4 software. The data was fitted to the equation: 
B= Bmax x [XI 
KD + [XI 
where B is the binding expressed in absorbance unit, B.. is the maximal binding when 
saturation is reached, [X] is the ligand (ADAMTS13) concentration and KD is the 
equilibrium dissociation constant. 
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2.11.1 Modified VWF: ADAMTS13 Binding Assays 
To further investigate the binding of ADAMTS13 to VWF the method used to capture 
VWF was modified to examine ADAMTS13 binding to different conformations. In the 
first modification MaxiSorp plates were coated with a monoclonal anti-VWF antibody, 
ESVWF8 (American diagnostica) that is directed against the C-terminus of VWF. The 
antibody was diluted 11500 in carbonate buffer, pH9.6 and plates were coated overnight 
at 4'C. Following removal of unbound antibody and washing with PBS-T, plates were 
incubated with 100[d per well VWF diluted to a final concentration of 5pg/ml in PBS-T 
for 2 hours at room temperature. After washing with PBS-T, ADAMTS13 was applied 
and detected as described in 2.11. 
The second modification examined ADAMTS13 binding to collagen bound VWF. 
Collagen plates were prepared as described 2.3.2 and following blocking were 
incubated with 100ýd per well VWF diluted to a final concentration of 5gg/ml for 2 
hours at room temperature. After washing with PBS-T, ADAMTS13 was applied and 
detected as described in 2.11. 
89 
2.12 GENERAL MOLECULAR BIOLOGY TECHNIQUES 
2.12.1 Agar Plates and Luria-Bertani (LB) Media ± Ampicillin 
LB media and LB agar were dissolved in ddH20 and autoclaved according to 
manufacture's instructions. Ampicillin was added to a final concentration of 100pg/ml 
once the temperature of the media was below 55"C. For agar plates 20ml of molten LB 
agar was poured into aI Ocm2 petri dish and allowed to set. LB media and LB agar was 
stored for a maximum of 2 weeks at 4*C. In some instances, blue/white screening was 
used to select positive recombinant clones. For this, 40[d of a 2% X-gal solution and 7[d 
of IPTG were spread on agar plates and allow to dry at least 2 hours before the plate 
was used. 
2.12.2 Restriction Enzyme Digests 
Restriction digests were performed using New England Biolabs restriction enzymes and 
buffers as stated in Appendix I. All digests were performed using -5ng DNA and 20U 
of the appropriate enzymes, diluted in the appropriate NEB buffer, for 2 hours at 37T. 
For restriction digests generating vector fragments to be used in subsequent downstream 
cloning applications, 5' and 3' phosphates were removed by to prevent re-ligation. For 
this, 5U of calf intestinal alkaline phosphatase (CIAP) (Invitrogen, UK) were added to 
the restriction digest reaction for the last 5mins. 
2.12.3 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used to visualise DNA fragments and separate them 
according to size. Agarose gels, 0.8-1.5%(w/v), were prepared using multi-purpose 
agarose (Bioline) in TBE buffer containing 51tg/ml SYBRTm safe DNA gel stain 
(Invitrogen, UK). The concentration of agarose depended on the size of DNA being 
separated. After dissolving the agarose, gels were poured and allowed to polyrnerise for 
20mins at 40C. Samples were diluted with loading buffer containing 40% sucrose to 
allow samples to deposit in the wells and Bromophenol blue as a tracking dye to 
monitor progressing of the samples. A lkb DNA ladder (NEB, UK) was also run 
alongside all samples. Electrophoresis was carried out at 75V constant, for 20-80mins. 
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2.12.4 Gel Extraction 
DNA bands containing desired fragments of desired material were purified from 
agarose gels using the QIAquick gel extraction kit (QlAgen, UK) as per manufactures 
instructions. Briefly, bands of interest were excised from the gel using a clean razor 
blade, weighed and solubilised with 3 volumes buffer QG for 10mins at 50'C. Once 
dissolved, Ix volume of isopropanol was added and the sample applied to the silica-gel 
column and centrifuged for Imin at 130OOrpm to bind DNA. 0.5ml Buffer QG was 
applied to the column and centrifuged for Imin to remove traces of agarose, then the 
0.75ml Buffer PE was applied to the column and centrifuged to wash the DNA. A 
further Imin spin was performed to remove all traces of wash buffer. DNA was eluted 
by the addition of 30ýtl Buffer EB and centrifugation for Imin at 130OOrpm. 
2.12.5 Ligations 
Vector and insert fragments to be ligated were visualised after gel extraction on agarose 
gels (as described) to roughly quantify the amount of DNA present and ligation was 
carried out with a vector: insert ratio of 1: 3. Vector and insert were mixed together with 
2gl 5x ligase buffer (50mM Tris-HCI, pH7.5, lOmM dithiothreitol, ImM adenosine 
triphosphate and 25lig/ml BSA), IgI T4 DNA ligase (Invitrogen) in a final reaction 
volume of 10[il, and incubated overnight at 41C. 
2.12.6 Transformations 
0.5-2gl of a ligation reaction or Plasmid were incubated with 20gi of Subcloning 
Efficiency Ma Pre-Competent cellsTm on ice for 30mins. Cells were then heat 
shocked for 20seconds at 37'C and returned to ice for 2mins. 200gl of pre-warmed SOC 
media (Invitrogen) was added to the cells and incubated for I hour at 37*C in a shaker 
at 250rpm. The cell suspension was then plated onto pre-warmed agar plates containing 
ampicillin and incubated overnight at 37"C. 
For mutagenesis reactions transformation were performed essentially the same way, but 
with the following changes: DH5a cells were replaced by XLIO-Gold ultra competent 
Ecoli cells (Stratagene) and following 30mins incubation on ice the cells were heat- 
shocked at 420C for 30 seconds. All subsequent steps remained the same. 
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2.12.7 Isolation of Plasmid DNA 
Isolation of plasmid DNA was performed using; plasmid Miniprep kits (Qiagen) for 
small scale plasmid isolation (up to 20pg DNA) and plasmid endo free Maxiprep kits 
(Qiagen, UK) for large scale plasmid isolation (up to 500gg DNA), both according to 
manufactures instructions. Both kits operate on a principle of bacterial cell lysis, 
followed by precipitation of denatured proteins, chromosomal DNA, cellular debris, 
then clean up of plasmid DNA. 
2.12.8 Site-Directed Mutagenesis 
Mutations were introduced in to VWF cDNA using the QuikChangee XL site-directed 
mutagenesis kit (Stratagene) in accordance with manufactures instructions. PCR 
reactions were performed using 2.5U high fidelity Pfu ultra DNA polymerase, 125ng of 
complementary primers containing the mutation of interest, I Ong of DNA template, IX 
reaction buffer, IOmM dNTP's and 3VI of QuikSolution in a final volume of 50pl. The 
primers used in each amplification reaction are shown in Appendix Il, with the 
introduced mutation underlined and in bold. The PCR amplification consisted of an 
initial denaturation (951C, Imin); 18 cycles of denaturation (951C, 50 sec), annealing 
(601C, 50 sec) and extension (68T, Imin per kb); and a final extension at 68T for 7 
minutes. Subsequently, PCR products were digested with IOU of Dpnl for 2 hours at 
37T, in order to remove the methylated parental DNA template that did not contain the 
desired mutation. The mutation reactions were transformed into XL-10 gold cells as 
described in section 2.12.6. 
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2.13 CLONING AND EXPRESSION VECTORS 
2.13.1 pfflueScript@ 
The pBlueScript*) 11 SK Phagemid vector (Stratagene), is a high-copy number, 3kb 
cloning vector. It contains a 21 member multiple cloning site (MCS) and contains a 
portion of the lacZ gene encoding for 131 amino acids of 0-galactosidase. As such 
blue/white screening maybe used to select recombinant clones. The presence of a 
recombinant insert in the MCS disrupts the lacZ gene, and no gene product is expressed. 
When cultured on agar plates containing X-gal the bacteria appear as white colonies. If 
the insert is not successfully inserted, the lacZ remains intact and is expressed, thus 
bacterial colonies will appear blue. The vector also contains the pUC origin that enables 
high-copy number replication in E. coli and an ampicillin resistance gene to allow for 
selection. 
pBluescriptk 11 SK (+/-) Phagemids 
f1± on 
ý: ") r, IcIIIr 
,, 
fIý -) on 
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Kpn I 
pBluescript 11 SK MCS 
3.0 kb Sac I 
\ 
-I 
pBluoscript 11 SK (+/-) Multiple Cloning Site Region 
(sequence shown S98-826) 
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Figure 2.1 pBlueScript cloning vector 
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2.13.2 pGEM-7Zf(+) 
pGEM-7zf(+) (Promega) is a 3kb cloning vector that shares the same features as the 
pBS vector. Although a IacZ gene is present in pGEM, blue/white selection was not 
used with this vector. 
Figure 2.2 pGEM cloning vector 
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2.13.3 peDNA3.1/Myc-His A(+) 
The pcDNA3.1 vector is 5.5Kb in length and it includes a cytornegalovirus (CMV) 
immediate-early promoter to drive high-level gene expression in mammalian cells, 
multiple cloning site (MCS), an ampicillin resistance gene to perform the selection of 
the vector in bacteria cells and a neomycin resistance gene to allow the selection in 
mammalian cells, a PUC origin which allows high-copy number replication and growth 
in Ecoli and a SV40 origin which allows episomal replication in cells expressing the 
SV40 large T antigen. The pcDNA vector used also contained a myc epitope to 
facilitate immunodetection, and a 6xHis C-terminal tag to allow purification. However 
these were not needed for expression of VWF, which was cloned into the Agel site, 
removing the sequence for the myc epitope and contained a stop codon, as such the C- 
terminal His tag was not expressed. 
Figure 2.3 peDNA3.1/myc-His A(+) mammalian expression vector 
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2.14 GENERATION OF FULL LENGTH VWF EXPRESSION VECTOR AND 
VWF MUTANTS 
2.14.1 Overview 
Plasmid pSVhVWF containing the full length VWF cDNA and some 5'untranslated 
sequence was a kind gift from Dr Said Enayat, (Birmingham Children's Hospital. ) To 
facilitate efficient expression of VWF and generation of VWF mutants, the full length 
cDNA was cloned into the mammalian expression vector pcDNA3.1 
Initially, the cloning vector pBlueScript (pBS) was mutated, using the mutagenesis 
primers in listed in Appendix 11, to remove the Kpnl restriction site from the multiple 
cloning site and this vector was designated pBS-kpn1 . 
Figure 2.1 shows the restriction 
sites present in VWF that were used to generate different fragments of VWF cDNA for 
the purpose of mutagenesis and cloning and the various VWF cDNA fragments that 
were generated. 
Figure 2.4 VWF restriction sites and digestion fragments 
The VWF cDNA contained in pSVhVWF is -8.7kb with the first 234bp comprising part of the 
5'UTR. Base number I is taken from the start codon. Shown on the figure are the restriction 
fragments used to prepare the final VWF construct. The 3' Agel site was introduced by PCR of 
the 3' end of the sequence described in the following section. The Xhol - KpnI fragment 
contains the sequence for residues 786-1584, encompassing the predicted A2 domain N-linked 
glycan sites at N1515 and N1574. This fragment was used to introduce mutations to prevent 
glycosylation at these sites. 
96 
2.14.2 Amplification of the 3' Terminal End of VWF 
A PCR product of the terminal 955bp of VWF was generated using primers VWFY fWd 
and VWF3' rev (Appendix II). The forward primer was designed to amplify VWF from 
base number 7487 and introduced 7 random bases followed by an XbaI restriction site 
before the start of the VWF sequence to be amplified. The reverse primer introduced an 
Agel site, followed by a SacI site then 7 random bases immediately after the VWF stop 
codon. PCR was performed using Platinum Plx high-fidelity DNA polymerase 
(Invitrogen, UK) in a reaction mixture containing IX pfx reaction buffer, 10mM 
dNTP's, 50MM MgS04,125ng of complementary primers and IOng template 
pSVhVWF DNA. The PCR amplification consisted of an initial denaturation (95C, 
2min); 27 cycles of denaturation (95"C, 30sec), annealing (53"C, 30sec) and extension 
(72"C, l5sec); and a final extension at 721C for 7 minutes. The resulting VWF3' PCR 
product was digested with Xbal and SacI then cloned into pBS-Kpnl that had been pre- 
digested and treated with CIAP, to form the vector pBS-kpnl VVvT3'. 
2.14.2 Generation of VWF Restriction Digest Fragments 
As shown in Figure 2.1 several VWF restriction fragments were generated to prepare 
the final construct. These was obtained by digestion of pSVhVWF with the appropriate 
enzymes and separated by agarose gel electrophoresis, followed by gel extraction. 
The BamHI - Sphl fragment was cloned into the BamHI and Sphl sites of 
pBS-kPnI VWF3'. The Sphl site was unique to the VWF3' PCR product that had been 
introduced into pBS, Kp, l . The resulting vector was 
designated pBS-kpnI VWF(BamHl- 
Agel). 
2.14.3 Generation of VWF Glycan Mutants 
The -2.4kb Xhol - KpnI fragment of VWF was cloned into the pGEM vector (pGEM- 
VWF(XhoI-Kpnl) and used to create mutations of VWF. The XhoI - KPnI fragment 
contained the sequence for residues 786-1584, encompassing the predicted A2 domain 
N-linked glycan sites at N1515 and N1574. Mutagenesis primers were designed to 
mutate the asparagine residues to glutamic acid residues. Three mutations were 
prepared; two single mutations, N1515Q and N1574Q and a double mutation (DM) of 
both sites. Mutations were generated using the QuikChangee XL site-directed 
mutagenesis kit (Stratagene) as described (section 2.12.8). The double mutant was 
produced by successive mutagenesis reactions. 
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2.14.4 Completion of Wild Type and Mutant VWF Constructs 
The constructs, pGEM-VWF(Xhol-Kpnl) that contained either wild type (wt) sequence 
or mutated sequences was digested with BamHI and KpnI and the resulting fragment 
was cloned into pBS-kpnI VVYrF(BamHI-Agel) that had been digested with BamHI and 
KpnI. Mutation of the KpnI site in the pBS vector was necessary to allow this step to 
occur. The resulting vectors contained the VWF DNA sequence from base pair 2951 to 
the stop codon and contained either wild type sequence or mutated sequence. 
To complete the full length VWF (FL-VWF) construct, the above vectors were digested 
with EcoRI and BarnHi and the EcoRI - BamHI (Figure 2.1) comprising the 5' end of 
VWF with some of the 5' UTR region, was cloned into the digested sites. The resulting 
vectors were designated pBS-Kpn'FL-VWF (wt, N1515, N1574 or DM) 
The final expression construct was generated by removing the FL-VWF cDNA from the 
above vectors by digestion with EcoRl and Agel and the resulting fragments were 
cloned into the EcoRl and Agel sites of pcDNA3.1/myc-His A(+). The steps used to 
generate the FL-VWF constructs are outlined diagrammatically in figure 2.2 
2.14.5 Sequencing 
All the vectors and mutations generated were verified by sequencing to ensure the 
absence of any unwanted PCR-introduced errors and to check the presence of mutations 
introduced by site-directed mutagenesis. DNA sequencing was performed at the 
Imperial College-MRC Genetics Core Facility using an ABI 3700 DNA analyser 
(Perkin-Elmer). 
2.14.6 Glycerol Stock 
To store bacteria transformed with the vector constructs, 900ýLl of the liquid culture was 
placed into 100pi glycerol (Sigma) to prevent ice crystals forming, vortexed and stored 
at -70'C. 
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2.15 CELL CULTURE 
2.15.1 General Tissue Culture 
All tissue culture was performed in a class II flow cabinet (FASTER BHG 2004, 
JENCONS-PLS) in a separate laboratory designated specifically for tissue culture. 
Aseptic technique was used at all times, and all surfaces of the flow cabinet and tubes, 
flasks etc were thoroughly cleaned with 70% ethanol. Cells lines were grown in 
humidified incubators (BIOHIT, Biological Instrumentation Service, Lancashire, UK) at 
37'C, in 5% C02. Frozen cells were kept in a liquid nitrogen container, at a temperature 
around -180"C. Cultured cells were visualised under an inverted microscope 
CK2 
(Olympus, Japan). 
2.15.2 Revival of Human Embryonic (HEK) 293T cells from Liquid Nitrogen 
HEK293T cells stored in 10% DMSO in liquid nitrogen were thawed at 37'C for Smins, 
then placed in a T75 tissue culture flask (Nunc) with 4ml of growth media [Minimal 
Essential Medium (MEM) (Sigma), supplemented with 10% Fetal Bovine Serum (FBS) 
(Biosera, UK), 5mM Penicillin/Streptomycin (Invitrogen, UK), 5mM L-Glutamine 
(Invitrogen) and Ix non-essential amino acids (NEAA, UK) (Sigma). ] Cells were 
allowed to attach for 45mins, then the media was changed to remove residual DMSO 
and dead cells. 
2.15.3 Cell Passage 
Once cells had reached 80-100% confluency they were passaged into larger culture 
flasks, or split into more flasks. Cells were washed twice with autoclaved PBS then 
detached from the flask surface with 0.5-Iml 0.25% trypsin/EDTA (Sigma). Cells were 
incubated for a maximum of 5mins at 37'C, then the bottom of the flask was tapped 3 
times to detach the cells. Trypsin was inactivated by the addition of growth media and 
cells seeded appropriately. 
2.15.4 Transient Transfection of HEK293T cells 
Transient transfection is used to produce recombinant protein in a short time period. 
The transfected DNA is not integrated into cell genome and therefore it is lost from 
cells after repeated rounds of DNA replication and cell division. HEK293T cells express 
high levels of SV40 large tumour (T) antigen, which allows episomal replication of SV- 
40 origin-containing plasmids (i. e. pcDNA 3.1). 
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Transfection of HEK293T cells with wt-VWF and VWF mutants was performed using 
lOmM polyethylenimine (PEI). A control transfection was also performed using empty 
pcDNA3.1/myc-His vector. HEK293T cells at -70% confluency were trypsinised and 
seeded onto I Ocm2 dishes at -2x 106 cells/dish in growth media till they reached 70% 
confluency. DNA solution was prepared by mixing 33gg of plasmid DNA per 10cm2 
dish with 0.625ml of sterile 150mM NaCl. The PEI solution was prepared by mixing 
75[d PEI with 0.625ml sterile l5OmM NaCl per dish. The PEI solution was then added 
drop wise to the DNA solution and allowed to incubate for 20mins at room temperature. 
During the incubation, growth media was removed from the cells and they were washed 
once with sterile PBS and once with Optimern conditioned medium (Invitrogen). 9mls 
of Optimern was then added to the cells and the DNATEI mixture was applied to the 
cells. Plates were carefully rocked to spread the transfection complex and were 
incubated for 2 days at 37T, 5% C02. The conditioned medium was collected and 
concentrated 10-fold using 100kDa cut off spin filters (Amicon). VWF concentration 
and multimer composition was determined by VWF ELISA and multimer gel analysis 
as described. 
2.16 FIXATION AND STAINING OF HEK293T CELLS FOR 
IMMUNOFLUORESCENCE MICROSCOPY 
For detection of VWF storage granules in HEK293T cells following transfection with 
VWF cDNA, transfections were performed as described in the previous section but with 
the following modification. Before the HEK293T cells were applied to the 10cm2 dish 
for transfection, sterile glass cover slips were applied to the plates and the HEK293T 
cells allowed to grow over them. 
Following transfection and 2 days incubation at 37'C, 5% C02 as described, the 
coverslips were removed and placed in 4 well plates (Nunc, UK) and washed 10 times 
with warm PBS. After washing the cells were fixed with 250pl per coverslip methanol 
that had been stored at -20*C. Coverslips were placed in a -20'C freezer for 5mins, then 
the methanol was removed with a pipette and the cells allowed to air dry for 20mins at 
room temperature. Polyclonal rabbit anti-VWF (Dako, UK) diluted 1/1000 in PBS- 
3%BSA was applied to the coverslips for 60mins, then the cells were washed 5 times 
with warm PBS. Following washing, Alexafluor 488 a-rabbit secondary antibody, and 
topro3 nuclear stain, both diluted 1/1000 in PBS-3%BSA were applied to the coverslips 
for 20mins in the dark. The coverslips were then washed 10 times with warm PBS and 
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mounted onto glass slides. Cells were visualised using a Zeiss LSM510 META 
fluorescence microscope, excitation at 488nm, emission 540nm. 
2.17 STATISTICAL ANALYSIS 
All quoted p values were obtained using the nonpararnetric Mann-Whitney U test and 
were calculated using Analyse-it for Microsoft EXCEL. 
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CHAPTER 3 
3. Effect of ABO and Bombay blood group on Plasma VWF Levels and 
Susceptibility to Cleavage by ADAMTS13 
3.1 INTRODUCTION 
As discussed, ABO blood group has a major effect on plasma VWF levels, with 
individuals of blood group 0 having levels 20-30% lower than non-0 blood groups. 
This is likely to be related to the fact that the N-linked glycans of VWF present the 
ABO(H) blood group sugars. How ABO blood group affects VWF levels is unknown, 
however evidence suggests that rate of VWF synthesis and/or secretion is not 
influenced by ABO blood group. 
Within the circulation the multimeric size of VWF is controlled by the VWF cleaving 
protease; ADAMTS13. Interestingly, an effect of ABO blood group on susceptibility to 
ADAMTS13 has been demonstrated, with blood group 0 VWF exhibiting the greatest 
susceptibility to ADAMTS 13 proteolysis. 
To further these observations, I have analysed VWF from individuals with the rare 
Bombay blood group. From Bowen's study it is apparent that loss of A/B sugars results 
in increased proteolysis by ADAMTS13. I therefore hypothesised that further removal 
of terminal sugars may increase the rate of proteolysis further. The rare Bombay 
phenotype provides an ideal reagent to investigate this since naturally altered glycan 
chains are presented due to the failure to synthesise H-antigen. 
The glycan structure of Bombay VWF was analysed with lectin ELISA and western 
blotting and plasma VWF levels were analysed by VWF: Ag ELISA and compared to a 
control group of healthy donors. Blood group specific VWF was then purified and 
subjected to ADAMTS13 cleavage to determine the effect of ABO/Bombay blood 
group on proteolysis. 
In order to assess VWF multimeric structure and analyse ADAMST13 cleavage, a 
VWF: collagen binding assay (CBA) and VWF multimer gel methods were established. 
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3.2 COLLAGEN BINDING ASSAY (CBA) 
In initial experiments a commercial CBA kit (Technoclone) was used to detennine 
collagen binding activity of plasma and purified VWF. However, this proved to be non- 
cost effective and therefore an in-house CBA ELISA was developed. 
Human type III collagen prepared from placenta by trypsin digestion (Sigma C-4407) 
was selected as the source of collagen since previous reports determined this was one of 
the most efficient types of collagen, in terms of VWF binding, commercially available. 
To detennine optimal collagen concentration for coating, MaxiSorp plates were coated 
with increasing collagen concentrations from 1ýtg/ml to 15[tg/ml, diluted in 50mM 
carbonate buffer, pH 9.2, for 24 hours at room temperature. After washing to remove 
unbound collagen, plates were blocked with 2%BSA-PBS-Tween, then incubated with 
normal pooled plasma diluted 1: 10-1: 320 and bound VWF was detected with anti- 
VWF-HRP. Optimal binding of plasma VWF to collagen, as reflected by the highest 
absorbance values and a dose response relationship between absorbance at 492nm and 
plasma dilution, was demonstrated when a collagen concentration of 5[tg/ml was used. 
(Figure 3.1) At concentrations higher than 5pg/ml the binding of VWF to collagen was 
decreased (Figure 3.1). In all subsequent experiments a final collagen coating 
concentration of 5ýtg/ml was used to prepare CBA plates 
Optimal coating time and stability of collagen coated plates was determined by coating 
plates with type III collagen for 0,2 hours, 24 hours, 48 hours, 7 days, 14 days, 21 days 
and 49 days at room temperature, then incubating with normal pooled plasma diluted 
1: 20. A small amount of binding was observed on plates coated for 2hours, however 
maximal binding was achieved when plates were coated overnight and no reduction or 
increase in binding was seen when plates were coated for up to 3 weeks, demonstrating 
that the plates were stable for at least three weeks (Figure 3.2A). After 7 weeks 
incubation, binding was greatly decreased (Figure 3.2A) Coated plates were therefore 
used within a maximum of three weeks. To determine the optimal amount of VWF to 
load on to each well, CBA plates were incubated with a total amount of VWF from 0- 
100ng. Binding was linear up to an amount of 50ng, after which binding plateaued, 
indicating the wells were saturated (Figure 3.213). To ensure the assay was sensitive to 
HMW-VWF multimers; HMW, medium MW (MMW) and LMW multimer 
preparations were standardised to the same VWF: Ag concentration and collagen 
binding analysed. The highest binding response was observed with HMW-VWF, (taken 
as 100% CBA), this response decreased for MMW-VWF (-47% CBA) and LMW-VWF 
104 
displayed minimal binding, (-9%) (Figure 3.2C). Finally, to confirm that the VWF 
interaction with collagen was specific, MaxiSorp plates were coated with 5gg/ml of, 
type III collagen, type IV collagen, (that does not bind VWF), and BSA. Plates were 
incubated with plasma diluted 1: 10-1: 320 and detected as described. Normal binding 
was seen between plasma VWF and type III collagen, however no binding could be 
detected between plasma VWF and either type IV collagen or BSA coated plates 
(Figure 3.21)). 
To calculate a value for collagen binding activity, a standard curve was prepared using 
normal pooled plasma and the % collagen binding activity (%CBA) of samples was 
deduced from the equation-of-the-line of the standard curve. To prepare the standard 
curve, Logio values were taken of the % normal pooled plasma, (i. e. 1: 10 dilution 
represented 100%; 1: 20 represented 50%) and were plotted along the x-axis. 
Absorbance of the standards was plotted along the y-axis and the equation-of-the-line 
and the Rý calculated using the "Add trendline" function in Microsoft Excel. The 
equation-of-the-line was given in the format: 
Yý MX -C 
Where: y is the absorbance value, m is the gradient of the slope, x is the %CBA and c is 
the x/y intercept. 
To calculate the %CBA of unknown samples the equation was rearranged to: 
X= (Y + C) /M 
Absorbance values (y) of the unknown samples were substituted into the equation and a 
Loglo value was obtained and converted to %CBA by use of the invLog function. 
A representative standard curve is presented in Figure 3.3. 
The coefficient of variation for both the inter and intra assay error was determined to be 
<5%, demonstrating that the assay was highly reproducible. The assay was also highly 
cost effective; costing 5 pence per sample compared to E2 per sample using 
commercially available CBA kits. 
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Figure 3.1 Optimal coating collagen concentration 
MaxiSorp plates were coated with placenta-derived human type III collagen, diluted 
from 1-15ýtg/ml in 50mM carbonate buffer, pH9.6 and incubated at room temperature 
for 24hours. After washing unbound collagen and blocking, wells were incubated with 
normal pooled human plasma diluted 1: 10-1: 320 and bound VWF was detected with 
anti-VWF-HRP. Maximal binding of VWF to collagen was observed with a coating 
concentration of 5[ig/ml. At concentration higher than 5Rg/ml, binding was decreased. 
In all subsequent assays plates were coated with 5[ig/ml collagen. 
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Figure 3.2 Collagen binding assay optimisation 
(A) Effect of coating time. MaxiSorp plates were coated with collagen for 2 hours up to 49 days, 
then incubated with plasma diluted 1: 20. A small binding response was seen with 2 hours 
coating time and maximal binding was reached after 24 coating time and remained stable for up 
to 21 days. After 49 days the binding response greatly decreased. Collagen coated plates were 
kept for a maximum of 21 days before use. 
(B) Optimal total VWF load. CBA plates were incubated with total VWF ranging from 0- 1 OOng 
and bound VWF detected as described. The binding response was linear up to a total load of 
50ng after which the wells were saturated and the binding response plateaued. 
(C) Type III collagen preferentially binds HAM- VWF. CBA plates were incubated with HMW, 
MMW and LMW-VWF standardised to the same VWF: Ag concentration. Maximal binding 
(defined as 100% CBA) was observed with HMW-VWF, decreased binding (47%) was 
observed with MMW-VWF, and minimal binding (9%) was observed with LMW-VWF- 
(D) Specific interaction of VWF with type III collagen. MaxiSorp plates were coated with 
5Rg/ml of either; type III collagen, type IV collagen or BSA diluted in 50mM carbonate buffer, 
pl-19.6 and incubated for 24hours. After washing and blocking, plates were incubated with 
plasma diluted 1: 10-1: 320 and bound VWF detected as described. VWF bound to type III 
collagen, but no binding was observed to either type IV collagen or BSA. 
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Figure 3.3 CBA standard curve 
Pooled normal plasma was used to construct a standard curve to determine %CBA of 
unknown samples. The Logl 0 value of % normal pooled plasma was taken and used to 
plot the x-axis, absorbance, values of the standards were plotted along the y-axis. 
Microsoft Excel was used to apply a line of best fit and calculate the equation-of-the- 
line and R? value. The equation-of-the-line was used to calculate a Loglo value using the 
absorbance values of the samples and %CBA determined by taking the invLog. 
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3.3 ABO(H) ANTIGEN ON BOMBAY/PARA-BOMBAY VWF 
Plasma samples from 47 individuals with the rare Bombay phenotype were collected 
(Bombay phenotype n--30, para-Bombay phenotype n--17) and the presence of H- 
antigen on VWF glycans was investigated by a semi-quantitative "H on VWF ELISA" 
and compared to the H-antigen expression on normal ABO blood group controls. 
Pooled group 0 plasma was used to generate a standard curve, with IU/ml group 0 
plasma set as IU H-antigen. Concentration of H-antigen was expressed as units of H per 
unit of VWF. The highest levels of H antigen were detected in blood group 0 samples; 
this was decreased in blood group A samples and only a small amount of H was 
detected in blood group AB samples. In Bombay individuals no evidence of H antigen 
presentation on VWF glycans was observed, confirming the Bombay phenotype of each 
sample, (Figure 3.4). Despite the fact that soluble ABH structures are found in the 
circulation of para-Bombay individuals, there was no evidence of H antigen 
presentation on VWF in this group. This observation suggests that ABH are added to 
the N-linked glycans of VWF within EC, rather than acquired in the peripheral 
circulation following secretion. Clearly both Bombay and para-Bombay phenotypes are 
thus associated with an alteration in the glycans structure of circulating VWF which is 
distinct from that observed in normal plasma VWF. 
Absence of H antigen presentation was also demonstrated by western blotting analysis 
of Bombay plasma samples. Duplicate samples of blood group 0 plasma and Bombay 
blood group plasma were run through 5% gels under reducing conditions and 
transferred to nitrocellulose membranes. Membranes were probed with anti-VWF-HRP 
to detect VWF and Ulex europaeus to detect H-antigen. Both 0 and Bombay plasma 
samples gave positive signals with anti-VWF-HRP which detected an -250kDa band, 
but only 0 plasma samples stained positive for the H-antigen with Wex europaeus 
detecting the same sized protein band. No bands were observed in the Bombay samples 
with Ulex europaeus (Figure 3.5), confirming that the H-antigen is not present on 
Bombay VWF. 
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Figure 3.4 H antigen on VWF ELISA 
The amount of H antigen on VWF was determined by ELISA and expressed as units of 
H per unit of VWF. Highest levels of H-presentation were observed on blood group 0 
VWF. No H-antigen presentation was detected on Bombay or para-Bombay VWF. 
1 
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Figure 3.5 H on VWF western blot 
0 VWF (lane 1) and Bombay VWF (lane 2) were detected in plasma by western blotting 
and probing with anti-VWF-HRP. Both samples are positive for VWF. H-antigen was 
detected by probing with the H specific lectin Ulex europaeus. 0 VWF gives a positive 
signal, demonstrating the presence of the H-antigen (lane 3), no band is detected in Bombay 
VWF (lane 4), thus Bombay VWF does not present the H-antigen. 
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3.4 VWF: Ag LEVELS IN BOMBAY PLASMA 
Plasma VWF levels of Bombay and para-Bombay plasma were determined by VWF: Ag 
ELISA and compared to a control group of healthy volunteer blood donors from 
Southampton Blood Transfusion Service (n--169: 64 group A; 18 group B; 15 group 
AB; and 72 group 0). Since H-antigen was not detected on the para-Bombay 
individuals, Bombay and para-Bombay samples were treated as one individual group. 
In keeping with previous reports, a significant effect of ABO blood group on plasma 
VWF: Ag levels was observed. Median levels were significantly lower in group 0 
individuals (median VWF: Ag = 0.78U/ml), compared to non-0. Amongst the non-0 
groups, AB individuals had highest levels, followed by group A and then group B 
(median VWF: Ag = 1.24,1.01 and 0.94U/ml respectively). (Figure 3.6) 
It was also observed that VWF: Ag levels in Bombay patients (median VWF: Ag 
0.69U/ml) were significantly lower than those observed in groups AB, A or B 
respectively (p= <0.05) Moreover, Bombay VWF: Ag levels were also lower than those 
in group 0 individuals, although this difference failed to achieve statistical significance 
p= 0.133 (Figure 3.6). 
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Figure 3.6 VWF levels in Bombay plasma 
VWF levels in Bombay plasma were determined by VWF: Ag ELISA and compared to 
normal controls. Significantly lower levels were observed in blood group 0 individuals 
compared to non-0 blood groups. Plasma levels of VWF were also significantly lower 
in Bombay patients compared to non-0 blood groups. Although Bombay VWF levels 
were lower than group 0 levels, this failed to reach statistical significance. Mean 
VWF: Ag levels are shown for each blood group. (*** p<0.001; ** p<0.01; * p<0.05, 
- p= 0.133). 
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3.5 PURIFICATION OF BLOOD GROUP SPECIFIC VWF 
To investigate the effect of ABO/Bombay blood group on cleavage of VWF by 
ADAMTS13, blood group specific VWF (from blood group AB, 0 and Bombay) was 
purified from human plasma by ethanol cryoprecipitation then gel filtered through a 
Sepharose 2B-CL gel filtration column to isolate the highest molecular weight VWF 
multimers. The column was eluted at a flow rate of Iml/min and thirty four 5ml 
fractions collected. 
In a typical purification, VWF began to elute at fractions 135-136 (Figure 3.7A). The 
early fractions eluted from the column were analysed by SDS-PAGE under reducing 
conditions and proteins were visualised by silver staining. In the early fractions (136- 
B 10) a single major -25 OkDa protein band was demonstrated, consistent with relatively 
pure monomeric VWF (Fig. 3.713). The VWF: Ag content of each fraction was assayed 
by ELISA, and multimer distribution analysed in low resolution VWF multimer gels. 
Early eluted fractions (136-1310) consisted predominantly of HMW-VWF, while later 
fractions were composed of intermediate and low molecular weight multimers 
respectively. This is illustrated by a loss of material at the top portion of the gel and the 
appearance of intermediate and low molecular weight bands (Figure 3.7Q. The typical 
VWF yield for the early eluted fractions was -I Ogg/ml. 
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Figure 3.7 Purification of blood group specific VWF from plasma 
A) Gel filtration of* cryoprecipitate. Cryoprecipitate was gel filtered through a 
Sepharose 213-CL gel filtration column to purify VWF and separate out the highest 
molecular weight VWF multimers. The column was eluted at I ml/min and 5ml fractions 
were collected. VWF began to elute from the column at fractions 135-136 and early 
fractions were analysed for purity by reducing gel electrophoresis followed by silver 
staining. B) Silver stain. Early eluted fractions (B6-B 10) demonstrated a single band at 
-250kDa consistent with pure monomeric VWF. The presence of other molecular 
species is detected in later fractions. Q Multimer analysis of eluted ftactions. Early 
eluted fractions and representative later eluted fractions were analysed in non-reducing 
low resolution VWF multimer gels as described. Early fractions (136-13 10) contain the 
highest molecular weight multimers. Later fractions eluted from the gel filtration 
contain medium to low molecular multimers. 
- 1w lw qw 
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3.6 PURIFICATION OF RECOMBINANT ADAMTS13 
Recombinant ADAMTS13 was prepared from HEK293 cells that had been previously 
stably transfected with the full length ADAMTS 13 cDNA, cloned into the mammalian 
expression vector pcDNA3.1 in frame with a C-terminal myc/His tag. (ADAMTS13 
clone was kindly provided by Dr James Rance). As described in materials and methods, 
cells were grown in T175 flasks until 20 flasks had been reached, (total media volume 
of 500ml). Expression was induced by the removal of growth media and addition of 
conditioned media. Conditioned media was collect after three days and concentrated to 
50ml using the LabscaleTm TFF system (Millipore) with the Pellicon XL lOkDa fllter. 
After desalting, ADAMTS13 was purified and concentrated by Ni2+ chelating affinity 
chromatography. Coomassie staining and Western blotting using an anti-ADAMTS13 
protease domain antibody highlighted the presence of the same prominent -190-2OOkDa 
band (Figure 3.8 - lane I and lane 2). Using an anti-myc epitope antibody revealed the 
presence of an additional but lower intensity -40kDa band. This minor species was 
believed to be a myclHis tagged C-terminal ADAMTS 13 degradation fragment that was 
co-purified with the full-length enzyme (Figure 3.8 - lane 3). 
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Figure 3.8 Purification of recombinant ADAMTS13 
ADAMTS13 was expressed by HEK293 cells stably transfected with the 
pcDNA3.1+ADAMTS13/myc-His expression vector. ADAMTS13 was purified from 
concentrated and desalted conditioned media using aN i2'-HiTrap column and 
electrophorised in 7.5% polyacrylamide gels. Lane I- Coomassie stain under non- 
reducing conditions, demonstrating a single -1 90kDa band. Lane 2&3- western blot 
analysis under reducing conditions with the anti-ADAMTS13 protease domain 
antibody and anti-myc epitope antibody, respectively. The same -1 90kDa band is seen 
in both lanes 2&3, confirming the presence of ADAMTS13. A smaller -40kDa 
species can be seen in lane 3 and represents an ADAMTS13 degradation product. 
(Figure kindly supplied by Mr Jonathon Lam) 
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3.7 CLEAVAGE OF BLOOD GROUP SPECIFIC VWF BY ADAMTS13 
To examine the effect of ABO/Bombay blood group on susceptibility of VWF to 
ADAMTS13 cleavage, purified fractions of AB, 0 and Bombay VWF, with 
comparable multimeric composition were standardised for VWF concentration and 
incubated with I OnM ADAMTS13, (that had been pre-activated with I OmM BaC12 for 
20mins at 37'C), IM urea and 20mM Tris-HCI, pH7.4. Sub samples were removed at 
specific time points, the cleavage reaction stopped by the addition of I OmM EDTA and 
ADAMTS13 cleavage assessed by CBA and VWF multimer analysis. 
In keeping with Bowen's previous observation, CBA analysis confirmed that O-VWF 
was proteolysed significantly faster by ADAMTS13 than AB-VWF, (p= <0.001) 
demonstrated by a significantly greater reduction in collagen binding at time points 
90mins; and 135mins (Figure 3.9). 
Furthermore, it was observed that Bombay VWF was proteolysed significantly faster 
than both blood group AB- and O-VWF, (p= <0.001) with no residual collagen binding 
activity remaining after 90mins incubation with ADAMTS 13. (Figure 3.9) 
This observation was corroborated by VWF multimer analysis (Figure 3.10). At time 
point zero the three VWF samples have similar multimeric composition, consisting of 
HMW multimers. After 45mins incubation with ADAMTS 13, the HMW multimers are 
lost and medium to low molecular weight multimers appear, however the extent of the 
loss of HMW multimers is slightly more apparent for 0 and Bombay VWF compared 
to AB VWF. After 90mins incubation with ADAMTS13 it is apparent that there is 
greater loss of Bombay VWF compared to 0 VWF; and greater loss of OVWF 
compared to AB VWF. 
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Figure 3.9 CBA analysis ADAMTS13 cleavage of blood group specific VWF 
AB, 0 and Bombay VWF was subjected to cleavage by ADAMTS13 and extent of 
proteolysis was analysed by CBA. After 90mins incubation with ADAMT13,0 VWF 
has been cleaved faster than AB; demonstrated by the greater reduction in collagen 
binding activity. Furthermore, Bombay VWF has been cleaved faster than 0 VWF, 
with no collagen binding activity remaining. After 135mins incubation the difference in 
collagen binding activity remains between the 0 and AB samples. (Values shown are 
the mean and standard deviation of 6 separate experiments performed in duplicate. ) 
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Figure 3.10 Multimer gel analysis of ADAMTS13 cleavage of blood group specific 
VWF 
At time point zero, the three VWF samples have comparable multimeric structure. After 
incubation with ADAMTS13 for 45mins it is apparent the Bombay VWF (Bom) is 
being proteolysed faster, illustrated by the greater loss of HMW material and the greater 
intensity of monomeric VWF compared to 0 and AB VWF. Likewise 0 VWF is being 
proteolysed faster than AB VWF. At time point 90mins, the difference between the loss 
of multimers is more apparent between the samples, with cleavage occurring in the 
order Bom>O>AB. 
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3.8 ANALYSIS OF BOMBAY VWF MULTIMERIC STRUCTURE AND 
COLLAGEN BINDING ACTIVITY 
In view of the lower plasma VWF: Ag levels, and the increased susceptibility to 
ADAMTS13 proteolysis observed in Bombay individuals, I proceeded to examine the 
VWF multimer distribution in Bombay plasma. In particular, I looked for any deficit in 
high-molecular weight multimers as seen in patients with type 2A Von Willebrand 
disease. The VWF multimer distribution of Bombay and para-Bombay plasmas was 
assessed by VWF multimer analysis in 1% agarose-SDS gels and by collagen binding 
assay. 
Plasma VWF: CB was significantly reduced in the Bombay samples (71U/ml) compared 
to normal ABO blood group controls (88U/ml for group 0), however the VWF: Ag to 
CBA ratio remained 1: 1 and was not different to other ABO blood groups (Figure 
3.1 IA). Thus the reduced plasma VWF: CB observed is solely due to the lower VWF 
levels in Bombay plasma. Furthermore, analysis of the multimeric structure of Bombay 
VWF demonstrated no loss of high molecular weight multimers; with multimer patterns 
similar to the normal control plasma. Therefore the increased cleavage of Bombay VWF 
does not alter its multimer distribution with in the circulation. 
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Figure 3.11 Analysis of Bombay VWF collagen binding and multimeric 
distribution 
A) Collagen binding qf Bombay VWF. VWF: CB was significantly reduced for Bombay 
VWF compared to normal control samples, however the VWF: Ag to VWF: CB ratio 
remained 1: 1, indicating the reduced CBA is due solely to the reduced VWF levels 
observed in Bombay individuals. B) Multimeric distribution. The multimer pattern of 
four representative Bombay samples as analysed in 1% agarose multimer gels are 
shown. No loss of high molecular weight multimers is apparent in the Bombay samples 
compared to the two normal controls. 
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3.9 VWF GLYCANS, CONFIRMATION AND ADAMST13 PROTEOLYSIS 
Since an effect of blood group on the rate of proteolysis was observed between AB, 0 
and Bombay VWF, it was hypothesised that changes in VWF glycans structure alter the 
conformation of VWF, such that accessibility to the ADAMTS13 cleavage site with the 
A2 domain is affected. To investigate this hypothesis VWF cleavage assays were 
repeated using cryodepleted plasma as the source of ADAMTS13. Cleavage assays 
were performed as described (Materials and Methods, section 2.7.1) using a range of 
urea concentrations (0.5-4M) and cleavage of VWF analysed by CBA. As the urea 
concentration increased from 0.5M to 2M, a significant increase in the rate of 
proteolysis was observed for each of the different blood groups studied (groups AB, 0 
and Bombay respectively). In the presence of 4M urea, proteolysis of HMW-VWF by 
ADAMTS13 was inhibited. At all concentrations of urea studied (<4M), Bombay VWF 
was proteolysed faster than either groups 0 or AB respectively. However this difference 
in susceptibility to ADAMTS13 proteolysis was most marked at IM urea. As the 
concentration of urea progressively increased, the difference between AB, 0 and 
Bombay became less apparent suggesting that with increased unfolding of VWF the 
ABO effect is diminished. This suggests that the ABO antigens may alter accessibility 
of ADAMTS13 to the cleavage site by altering the conformation of the VWF molecule. 
Next page - Figure 3.12 Effect of increasing urea concentration on susceptibility of 
blood group specific VWF to ADAMTS13 proteolysis 
Blood group specific VVvT was subjected to ADAMTS13 proteolysis using 
cryodepleted plasma as the source of ADAMTS13. As the urea concentration increased 
from 0.5-2M the overall rate of proteolysis increased, demonstrated by the greater loss 
of CBA at time 90mins with increasing urea concentration. At all urea concentrations 
Bombay VWF is proteolysed faster than 0 VWF, that is proteolysed faster than AB 
VWF. The effect is most obvious using IM urea. However with increasing urea 
concentration the difference in the rate of cleavage observed between blood groups is 
diminished. 
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3.10 DISCUSSION 
3.10.1 Optimisation of Collagen Binding Assay and Multimer Gels 
In order to assess the multimeric nature of VWF it was essential to optimise two 
methods; VVYT: CB and VVvT multimer analysis. 
In early experiments a commercial CBA kit manufactured by Techonclone was used to 
measure VWF collagen binding; however the assay proved to be unreliable and was non 
cost effective, with each sample costing -E2 to analysis. Thus an in-house VWF CBA 
ELISA assay method was developed. 
Type III collagen prepared for human placenta by trypsin digest, manufactured by 
Sigma-Aldrich UK, was selected as the collagen source. This was based on previous 
reports, that had demonstrated this particular type of collagen preparation was highly 
efficient at binding VWF in a dose dependent manner. 155,325-328 
Coating conditions were investigated by coating plates with various dilutions of 
collagen in carbonate buffer. In keeping with previous studies optimal coating of 
MaxiSorp plates was achieved with a low collagen concentration of 5ýLg/ml, as 
demonstrated by the highest amount of VWF bound. 328 This most likely reflects optimal 
spacing of collagen molecules on the surface of the plate for VWF binding at this 
concentration, at higher concentrations, optimal spacing of collagen cannot occur and 
therefore VVvT binding is decreased. 328 
Optimal coating time was also investigated because several studies have reported 
problems with coating conditions and times with long incubation times needed to fully 
coat plates with collagen. As figure 3.2A showed, optimal binding of VWF to collagen 
occurs after a collagen coating time of 24 hours and the plates remain stable for >21 
days, with no decrease in VWF: CB. The assay was also able to effectively distinguish 
between different VWF multimer sizes, with as expected, the highest molecular 
multimers giving the best binding response. This was essential if the assay is to be used 
to assess VWF cleavage by ADAMTS13. The specific nature of the VWF-type III 
collagen interaction was investigated by coating plates with type III collagen, BSA and 
type IV collagen, that does not bind VWF. As figure 3.21) shows no binding of VWF to 
either BSA or type IV collagen was detected. Finally the intra and inter experimental 
error were both <5%, demonstrating that the assay was highly reproducible. Therefore 
the assay was suitable to use for the analysis of VWF multimeric composition and to 
assess ADAMTS 13 cleavage of VWF. 
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3.10.2 Multimer Analysis 
VWF multimer analysis is used to visualise the multimeric nature of VWF. Although 
less sensitive than the CBA and one can not easily extrapolate a numerical result for 
statistical analysis, they do provide a good corroboration of any observations made with 
collagen binding methods. 
VWF multimer analysis is a technically demanding method, with no standardised 
protocol. The gold standard of VWF multimer analysis is often considered to be the 
method of Enayat and Hill, using a horizontal electrophoresis system and visualisation 
of VWF multimers with radioactive iodine (1125 ), however this is only performed in a 
few specialised centres. 78 Typically, the method will vary from lab-to-lab, but normally 
samples are electrophoresed in a non-reduced state through agarose gels in horizontal 
electrophoresis systems, with gels cast using in house apparatus and separate stacking 
and running gels. VWF multimer bands maybe visualised by autoradiography, 78,329 
330-333 334,335 peroxidise mediated staining, or luminography. The method can be time 
consuming, with the whole process from casting the gel to final visualisation of VWF 
multimer bands, taking up to 5 days. A number of disadvantages exist with horizontal 
electrophoresis systems; horizontal systems are prone to perturbation by temperature 
fluctuations, nonuniformity in the field strength of the current, evaporation and 
condensation and electroendoosmotic effects causing compression of the gel that 
effectively alters the agarose concentration. Furthermore, the use of separate stacking 
and running gels requires the formation of a binary gel in which the junction between 
stacking and running gel is often poorly formed due to the formation of a film at the site 
where the running gel is sliced before application of the stacking gel. 
In initial attempts at VWF multimer analysis, a horizontal gel system was used, 
however this proved to be unsuccessful, with the quality of gels being poorly 
reproducible and the method highly time consuming for the number of samples it was 
possible to analyse. To overcome this a multimer gel was optimised combining two 
published methods that used vertical gel electrophoresis systems. 336,337 Based on these 
studies a method was developed where vertical mini-gels were cast without the need for 
separate stacking and running gels using a Tris-glycine-SDS buffer. Electrophoresis of 
the samples normally took -3 hours with the buffer temperature kept between 10- 1 6'C. 
Following electrophoresis, western blotting was performed has as been described 
previously for high molecular weight proteinS338 and following blocking of non-specific 
sites, membranes were probed with anti-VWF-HRP and visualised with ECL 
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chemiluminescent kit (Amersharn). The method was highly reproducible and could be 
completed in less than a day, fin-thermore up to 20 samples could be analysed under the 
same experimental conditions, making the method highly time efficient. Although this 
method would require further optimisation for the use in a diagnostic environment, for 
the purpose of analysing basic VWF multimer structure and cleavage of VWF by 
ADAMTS 13, it was highly effective. 
3.10.3 Plasma VWF levels and the Bombay Phenotype 
A well established association has been recognised between ABO blood group and 
plasmas VWF levels, with individuals of blood group 0 having plasma VWF levels 25- 
30% lower than those of non-0 blood groups (A, B and AB). The physiological 
mechanism by which ABO blood group affects VWF levels is unknown, however the 
ABH antigenic determinants have been identified on the N-linked glycans of plasma 
VWF according to the blood group of the individual. Despite the fact that these different 
blood group antigens are expressed on a minority of the N-linked chains of plasma 
VWF, and that they differ only with respect in regards to a single sugar moiety, they 
significantly influence plasma VWF: Ag levels. To further explore this observation, 
samples were collected from 47 individuals with the rare Bombay / para-Bombay blood 
group. 
The Bombay blood group was first identified by Bhende et al in three unrelated 
individuals in Mumbai, (formerly Bombay) in 1952, who failed to present H-antigen on 
the surface of their red blood cells and had plasma antibodies that could react with the 
O(H), A and B antigens. 339 The failure to present H antigen is due to mutations of the H 
gene (FUTI) and of the Se gene (FUT2) that encode distinct al-2 fucosyltransferases. 
340 
The H gene regulates the expression of H antigen on red blood cells, 341,342 and the Se 
gene regulates the expression of H antigen in the gastrointestinal tract and in 
343 secretions. Individuals with the true Bombay phenotype are homozygous for null 
alleles at both the H and SE gene loci and therefore do not present H antigen on the 
surface of red blood cells and do not secrete H antigen. 339,343 Individuals with the para- 
Bombay phenotype are homozygous for null alleles at the H locus but have at least one 
functional SE allele; 343,344 such that H-antigen is found in their secretions. 
The frequency of the Bombay and para-Bombay phenotypes is low; -1 per million 
individuals in Europe is affected34' although higher frequencies are observed in Japan, 
(I in 300,000) India, (I in 10,000) and Taiwan (I in 8000, para-Bombay). 346,347 Neither 
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phenotype appears to confer any deleterious effects, except in circumstances requiring 
blood transfusion, where Bombay and para-Bombay individuals are incompatible with 
all donors except other H-deficient individuals. 343 
Analysis of plasma VWF of individuals with the Bombay and para-Bombay phenotype 
confirmed the failure to express the H-antigen, with both lectin ELISA and western 
blotting confirming the H-antigen was not presented on VWF. This was compared to 
normal ABO blood type samples that did present the H antigen and also demonstrated 
by lectin ELISA and western blotting. The observation that no H on VWF expression 
was found in para-Bombay individuals in spite of the fact that soluble ABH structures 
are secreted into their circulation, 343 indicates that ABH sugars are added to the N- 
linked glycan chains during the extensive post-translational modifications that VWF 
undergoes in EC prior to secretion. (Since no H antigen was detected on VWF from 
either Bombay of para-Bombay individuals, it was decided to treat them as one single 
group, referred to as Bombay. ) 
Quantification of plasma VWF levels in the Bombay samples compared to normal ABO 
controls, confirmed the observation that plasma VWF levels are generally lower in 
blood group 0 individuals, and furthermore it was observed that VWF levels in the 
Bombay individuals were significantly lower than levels in the non-0 blood groups. 
Although VWF: Ag levels were also lower in Bombay individuals compared to 
individuals of group 0, this result failed to achieve significance. 
It is still unclear how the ABO(H) sugars influence plasma VWF levels. However, since 
the FUTI and FUT2 loci responsible for the Bombay/para-Bombay phenotypes are 
located on chromosome 19, distinct from the ABO locus on chromosome 9, the effect is 
likely be due to a functional effect of the ABH antigen presentation, rather than rather 
than linkage-disequilibrium between the ABO locus and another unidentified VWF 
regulatory locus. 320 Current data also suggests that the effect is not due to an influence 
on the rate of VWF synthesis and /or secretion, although this has been difficult to 
investigate since VWF synthesised in vitro has a different glycan structure to that of 
plasma VWF, particularly in that in vitro synthesised VWF fails to present the ABO(H) 
sugars. 348,349 However, ABO blood group status has no effect on plasma levels of the 
VWF propeptide, which is released in a 1: 1 ratio with VWF; 350 no effect is observed on 
platelet VWF, that does not present the ABO sugarS35 1, and finally ABO does blood 
group does not influence the rate of VWF secretion from the regulated pathway 
352 following DDAVP administration. It therefore seems likely that the ABO effect is 
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mediated by proteolysis and/or secretion. The interesting observation that ABO blood 
group altered susceptibility to cleavage by ADAMTS13 was therefore investigated 
using Bombay VVvT. 
3.10.4 ADAMTS13 Proteolysis of Blood Group Specific VWF 
Ethanol cryoprecipitation and gel filtration was used to purify blood group specific 
VWF from AB, 0 and Bombay plasma. Cryoprecipitation exploits the fact that VWF is 
a cold insoluble protein and thus proteins (including VWF) that precipitate out of 
353 solution during thawing from -80T to 40C are isolated for further purification. The 
factors governing the cryoprecipitation of VWF are unknown, however it has been 
demonstrated that fibronectin needs to be present in the plasma for efficient 
354 cryoprecipitation. Gel filtration or size exclusion chromatography separates proteins 
on the basis of size; larger proteins are unable to enter the gel filtration matrix and are 
eluted from the column first, smaller proteins are able to enter the matrix and thus their 
passage through the column is retarded and they are eluted in later fractions. A large 
Sepharose 2B-CL column was used to separate out the highest molecular VWF 
multimers and as shown the earliest eluted fractions contained the highest molecular 
weight VWF, which was demonstrated by silver staining to be free of contaminants. 
Bowen (2003) recently reported that VWF of different ABO blood groups exhibited 
different susceptibility to specific cleavage by ADAMTS 13 (0 ý: B>Aý: AB). 324 
In this study, cleavage of blood group specific VWF with ADAMTS13 and subsequent 
analysis with CBA and VWF multimer gels, confirmed that 0 VWF was proteolysed by 
ADAMTS13 faster than AB VWF and extended this observation to include Bombay 
VWF, which was proteolysed faster than both 0 VWF and AB VWF. The exact 
mechanism by which glycosylation and the presence of ABO blood group sugars can 
influence susceptibility of VWF to cleavage by ADAMTS13 remains unknown and 
forms the subject of further investigation in the preceding chapters. 
A previous study observed an inverse correlation between H antigen expression and 
VWF levels. O'Donnell et al (2002) demonstrated that H antigen expression was 
highest in group 0 individuals, and in group A individuals was inversely correlated with 
A transferase expression, such that H-antigen expression was highest in the order 
A20 I >A1O1>A1A1.322 (Since A transferase expression is highest in AIAI individuals. ) 
A correlation was also observed between H antigen expression and VWF levels in 
group 0 individuals, with increased amounts of H antigen resulting in lower VWF 
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levels. It was suggested that the expression of the terminal fucose moiety (i. e. H 
antigen) was responsible for the variation in VWF levels, with higher levels of H 
resulting in lower plasma VWF levels, and this was possibly mediated through 
accelerated clearance via a fucose-mediated mechanism. 322 Indeed distinct hepatic 
286,355 fucose receptors have been characterised. However, since plasma levels were 
lower in Bombay individuals, that do not present terminal fucose residues, it seems 
unlikely that terminal fucose presentation is responsible for determining plasma VWF 
levels. From the data I have obtained however, it is possible to draw an indirect 
relationship between oligosaccharide chain length and the susceptibility to cleavage by 
ADAMTS13. Moreover the length of the glycan chain correlates with plasma VWF 
levels - so that levels are highest in group AB, intermediate in groups A and B, lower in 
group 0 and lowest in Bombay. This hypothesis also fits with previous observations 
regarding the dosage effect of ABO genotype on the amount of ABH expressed per unit 
VWF (AAl > A101 > A201 > 0101). 319,320,322 
How the length of the glycan chain may affect ADAMTS13 proteolysis is unclear. One 
hypothesis is that the glycan structures affect the conformation of VWF; with Bombay 
and 0 VWF, that have the shortest glycan chains, being able to adopt a conformation 
more permissive to ADAMTS 13 cleavage. Glycosylation is known to directly affect 
protein folding and thus the glycans of VWF may play an important role in mediating 
and maintaining the tertiary structure of VWF. 
To investigate this, cleavage of AB, 0 and Bombay VWF by ADAMTS13 was repeated 
using increasing urea concentrations to "open up" VWF and mimic the effect of shear 
stress that VWF is subjected to in vivo. With increasing urea concentration the overall 
rate at which WVF was proteolysed by ADAMTS 13 was increased, suggesting that 
with increasing urea concentration more VWF molecules adopt a confirmation apt to 
ADAMTS13 cleavage. The ABO effect on cleavage was most pronounced at IM urea, 
but with increasing urea concentration the difference between the groups was 
diminished. This provides support to the hypothesis that the tenninal VWF sugars alter 
the permissiveness of the molecule to ADAMTS 13 cleavage. 
How this effect on susceptibility to ADAMTS13 proteolysis is translated into a 
quantitative effect on plasma VWF levels remains unclear. However it is interesting that 
despite the increased rate of cleavage, plasma multimer analysis in Bombay individuals 
appeared normal. Although the collagen binding activity of Bombay VWF was 
significantly lower than normal, the CBA to VWF: Ag ratio was normal (1: 1), indicating 
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that the lower CBA was due to the lower VWF: Ag level. Furthermore, plasma multimer 
distribution was normal in the Bombay plasmas. This apparent paradox between an 
increased susceptibility to ADAMTS13, yet normal plasma multimer distribution, has 
previously described in association with the Tyrl584Cys polymorphism of VWF. 356 
Although this polymorphism does not result in any VWD like phenotype, it was 
demonstrated that it conferred an increased susceptibility to ADAMTS13 cleavage but 
still retained normal multimer distribution. 356 Once again, this polymorphism may result 
in a VWF molecule that is more readily able to adopt the confirmation required for 
ADAMTS13 cleavage. 
How these observations are integrated in vivo remains to be explored. Increased 
proteolysis alone is unlikely to be the sole mechanism for the differences observed in 
VWF levels between blood groups. However, the lower levels in combination with the 
increased rate of proteolysis does none the less suggest that there is a link between 
proteolysis and clearance. However the relationship between ADAMTS 13 cleavage, 
VWF multimer size and rate of clearance has yet to be established. 
In conclusion, the results presented in this chapter demonstrate that plasma levels of 
VWF in Bombay individuals are significantly lower than levels observed in non-O 
blood groups and are also lower than levels observed in blood group 0. Bombay VWF 
is also more susceptible to cleavage by ADAMTS13 than 0 VWF, which is more 
susceptible to ADAMTS13 cleavage than AB VWF. It is hypothesised that the altered 
propensity to ADAMTS13 cleavage is due to the size of VWF glycan chain affecting 
the ability of VWF to adopt a conformation permissive for ADAMST13 cleavage. This 
hypothesis is pursued in Chapters 5 and 6 by making further modifications to the VWF 
glycans. 
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Chapter 4 
4. ANALYSIS OF VWF GLYCAN STRUCTURE 
4.1 INTRODUCTION 
Based on its primary amino acid structure, the VWF monomer is predicted to contain a 
number of N-linked and 0-linked glycosylation sites. Although there has been some 
detailed chemical analysis of the overall structure of the glycans, chains; in particular the 
observation that the N-linked glycans present the ABO(H) sugars, a number of 
questions remain unresolved. For example, it is not known which specific sites present 
the blood group sugars and indeed, if all the predicted sites are occupied by glycan 
chains. Furthermore, Matsui et al's original analysis of the N-linked glycans does not 
give information about their sialylation status. 
The observation that VWF glycans present the ABO(H) sugars is particularly pertinent 
with regard to the results presented in the previous chapter. Given the demonstrated 
ABO effect on ADAMTS13 cleavage and the proximity of two predicted N-linked sites, 
N1515 and N1574, to the ADAMTS13 cleavage site at Y1605MI606, it becomes 
critical to know whether these sites are glycosylated and if they present blood group 
sugars. Presence of the ABO(H) sugars at these sites may illuminate the potential role of 
these glycans in mediating susceptibility to ADAMTS 13 cleavage. 
To further analyse the glycan structure of VWF, the primary VWF protein sequence was 
analysed using neural network algorithms to predict the probability of potential 
glycosylation sites being occupied. Furthermore, parts of the human VWF protein 
sequence were aligned with the VWF sequence of other species and with other proteins 
sharing homologous domains. Proteolytic fragments of purified VWF were generated 
and sequenced and analysed for the presence of glycan chains and the ABO blood group 
sugars. 
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4.2 INSILICO ANALYSIS OF VWF GLYCAN STRUCTURE 
4.2.1 Prediction of 0 and N-linked Glycosylation Sites in VWF 
The NetOGlyc and NetNGlyc algorithms use a jury of artificial trained neural networks 
to predict the probability of a potential 0- or N-linked glycan site being occupied based 
on the amino acid sequences surrounding the potential site. The algorithms are available 
from: 
httD'//www. cbs. dtu. dk/services/-NetOGly - 0-linked glycosylation prediction 
http: //www. cbs. dtu. dk/services/NetNGly - N-linked glycosylation prediction 
In both programmes potential sites are assigned an 0 or N-linked glycosylation 
potential score, ranging from 0 to 1. The value of 0.5 is deemed to be the threshold 
value, over which, sites are likely to be occupied. 
0-finkedglycosylation 
Based on the basic amino acid structure, known rules governing O-linked glycosylation 
and initial observations made by Titani et al, 16 VWF is predicted to contain 10 O-linked 
glycan chains: T1248, T1255, T1256, S1263, T1468, T1477, S1486, T1487, T1679, 
T2298. 
The results of the NetOGlyc analysis gave positive (over the 0.5 threshold) scores for 5 
sites; T1248, T1468, T1477, T1679, T2298, furthermore a 6th additional O-linked site 
was predicted to occur at T 185 9, this site was not predicted to be occupied based on the 
primary amino acid sequence of VWF. (Figure 4.1) 
Sites T1255, T1256, S1263, S1486, T1487 are all predicted to fall below the 0.5 
threshold value and as such may not be occupied by an O-linked glycan chain. (Figure 
4.1) 
N-linked glycosylation 
Based on the basic amino acid structure, the pro-VWF monomer is predicted to contain 
sixteen N-linked glycosylation sites, four sites within the propeptide; N99, N156, N211 
and N666 and twelve sites within the mature subunit; N857, N1147, N1231, N1515, 
N1574, N2223, N2290, N2357, N2400, N2546, N2585, N2790. 
The results of the NetNGlyc analysis gave positive scores for 13 sites; N99, N156, 
N21 1, N666, N857, N1231, N1515, N1574, N2223, N2357, N2400, N2585, N2790. 
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Sites, N2290, N2546, N2635 were all given values lower than 0.5, indicatifig that these 
potential sites may not be utilised. (Figure 4.2) 
As mentioned (Introduction, Section 1.14.1), there are exceptional cases where 
glycosylation can occur at the sequence N-X-C. 230 Within the primary VWF sequence 
there are nine potential N-X-C sites that could be glycosylated, two in the propeptide, 
N368 and N819, and seven in the mature subunit: N847, N1147, N2210, N2416, 
N2526, N2531 and N2625. To predict glycosylation at these sites, the NetNGlyc 
algorithm was used to predict the potential glycosylation status of all asparagine 
residues with in the VWF sequence. 
The results of the prediction returned positive scores for; N368, N819, N847, NI 147, 
and N2526. A borderline score of exactly 0.5 was obtained for site N2210. Therefore 
there is the potential for these sites to be occupied by an N-linked glycan chain. 
Sites; N2416, N2531 and N2625 all returned below threshold scores and are highly 
unlikely to be glycosylated. 
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4.2.2 Alignment of VWF A2 Domain Sequences 
As discussed, two of the predicted N-linked glycan sites occur with in the VWF A2 
domain in close proximity to the ADAMTS 13 cleavage site; N 1515 and N 1574 and the 
NetNGlyc prediction server gave positive scores for both sites. Thus both sites are 
likely to be occupied. To further investigate this, a protein sequence alignment was 
performed to align the human VWF A2 domain sequence against 58 other species with 
known VWF A2 domain sequences. Sequences were obtained from the Swiss-Prot 
protein database, (available at http: //www. expasy. orv, /cizi-bin/sprot-search- 
de? von%20willebrand%20factor) and were aligned using AliBee Multiple Alignment 
(available at http: //www. genebee. msu. su/services/malign reduced. html) 
The sequence alignment shows that the VWF A2 domain is highly conserved with 
>80% homology between species. (Figure 4.3) Furthermore the two glycosylation sites 
N 1515 and N 1574 are highly conserved. The N 1515 site, (highlighted blue) is present in 
all but three of the sequences analysed and the N1574 site (highlighted yellow) was 
present in the all the sequences (Figure 4.3). It is also interesting to note that the two 
amino acids downstream, and the three amino acids upstream of the N1574 N-linked 
glycan triplet sequon are also conserved throughout the 59 analysed VWF A2 domain 
sequences, suggesting that conservation of these sites may be important in enabling 
efficient N-glycosylation of N 1574. (Figure 4.3). 
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4.3 EXPERIMENTAL ANALYSIS OF VWF GLYCAN STRUCTURE 
4.3.1 Purification of VWF from Haemate P- Gel Filtration 
In order to analyse the glycan content of VWF in more detail, a large quantity of highly 
pure VWF was required. To obtain this, VWF was purified from a commercial VWF- 
FVIII concentrate; Haemate P. This concentrate is reported to contain the highest 
content of HMW VWF multimers and has been shown to have a multimer pattern 
resembling normal human plasma. 357,358 
Lyophilised Haernate P was resuspended in 10mls of ddH20, then gel filtered through a 
Sephacryl 400 gel filtration column. The column was eluted at a flow rate of Iml/min 
and Sml fraction were collected. Protein began to elute from the column typically at 
fraction B6. (Figure 4.4) Early eluted fractions and selected later fractions were 
analysed by SDS-PAGE under reducing conditions in 4-12% gels and protein bands 
were visualised by Coomassie staining. Fractions B6-DI2 demonstrated a major 
250kDa band, consistent with monomeric VWF. (Figure 4.4) To remove contaminating 
proteins and to concentrate the VWF samples, fractions B6-DI2 were pooled and 
further purified using Heparin-Sepharose affinity chromatography. 
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Figure 4.4 Gel filtration of Haernate P 
Haernate P was gel filtered through a Sephacryl 400 gel filtration column and 5ml 
fractions were collected. Protein began to elute from the column typically at fraction B6 
(Top frame). Early eluted fractions and selected later fractions were analysed using 
reducing SDS-PAGE in 4-12% gels followed by Coomassie staining (Bottom frame). 
Fractions B6-1312, demonstrating a major 250kDa band consistent with monomeric 
VWF, were pooled and VWF was further purified by Heparin-Sepharose 
chromatography. 
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4.3.2 Purification of VWF from Haemate P- Heparin-Sepharose Chromatography 
To obtain pure, concentrated VWF, the gel filtered Haernate P was passed over a 
Heparin-Sepharose column. In initial experiments, the sample was applied to a Iml 
Heparin fast flow column (Amersham) at a flow rate of 2ml/min. The final yield of 
VWF, although pure, was quite low. To increase the recovery of VWF, a SK-16 
chromatography column was packed with 30mls of Heparin-Sepharose-6-fast-flow 
according to manufacturers instructions and gel filtered Haemate P was applied to the 
column at a VWF final concentration of 2mg/ml using flow rates; 0.4,0.8 and 
1.6ml/min. The greatest recovery of VWF (-94%) was achieved using a column 
loading flow rate of 0.4ml/min. (Figure 4.5) 
For subsequent purifications, the total B6-D12 gel filtered Haemate P pool, was passed 
over the 30ml Heparin-Sepharose column at flow rate of 0.4ml/min. After loading the 
sample and allowing baseline to return to zero, the column was eluted with 300mM 
NaCl at a flow rate of Iml/min. In a typical purification five fractions of -10ml were 
collected, typically the first 3 fractions contained the majority of the VWF. (Figure 
4.6A) 
VWF concentration was determined by VWF: Ag ELISA; with typical yields of 
-350gg/ml. Purity was assessed by SDS-PAGE in 4-12% gels, followed by Coomassie 
and silver staining (Figure 4.6 B&Q 
With Coomassie staining the major 25OkDa band was visible, as were the two 
ADAMTS13 cleavage products at 176 and 140kDa. (Figure 4.613) Silver staining 
confirmed the purity of the sample, with the observation of the major 250kDa band and 
the smaller ADAMTS13 cleavage product bands. A band of -I OOkDa was also seen on 
the silver stain, this may represent the VWF propeptide. (Figure 4.6C) Interestingly, it 
was also possible to clearly see that the major 25OkDa band is a doublet. (Figure 4.6C) 
The reason for this is unknown, however the two bands may represent VWF with 
differing glycosylation patterns. Normally when the doublet band is observed, the band 
of the highest molecular weight represents the major species. The multimeric 
composition of the samples was analysed by VWF multimer analysis. (Figure 4.61)) 
The flow through fractions contained a small quantity of low molecular weight 
multimers, and the eluted fractions were comprised of mainly high to medium 
molecular weight multimers. 
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Figure 4.5 Effect of sample loading flow rate on VWF recovery from a Heparin- 
Sepharose column 
A total of 2mg/ml of VWF was loaded on to a 30ml Heparin-Sepharose column at flow 
rates 0.4,0.8 & 1.6ml/min and eluted at Iml/min. The greatest recovery of VWF was 
obtained using the slowest flow rate of 0.4mi/mins. 
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Figure 4.6 Heparin-Sepharose purification of gel filtered Haeniate P 
Pooled fractions 136-1312 of gel filtered Haernate P were passed over a 30ml Heparin-Sepharose 
column and the column eluted with 300mM NaCl. Three fractions, A3-A5 were analysed for purity 
by reducing SDS-PAGE followed by Coomassie staining (gel B) and silver staining (gel C). In both 
cases only the major 250kDa band and the 176kDa and 140kDa ADAMTS 13 cleavage products are 
present, indicating the fractions are of high purity. A fifth band is also seen on the silver stain at 
-100kDa and most likely represents the VWF propeptide. The multimeric pattern was determined 
using VWF multimer analysis (gel D). The flow through fractions contained a small number of low 
molecular weight multimers, whilst fractions A3-A5 contained the highest to medium molecular 
weight VWF multimers. 
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4.3.3 Preliminary Glycan Profile of VWF N-linked Glycans 
A detailed analysis of the N-linked glycan structures of VWF was performed by Matsui 
et al on de-sialyated fragments using chemical techniques. 23 Oligosaccharides were 
liberated from VWF by hydrazionolysis and subjected to enzymatic and chemical 
separation and microsequencing. The majority of the N-linked glycans, as previously 
described, were the complex type with the majority (78.2%) being the bi-antennary type 
and of these, -13% terminated in ABO blood group sugars. 23 Matsui et al also noted a 
small minority (0.8%) of high mannose structures. 23 Whilst this study provides useful 
data, it does not give any information on the sialylation status of the glycans and 6% of 
the isolated chains were too complex to analyse with the methods available. 
Furthermore no information is given on what specific glycan structures are present at 
specific sites. 
To further analyse the N-linked glycans of VWF a preliminary mass spectrometric 
profile was obtained of N-linked glycans released from VWF by digestion with PNGase 
F. (This data was kindly provided by Dr James O'Donnell) 
The preliminary results confirmed that VWF N-linked glycans present the ABO blood 
group sugars and indicated that approximately half of the biantennary glycans are non- 
sialyated and up to 40% of the biantennary glycans carry the ABO antigens. In addition 
the number of high mannose structures is considerably greater than that reported by 
Matsui et al (Figure 4.7). 
Next page - Figure 4.7 Preliminary glycan profile of VWF N-linked glycans 
A preliminary analysis of VWF N-linked glycans was obtained by release of N-linked 
glycans by PNGase F digestion and purification followed by mass spectrometric 
profiling. Selected glycan structures are labelled - High mannose, H and A antigens, 
biantennary disialylated and biantennary non-sialylated. 
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4.3.4 Presence of H-antigen on the ADAMTS13 Cleavage Products of VWF 
Although the blood group sugar determinants have been demonstrated to be presented 
on the N-linked glycans of VWF, it is not known which specific N-linked sites are 
modified with the ABH sugars. Matsui et al estimated that - 13% of the N-linked chains 
presented blood group structures, suggesting that only a limited number of sites were 
modified in this way. It remains to be established if only certain sites present the ABO 
sugars or if they are distributed throughout the N-linked glycans. 
ADAMTS13 cleavage of VWF results in two cleavage products of 140kDa and 
176kDa. The 140kDa fragments contains N-linked sites: N857, N 1147, N 123 1, N 1515 
and N1574. The 176kDa fragment contains sites: N2223, N2290, N2357, N2400, 
N2546, N2585, N2790. To determine if the ABH sugars were present on both of these 
fragments, purified VWF was digested with ADAMTS 13 and cleavage was analysed by 
reducing SDS-PAGE in 5% gels, followed by western blotting and probing with the 
anti-H lectin Ulex europaeus. At time point zero, a single 250kDa band is observed 
corresponding to reduced monomeric VWF and as expected this is positive for the H- 
antigen. At time points 2 and 4 hours the intensity of the 250kDa band is decreased and 
the 140kDa and 176kDa ADAMTS13 cleavage products have appeared. Both stain 
positive for the H-antigen, demonstrating the H sugar is presented on glycans both sides 
of the ADAMTS 13 cleavage site. 
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Figure 4.8 H-antigen on ADAMTS13 cleavage products 
VWF was digested with ADAMTS 13 and cleavage analysed by SDS-PAGE in 5% gels 
followed by western blotting and probing with the H-antigen specific lectin, Ulex 
europaeus. At time zero only the 250kDa band is present, after incubation with 
ADAMTS13 for 2 and 4 hours the 176kDa and 140kDa cleavage products appear. 
whilst the 250kDa reduces in intensity. Both the cleavage products stain positive for the 
presence of the H-antigen. 
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4.3.5 Trypsin Digestion of VWF and Ion-Exchange Chromatography 
In order to determine if the two N-linked glycan sites located at N1515 and N1574 are 
occupied and if they present the ABH sugars, a tryptic fragment of VWF was generated 
encompassing these two sites. This VWF fragment has been previously described by 
Pared et al and was demonstrated to be an -55kDa species under reducing conditions 
corresponding to amino acids 1493-1887. 
Based on the previous study by Pareti et al; -5mg of purified VWF was digested with 
trypsin for 30mins and passed over a Mono Q ion-exchange column. This method was 
used in the Pareti at al study to specifically isolate the 55kDa band. The column was 
eluted with a 0-500mM NaCl gradient and fractions A3-A8 were collected 
corresponding to generated peaks. Collected fractions were analysed using SDS-PAGE 
in 10% gels under reducing conditions and Coomassie staining, with protein bands 
detected in fractions A3, A4 and A5. Fraction A4 contained a major band of -55kDa, 
with two smaller and much fainter bands. The 55kDa species was also present in 
fraction A5, but at much less intensity. No protein bands were detected in fractions A6, 
A7 or A8. This may have been due to insufficient protein in the fractions for detection 
by Coomassie staining. 
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Figure 4.9 Ion-exchange chromatography of trypsin digested VWF 
Trypsin digested VWF (5mg/ml) was passed over a Mono Q ion exchange column and 
the column eluted with a 0-500mM NaCt gradient (Top frame). Six fractions, A3-A8 
were obtained and were analysed by reducing SDS-PAGE followed by Coomassie 
staining (Bottom frame). Fractions A3-A5 contained protein bands with the major 
species being an -55kDa band present in fraction A4 and to a lesser extent in fraction 
A5. 
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4.3.6 Analysis of VWF Tryptic Fragment 
Since the major VWF tryptic fragment obtained by ion-exchange chromatography was 
consistent in terms of size with the previously reported 55kDa fragment, fraction A4 
was furthered analysed. Under non-reducing conditions the band migrated with an 
apparent molecular weight of 44kDa, (Figure 4.1 OA) consistent with previous reports 
and the fragment was also proteolysed by ADAMTS 13, (Figure 4.1 OB) showing that at 
least the A2 portion of the VWF molecule is present in this fragment. Furthermore 
proteolysis of the fragment by ADAMTS13 resulting in the appearance of an -30kDa 
cleavage product, consistent with the C-terminus of the fragment occurring at the end of 
the A3 domain. 
N-terminal sequencing of the band (performed by Alta Biosciences, UK) demonstrated 
an N-terminal sequence of NSMVL corresponding to amino acids 1493-1497 of the 
mature VWF subunit. Based on the molecular size of this fragment and potential trypsin 
cleavage sites, the C-terminus is amino acid 1887. Thus the isolated fragment 
corresponds to amino acids 1493-1887, comprising the VWF A2 and A3 domains and 
encompassing the N 1515 and N 15 74 glycan sites only. 
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Figure 4.10 Analysis of VWF tryptic fragment 
A) The major VWF fragment in fraction A4 migrates under non-reducing conditions 
with an apparent molecular weight of -44kDa consistent with previous studies. 
B) The fragment is also cleaved by ADAMTS13 demonstrating that at least part of the 
A2 domain is contained with in the fragment. With increasing time the intensity of the 
55kDa band is reduced and the 30kDa cleavage product appears. 
N-terminal sequencing of the 55kDa band and analysis of its molecular weight and 
potential trypsin cleavage sites, confirmed that it was the previously reported VWF 
fragment spanning amino acids 1493-1887. 
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4.3.7 Analysis of Glycosylation and Presence of H-antigen on VWF 55kDa Tryptic 
Fragment 
In order to determine if the 55kDa fragment was glycosylated, the fraction was digested 
with PNGase F overnight at 37'C, followed by western blotting and probing with anti- 
VWF-HRP. Three separate bands were observed, (Figure 4.11, Panel C) demonstrating 
that both the N1515 and N1574 sites must be glycosylated: Band 1 corresponding to the 
presence of both glycans, band 2 the presence of only one of the glycans and band 3 
removal of both glycans. 
The fragment was also analysed for the presence of the H-antigen. Following gel 
electrophoresis and western blotting, lanes were probed with either anti-VWF-HRP or 
Lflex europaeus. When probed with the anti-VWF the major species is the 55kDa band, 
but the smaller, less intense bands observed with Coomassie staining are also present, as 
is a doublet band of -1 7kDa not present on the Coomassie stain. (Figure 4.11, lane A) 
When probed with Ulex europaeus only the 55kDa band stains positive for the H- 
antigen; (Figure 4.11, lane B) demonstrating that either one or both of the N-linked 
present the blood group sugars. The lack of positive signal from the other bands may be 
due insufficient material in the sample to produce a positive, however even on 
overexposure of the blot no positive signal was seen suggesting that these bands either 
do not contain glycan chains or glycans presenting H-antigen. 
To determine if one or both of these glycans present the H-antigen; the PNGase F 
digestion was repeated and following electrophoresis and western blotting, membranes 
were probed with b7ex europaeus (to detect H-antigen). Two bands were visible after 
PNGase F digestion, (Figure 4.11, Panel D) however the lower molecular weight band 
was of decreased intensity. It seems likely, although not confirmed that both glycans 
present the H-antigen and are thus also able to present A and B blood group antigens. 
The PNGase F digest was also probed with EBL to detect terminal sialic acid residues. 
The same pattern of two bands, with Band 2 being less intense than Band I was 
observed, indicating that both glycans also present terminal sialic acid. Furthermore, the 
observation that these two glycans present sialic acid and H-antigen demonstrates that 
these glycans are likely to be of the complex type. 
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Figure 4.11 Analysis of glycosylation and presence of H-antigen on VWF 55kDa 
tryptic fragment 
Following reducing SDS-PAGE and western blotting, the VWF 55kDa fragment was 
probed with anti-VWF-HRP (lane A) and Ulex europaeus (lane B). Probing with anti- 
VWF shows the presence of the 55kDa band and of the smaller, less intense species 
observed with Coomassie staining (see figure 4.7). An -I 7kDa doublet band. not seen 
on the Coomassie stain, is also present. The 55kDa fragment stains positive with the 
anti-H lectin, demonstrating that one or both of the glycans on the fragment present the 
H-antigen. Upon digestion with PNGase F, three discrete bands can be seen (panel C), 
demonstrating that both the N1515 and N1574 sites are utilised. Band I representing 
both glycans intact; Band 2- only one of the glycans removed and Band 3- both 
glycans removed. The PNGase F digested fragment was also probed with the anti H 
lectin (panel D). Band I represents both glycans intact. Band 2 represents one glycan 
chain removed and stains positive for the H-antigen but to a lesser extent than Band 1, 
suggesting that both sites present the H-antigen. Probing with EBL to detect terminal 
sialic acid also showed the same pattern of two bands, with Band 2 being of less 
intensity, demonstrating that both glycans may also present terminal sialic acid. 
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4.4 DISCUSSION 
4.4.1 In Silico Analysis of VWF Glycan Structure 
The glycan moiety of VWF forms approximately 15-20% of its total molecular weight. 
N-linked glycans comprise 70% of the carbohydrate and 0-linked chains the remaining 
3 0%. 254 There has been limited study of the 0-linked glycans, although it has been 
demonstrated the major 0-linked glycan is composed of the disialyted core I 
structure. 257 More extensive work has been performed on the N-linked glycans, with a 
detailed study by Matsui et al (1992) demonstrating by chemical analysis, that the major 
type of N-linked glycan present in VWF was the complex biantennary type. 23 
Furthermore and highly significantly, the N-linked glycans of VWF were shown to 
present the ABO blood group sugars. 23 
Whilst these studies provide information about the structure of the VWF glycan chains, 
a number a factors still need to be resolved. For instance, it is not known what potential 
glycosylation sites are actually occupied. A recent estimate based on the analysis of 749 
well-characterized glycoproteins suggested that -34% of potential N-linked 
glycosylation sites are not occupied . 
359 Furthermore, whilst the N-linked glycans of 
VWF have been shown to present the ABO sugars, it is not known what specific sites 
are decorated with them. This is particularly pertinent with regard to the observation 
that ABO blood group alters susceptibility of VWF to cleavage by ADAMTS13. 
To therefore further investigate this, I have analysed the glycan structure of VWF and 
paid particular attention to the potential N-linked glycan sites in close proximity to the 
ADAMTS13 cleavage site. 
The initial observation that VWF contained 12 N-linked sites and 10 0-linked sites was 
made by Titani et al. 16 This was based on the primary amino acid structure of VWF, 
known rules regarding 0-linked glycosylation and experimental evidence obtained 
whilst determining the amino acid sequence of VWF. However no direct study has been 
performed to map the glycan sites and determine if they are occupied. 
I analysed the probability of the potential N and 0-linked sites being glycosylated by 
using the NetNGlyc and NetOGlyc algorithms to predict glycosylation status based on 
the primary amino acid sequence of VWF. 360 
From the results of the 0-linked prediction, five of the original predicted 0-linked sites; 
T1248, T1468, T1477, T1679, T2298 were given positive scores, and are therefore 
likely to be occupied and one site not found in Titani's study, T1859, was also predicted 
to be occupied by an 0-linked glycan. 
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Based on the -original prediction it was interesting that 8 of the O-linked sites were 
clustered around the Al domain at sites; T1248, T1255, T1256, S1263 and T1468, 
T1477, S1486, S1487. However, based on the NetOGlyc prediction only three of these 
sites are occupied. Experimental evidence suggests that the predicted cluster of 0- 
linked glycans around the VWF Al domain are important for the VWF-GPlb 
interaction, 280 and therefore finther study is needed to confirm the occupancy of these 
sites, but the work presented in this thesis will focus on the N-linked glycans of VWF. 
From the results of the NetNGlyc prediction, it was predicted that VWF contains 
thirteen N-linked sites in the NXT/S sequon, with four of these occurring in the 
propeptide. The two A2 domain glycans, N1515 and N1574 both scored positive and in 
particular N 1574 scored 0.75, indicating it is highly probable that this site is occupied. 
Three of the originally predicted sites, N2290, N2546 and N2635 all fell below the 
threshold value and are therefore less likely to be occupied. These sites all occur in the 
C-terminal region of the molecule where the likelihood of N-linked glycosylation is 
decreased. 230 
Titani et al also predicted a probable glycosylation site at N 1147, in the sequence N- 
S-C. There are also nine other potentials sites in VWF with a N-X-C sequence. 
Prediction of glycan occupancy on these sites returned positive scores for sites N368, 
N819, N847, N 1147, and N2526 and a borderline score of exactly 0.5, for site N221 0. 
Significantly, NI 147 received a high score, 0.75, indicating it is highly probable that 
this site is occupied. Occupancy of the other sites remains to be investigated. The 
presence of N-linked glycans at the N-X-C sequon has been noted in other proteins, 
including human and bovine protein C. 361 Addition of a glycan chain at this sequon is 
rare however due to the inefficiency of the oligosaccharyltransferase to transfer the 
precursor glycan chain to the protein. 362 It is also interesting to note the prediction of 
four N-linked sites within the propeptide. Plasma levels of VWFpp were determined not 
to be significantly different between blood groups, 321 this may be highly significant in 
that the propeptide has been shown not to present the ABO blood group sugarS. 363 
Although the NetOGlyc and NetNGlyc provide information about the potential 
glycosylation status of a molecule, they are only predictions and results need to be 
interpreted with a degree of caution and confirmation of glycosylation needs to be 
determined experimentally. 
As previously described two potential N-linked sites flank the ADAMTS13 cleavage 
site within the A2 domain with both these sites; N1515 and N1574 predicted to be 
154 
occupied. To further analyse this, I aligned the human VWF A2 domain sequence was 
against known VWF A2 domain sequences from 58 other species. The protein 
alignment shown in Figure 4.3 demonstrates that the sequence of the A2 domain is 
highly conserved with >80% homology between species. Significantly, the N1515 and 
N1574 sites are also highly conserved suggesting they play an important role within the 
molecule. The N1515 site is present in all but three of the sequences; with the sequon, 
NXS where X is either R or K. In the three sequences that do not contain this sequence, 
one contains the sequon NRC that still may potentially be glycosylated. The N 15 74 site 
is conserved throughout all the 59 sequences, with the sequon being either NRT, NQT, 
or NGT. It was also observed that the two downstream amino acids and three upstream 
amino acids around N1574 were also conserved throughout, with the region 
GGNXTNTG being the most highly conserved portion of the aligned A2 domains. As 
previously discussed, the initial step in the addition of a glycan chain to a growing 
peptide chain occurs on the luminal side of the ER with transfer of the 
G1C3Man9G1cNAC2 structure to the nascent polypeptide chain by the enzyme 
oligosaccharyltransferase (OST). Successful transfer of the glycan structure is thought 
to be dependent on the amino acids in close proximity to the asparagine residue. 364,365 it 
is therefore feasible that the amino acids surrounding N1574 are important in 
facilitating successful glycosylation of the site. The highly conserved nature of the sites 
also suggests that both sites are important and are required for proper VWF 
structure/function. 
Although VWF is only found in vertebrates, the VWF A domains (VWA) are present in 
proteins from Eukaryota (Metazoa, fungi, plants, and protists), Eubacteria, and 
Archaea. 366 In the most ancient organisms VWA domains are present in intracellular 
proteins involved in functions such as transcription, DNA repair, ribosomal and 
membrane tranSport. 366 Within higher organisms, VWA domains are principally found 
in cell adhesion and matrix proteins; such as VWF, collagens, matrilins, integrins and 
complement proteins. 367 Based on the resolved crystal structure of homologous proteins, 
a molecular model of the A2 domain has been determined (Figure 4.12). 161 From this 
model it is apparent that the N1515 and N1574 sites are located on the outside of the 
domain, with the N1515 site located on an alpha-helix and the N1574 site located on a 
loop. How these glycans affect the conformation of the A2 domain is unclear and 
indeed it needs to be considered that VWF contains other domains that may interact 
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with the A2 domain. Furthen-nore, although only speculative, one or both of the glycans 
could affect access to the ADAMTS 13 cleavage site. 
Figure 4.12 Predicted model of the VWF A2 domain 
The two A2 domain glycans are predicted to occur on the outside of the domain, with 
N1515 located on an alpha-helix and N1574 on a loop region. The ADAMTS13 
cleavage site is shown in red in the centre of the model. 
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4.4.2 Experimental Analysis of VWF N-linked Glycans 
To confirm that sites N1515 and N1574 were indeed occupied by N-linked glycan 
chains and to determine if they presented the blood group sugars a previously described 
142 
55kDa tryptic fragment of VWF was isolated, that spanned residues 1493-1887. 
In order to achieve this VWF was first purified from a commercial VWF-FVIII 
concentrate, Haemate P. This was achieved by a combination of gel filtration and 
Heparin-Sepharose chromatography. 
As described for the purification of blood group specific VWF, gel filtration separates 
proteins on the basis on size; thus HMW-VWF was the first protein to be eluted from 
the column, at fraction B6 and was eluted up to fraction D12. These VWF positive 
fractions, demonstrated in reducing SDS-PAGE as an -25OkDa band were pooled, and 
contaminating proteins removed by Heparin-Sepharose chromatography. 
Heparin-Sepharose affinity chromatography exploits the fact that VWF contains binding 
sites for heparin, principally in the Al domain. 124 On applying the sample to the 
column, VWF was able to bind to the immobilised Heparin, allowing other proteins to 
pass through. Once all unbound protein was eluted form the column, the bound VWF 
was eluted with NaCl that competed with the VWF for binding to Heparin. Optimal 
purification of VWF was achieved using a SK-16 column packed with 30ml of Heparin- 
Sepharose 6 fast flow (Amersharn) with the gel filtered Haernate P sample applied over 
the column at a flow rate of 0.4ml/min. At higher loading flow rates the recovery of 
VWF was lower. The slower flow rate probably gives optimal time for the interaction to 
occur between VWF and Heparin. Eluted VWF fractions were pure, demonstrated by 
silver staining and were comprised of high to medium molecular multimers. The flow 
through fraction from the Heparin-Sepharose column contained the lowest molecular 
weight multimers, indicating that HMW-VWF has a greater affinity for Heparin. 
From Matsui et al's study it was predicted that -13% of the VWF N-linked glycan 
chains presented the ABO sugars, but as discussed, no evidence is given regarding the 
specific sites that present them. In an attempted to elucidate which sites do present the 
ABO sugars, VWF was digested with ADAMTS13 to produce the two ADAMTS13 
cleavage products. The N-terminal fragment spanning residues 763-1605 encompassing 
sites N857, N1147, N1231, N1515 and N1574 and the C-terminal fragment, residues 
1605-2813 encompassing sites N2223, N2290, N2357, N2400, N2546, N2585 and 
N2790. Analysis of the digestion in SDS-PAGE, followed by western blotting and 
probing with Ulex europaeus demonstrated that the H-antigen was present on both 
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fragments. Furthermore the intensity of the cleavage product bands suggests that a 
number of the N-linked sites on both fragments were presenting H-antigen. 
To isolate the 55kDa fragment of VWF, purified VWF was subjected to trypsin 
digestion as and the digest passed over a Mono Q ion exchange column as described. 142 
A number of fractions were eluted from the column, with fraction A4 containing an 
-55kDa band under reducing conditions. Further characterisation of the fragment 
showed that under non-reducing conditions it migrated with an apparent molecular 
weight of -44kDa and it was also cleaved by ADAMTS 13, demonstrating that at least 
part of the A2 domain was present. Finally, N-terminal sequencing of the molecule 
confirmed that the fragment began at residue 1493. 
The presence of three bands detected by western blotting and probing with anti-VWF- 
HRP, after PNGase digestion of the fragment confirmed that both sites; N1515 and 
N1574 were occupied. Each band represents a particular state of glycosylation; i. e. both 
glycans present, one glycan present, neither glycan present. 
Probing with Ulex europaeus demonstrated that these glycans present the H-antigen and 
are thus able to present the A and B antigens. Analysis of the blot also suggests that 
both sites present the H-antigen (Figure 4.11). However, further investigation is need to 
confirm this observation. In the same way, analysis with EBL also showed that both 
glycans appear to present terminal sialic acid. The presence of these sugar residues also 
show that both glycans must be of the complex type. 
This result significantly demonstrates that the two potential N-linked glycan sites within 
the VWF A2 domain are firstly occupied, and secondly present the H-antigen, and are 
thus able to present the A/B sugars. It is still unclear how the blood group sugars 
mediate susceptibility to ADAMTS13 cleavage, but it is certainly an interesting 
observation that the two glycans in closest proximity to the ADAMTS13 cleavage site 
present them. The functional implications of altering VWF glycan structure is examined 
in the next chapter. 
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CHAPTER 5 
5. EFFECT OF VWF GLYCAN MODIFICATION ON THE 
INTERACTION WITH ADAMTS13 
5.1 INTRODUCTION 
A number of previous studies have been performed investigating the effect of VWF 
glycan modification on VWF function. The majority of these have focused on the 
effects of removing terminal sialic acid and galactose residues from plasma derived 
VWF, and have provided sometimes conflicting results. Although some studies have 
been carried out examining the effect of VWF glycan structure on susceptibility of 
VWF to proteolysis, as yet, no study has been performed to investigate the role VWF 
glycans; play in mediating the interaction with ADAMTS13. This is particularly 
pertinent with regard to the observations presented in Chapter 3, that ABO blood group 
sugars presented on the N-linked glycans of VWF mediate susceptibility to 
ADAMTS13 proteolysis. Since these naturally occurring alterations in VWF glycan 
structure have a profound effect on VWF cleavage by ADAMTS13, it is probable that 
other modification of VWF glycan structure will also affect the interaction of the 
molecule with ADAMTS 13. 
To investigate this further, highly purifled VWF was digested with specific 
endo/exoglycosidases to modify the glycan structure of the molecule and the extent of 
glycan removal was analysed with sugar specific lectins. The function of glycan 
modified VWF was analysed by CBA and VWF multimer analysis, and the interaction 
of glycan modified VWF with ADAMTS 13 was assessed by ADAMTS 13 cleavage and 
binding assays. 
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5.2 GLYCOSIDASE DIGESTION AND LECTIN ANALYSIS 
In order to assess the role of specific sugar residues/structures on VWF function, the 
glycan structure of VWF was altered by digestion with endo and exoglycosidases. 
VWF purified from Haemate P by a combination of gel filtration and Heparin- 
Sepharose chromatography, (described in Section 2.2) was subjected to digestion with 
endo and exoglycosidase enzymes as described in Section 2.9. 
1) a-2(3,6,8,9) Neuraminidase to remove terminal sialic acid residues 
2) P-galactosidase to remove terminal galactose residues 
3) A combination of both neuraminidase and P-galactosidase to remove sialic 
acid and then exposed galactose residues 
4) PNGase F to remove whole N-linked glycan chains at the linkage between 
protein and glycan 
5) PNGase F and sialic acid to remove whole N-linked glycan chains and 
terminal sialic acid present on 0-linked glycans 
A panel of lectins were used to assess the alteration in glycan structure achieved 
(described in Section 2.10) 
1) Elderberry Bark lectin (EBL) - terminal sialic acid resides 
2) Ricinus Communis Agglutinin I (RCA-1) - terminal galactose residues 
3) Concanavalin A (ConA) - whole N-linked glycan chains 
In keeping with previous reports, treatment of VWF with neuraminidase (Neu-VWF) 
resulted in the removal of >99% of sialic acid residues as demonstrated by a total loss of 
EBL binding (Figure 5.1). Treatment with P-galactosidase resulted in the removal of 
-20% of galactose residues (Pgal-VWF), demonstrated by an -20% decrease in RCA-I 
binding (Figure 5.1). Treatment of VWF with both neuraminidase and P-galactosidase 
(Neu/pgal-VWF) resulted in the removal of >99% sialic acid and increased removal of 
galactose, with a 47% reduction in RCA-I binding. Increasing the final concentration of 
P-galactosidase in the digestion or alteration of reaction conditions did not result in 
increased galactose removal. 
Digestion of VWF with PNGase F (PNG-VWF) resulted in the removal of >90% of the 
N-linked glycan chains (Figure 5.2). Since the vast majority of the N-linked glycans 
were able to be removed by PNGase F, the PNG-VWF was analysed for sialic acid 
content. As demonstrated by EBL binding, PNG-VWF had -35% less sialic acid than 
control VWF (Ctrl-VWF), demonstrating that -65% of VWF sialic acid is presented on 
the 0-linked glycan chains (Figure 5.2). 
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Figure 5.1 Lectin analysis of a-2(3,6,8,9) neuraminidase and P-galactosidase 
digested VWF 
Purified VWF was subjected to glycosidase digestion with neuraminidase and 
galactosidase and removal of sugars analysed with EBL specific for sialic acid and 
RCA-I specific for galactose. Digestion with neurarninidase resulted in >99% removal 
of sialic acid residues. Digestion with P-galactosidase resulted in an -20% reduction in 
RCA-I binding and digestion with both enzymes resulted in >99% sialic removal and 
increased galactose removal with an -47% drop in RCA-I binding. 
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Figure 5.2 Lectin analysis of PNGase F and ct-2(3,6,8,9) neuraminidase digested 
VWF 
Purified VWF was treated with PNGase F, neuraminidase and a combination of both 
enzymes and removal of sugars analysed with Con A, specific for N-linked glycan 
structures and EBL, specific for terminal sialic acid residues. Treatment of VWF with 
PNGase F resulted in the removal of >90% of the N-linked glycan chains, demonstrated 
by only minimal binding to Con A compared to Ctrl-VWF. Detection of sialic acid 
residues on PNG-VWF showed that it has -35% less sialic acid than Ctrl-VWF. Thus 
the remaining -65% of VWF sialic acid is presented on the O-linked glycans. Treatment 
of VWF with both PNGase F and neuraminidase (Neu/PNG-VWF) resulted in only 
minimal binding to Con A and EBL. (Error bars represent the mean and standard 
deviation of six separate digestions of 3 different VWF preparations). 
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5.3 CONFIRMATION OF VWF N-LINKED GLYCAN REMOVAL 
Unexpectedly, digestion of VWF with PNGase F resulted in the removal of virtually all 
the N-linked glycan chains. It was hypothesised that the detection method used to 
analyse the removal of the N-linked glycans may only detect N-linked glycans on the 
surface of globular VWF and that N-linked structures may be present in the folded 
multimeric structure that were inaccessible to PNGase F and Con A. 
To finther analyse the removal of the N-linked glycan chains, Ctrl-VWF and PNG- 
VWF were bound directly to a MaxiSorp plate, which previous studies have 
demonstrated results in VWF taking on its open, elongated conformation. 368 Binding of 
Con A to Ctrl-VWF and PNG-VWF was as previously observed, with >90% loss of 
Con A binding to PNGase F digested VWF, (Figure 5.3A) suggesting that the N-linked 
glycans of VWF are accessible to PNGase F while VWF is in a globular conformation 
and are not buried within the fully folded multimeric structure. 
To further confirm this observation, VWF was reduced then digested with PNGase F 
and analysed by reducing SDS-PAGE in 3-8% gels to compare the shift in band 
migration compared to Ctrl-VWF and non-reduced VWF digested with PNGase F 
(Figure 53B). Compared to Ctrl-VWF, both the PNGase digested samples migrate 
further through the gel, demonstrating a reduction in molecular weight consistent with 
glycan removal. However there is no observable difference in migration between the 
two samples, indicating that similar amounts of N-linked glycans have been removed 
from both. Therefore digestion of VWF with PNGase F does indeed remove the vast 
majority of N-linked glycans from the molecule. 
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Figure 5.3 Conformation of VWF N-linked glycan removal 
A) PNGase F digested VWF was further analysed using a modified plate binding assay 
where control and PNGase F digested VWF were directly bound to a MaxiSorp plate 
and probed with Con A. Compared to Ctrl-VWF; PNG-VWF demonstrated only 
minimal Con A binding (<10%) confirming that almost all the N-linked glycans are 
removed by PNGase F digestion. 
B) Reduced VWF was digested with PNGase F and its mobility in 3-8% gels compared 
to non-reduced PNGase F digested VWF and control VWF. Ctrl-VWF migrated with an 
approximate molecular weight of 250kDa (lane 1). Non reduced (lane 2) and reduced 
(lane 3) PNGase F digested VWF both migrated further in the gel compared to wild 
type, but no difference in migration was seen between the two samples. 
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5.4 MULTIMERIC STRUCTURE AND COLLAGEN BINDING OF GLYCAN 
MODIFIED VWF 
Previous reports have been conflicting as to whether modification of the glycan 
structure of VWF affects its multimeric pattern and collagen binding potential. To 
investigate this, the glycan modified VWF preparations were analysed in VWF 
multimer gels and by C BA. (Refer to Section 2.11 for KD determination. ) 
The multimeric structure of Neu-, Pgal-, Neu/pgal- and PNG-VWF did not differ from 
that of Ctrl-VWF (Figure 5.4). The only observable difference was a band shift with 
PNG-VWF, consistent with a decrease in molecular weight following removal of the N- 
linked glycan chains (Figure 5.4). Furthermore, alteration of the glycan structure did not 
affect the affinity of VWF for collagen, (Figure 5.5) with all the VWF preparations 
binding to collagen with similar affinity and with KI) comparable to previously 
published values for plasma derived VWF: K[) = Ctrl 1.3nM, Neu 1.8nM, Pgal 1.5nM, 
Neu/pgal 1.6nM, PNG 1.6nM. (KD based on VWF monomeric weight of 250kDa). 
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Figure 5.4 Multimer analysis of glycan modified VWF 
The multimeric structure of glycan modified VWF was analysed in 1.8% agarose 
multimer gels. The multimeric structure of Neu-, Pgal-, Neu/Pgal- and PNG-VWF did 
not differ from that of Ctrl-VWF. The multimeric structure of PNG-VWF was also the 
same as Ctrl-VWF, however a band shift is observed with the PNG-VWF sample due to 
the decrease in molecular weight. 
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Figure 5.5 Binding of glycan modified VWF to collagen 
The ability of glycan modified VWF to binding to collagen was analysed using CBA. 
All the preparations of VWF bound to collagen with similar affinity (KD = 1.3-1.8nM) 
comparable to previously published values (KD = J-7nM). The KD concentration is 
based on a VW monomeric weight of 250kDa. * 
* The monomeric weight of 250kDa was used to allow a KD to be calculated, although it should be noted 
that due to the removal of sugars structures the monomeric weight of the glycan modified samples will be 
reduced. However, as is apparent from the graph, no difference in collagen binding was observed and the 
binding curves still remained the same if the VWF concentration was expressed in pg/r4j. Furthermore, 
no difference was 
' 
'seen between the"reactivity of the glycan modified samples to the anti-VWF-HRP 
pqjYClonal antibody. 
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5.5 EFFECT OF VWF GLYCAN MODIFICATION ON SUSCEPTIBILITY70 
CLEAVAGE BY ADAMTS13 
Since the ABO(H) sugars affected the susceptibility of VWF to cleavage by 
ADAMTS13, it was hypothesised that other sugar structures or further reduction to the 
length of the N-linked glycan chains may also affect cleavage of VWF by ADAMTS 13. 
It was not possible to obtain sufficient quantities of Pgal-VWF and Neu/Pgal-VWF to 
obtain data on the interaction with ADAMTS13, therefore the following presented data 
focuses on the effect of terminal sialic removal and whole N-linked glycan removal on 
the interaction with ADAMTS 13. 
5.5.1 Effect of VWF Sialic Acid on Susceptibility to Cleavage by ADAMTS13 
Previous studies demonstrated that Neu-VWF* was more susceptible to proteolysis by a 
number of proteases including, trypsin, chymotrypsin and plasmin. It is therefore 
possible that terminal sialic acid residues may protect against ADAMTS 13 cleavage. 
Wild type and Neu-VWF were incubated with ADAMTS13 and extent of cleavage 
analysed using CBA and VWF multimer gels. Surprisingly, Neu-VWF was proteolysed 
at a significantly slower rate slower rate by ADAMTS13 than Ctrl-VWF as 
demonstrated by CBA (Figure 5.6). At all time points (60,120 and 240mins) 
Neu-VWF had significantly more collagen binding potential than Ctrl-VWF 
(p = <0.0001). 
This effect was visualised by VWF multimer analysis (Figure 5.7). At time zero all the 
VWF preparations have a similar multimeric pattern. However is it apparent at time 
points 60mins and 120mins that Neu-VWF is less susceptible to cleavage by 
ADAMTS 13, demonstrated by less reduction of HMW multimers. 
* The term Asialo VWF (Neu-VWF) has been used in previous studies to describe neuraminidase treated 
VWF. Neuraminidase treated VWF in this study is referred to as Neu-VWF and the use of the term 
AsVWF refers to previous work. 
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Figure 5.6 Collagen binding assay of ADAMTS13 cleavage of Ctrl and Neu-VWF 
Control and Neu-VWF were subjected to proteolysis by ADAMTS13 and the extent of 
cleavage analysed by CBA. Over the time course Neu-VWF (red) was proteolysed 
slower than Ctrl-VWF (black), demonstrated by significantly higher collagen binding 
activity at all time points compared to Ctrl-VWF; p=<0.0001. (Error bars represent the 
mean and standard deviation of 8 separate experiments performed using 3 different 
VWF preparations. 
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Figure 5.7 Multimer gel analysis of ADAMTS13 cleavage of Ctrl and Neu-VWF 
At time point zero (TO) the multimer pattern for CtrI and Neu-VWF is similar, however 
it is apparent at time points 60min and 120mins that Neu-VWF has been cleaved at a 
reduced rate by ADAMTS13, demonstrated by less reduction of HMW multimers and 
appearance of lower molecular weight bands compared to Ctrl-VWF. 
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5.5.1.2 Effect of sialic acid removal from blood group specific VWF on 
susceptibility to ADAMTS13 proteolysis 
As shown in chapter 3, ABO blood group has an effect on the ability of ADAMTS 13 to 
cleave VWF, with group 0 VWF being more susceptible to ADAMTS 13 proteolysis. In 
light of the observation that removal of sialic acid from VWF decreases proteolysis by 
ADAMTS13, an issue was raised as to whether the ABO effect would remain following 
removal of sialic acid from blood group specific VWF. To investigate this, HMW 0 and 
AB VWF, (purified as described Section 2.1), was incubated with neuraminidase or 
20mM Tris-HCl, pH 7.8, as a control. The samples; O-VWF, AB-VWF, Neu-0-VWF 
and Neu-AB-VWF were then incubated with ADAMTS13 and cleavage analysed by 
CBA. As previously shown, O-VWF is proteolysed faster by ADAMTS13 than AB- 
VWF; at time points 30mins and 60mins a significant difference (p= <0.005) is seen 
between the ability of the samples to bind collagen, with O-VWF demonstrating lower 
collagen binding activity (Figure 5.8). The CBA also shows that Neu-0-VWF and Neu- 
AB-VWF are cleaved significantly slower than the wild type samples, (p=0.0001), 
demonstrated by higher collagen binding activity at all time points. However, the ABO 
effect is no longer observed with Neu-0 and Neu-AB-VWF samples; with both de- 
sialylated samples being cleaved at a similar rate (Figure 5.8). 
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Figure 5.8 The effect of sialic acid removal from blood group specific VWF on 
susceptibility to cleavage by ADAMTS13 
Blood group specific 0 and AB VWF purified as previously described was incubated in 
the presence or absence of neuraminidase then subjected to cleavage by ADAMTS13 
and the extent of proteolysis was analysed by CBA. In keeping with the previous 
observations, O-VWF (black) was proteolysed significantly faster than AB-VWF (red), 
p= <0.05. Also in keeping with previous observation, the Neu-VWF samples were 
cleaved significantly slower by ADAMTS13, p= <0.0001, however the ABO effect on 
ADAMTS13 proteolysis was lost, with both Neu-0-VWF (green) and Neu-AB-VWF 
(blue) being cleaved at similar rates. (Error bars represent the mean and standard 
deviation of 4 separate experiments performed in duplicate. ) 
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5.5.2 Effect of VWF N-linked Glycans on Susceptibility to Cleavage by 
ADAMTS13 
The comparison of ADAMST13 cleavage of AB, 0 and Bombay VWF has shown that 
the removal of sugar residues renders VWF more susceptible to proteolytic cleavage. It 
therefore follows that further reduction of the glycan chain or total removal of glycans 
chains may also leave VWF still more prone to proteolytic cleavage. Furthermore, as 
has been discussed, a number of studies have shown that the glycan component of 
proteins can protect against proteolytic attack. 
To determine the role of VWF N-linked glycosylation on cleavage of the molecule by 
ADAMTS13, PNG-VWF was incubated with ADAMTS13 and the extent of cleavage 
analysed by CBA. 
PNG-VWF was shown to be cleaved faster than Ctrl-VWF by ADAMTS13, 
demonstrated by lower collagen binding activity at all time points (Figure 5.10). In 
particular the initial extent of proteolysis was significantly faster for PNG-VWF 
(p= <0.0001), with the greatest difference in CBA seen at time points 30mins and 
60mins. 
Since the PNG-VWF was cleaved faster than Ctrl-VWF, and Neu-VWF cleaved slower, 
an ADAMTS13 cleavage assay was performed subjecting Ctrl-, Neu-, PNG- and 
Neu/PNG-VWF to ADAMTS13 proteolysis in order to determine the contribution of 
the O-linked sialic acid residues on ADAMTS13 cleavage. As already observed, Neu- 
VWF was proteolysed slower than Ctrl-VWF and PNG-VWF was proteolysed faster. 
Neu/PNG-VWF was cleaved faster than Ctrl-VWF at a rate similar to PNG-VWF 
(Figure 5.11). Removal of the sialic acid from the PNG-VWF sample did offer some 
slight protection from cleavage, with the collagen binding activity of the Neu/PNG- 
VWF samples being slightly higher (-5%) at all time points, although this failed to 
reach significance. 
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Figure 5.10 Collagen binding assay of ADAMTS13 cleavage of control and PNG- 
VWF 
Control and PNG-VWF were subjected to proteolysis by ADAMTS 13 and the extent of 
cleavage analysed by CBA. PNG-VWF (blue) was proteolysed faster than CtrI-VWF 
(black), demonstrated by significantly reduced collagen binding activity (p=<0.0004 at 
time points 30mins and 60mins), compared to Ctrl-VWF. 
(Error bars represent the mean and standard deviation of 8 separate experiments 
perfanned using 3 different VWF preparations) 
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Figure 5.11 Cleavage of Neu/PNG-VWF 
Neu/PNG-VWF was subjected to cleavage by ADAMTS13 and compared to Ctrl, Neu 
and PNG-VWF preparations. As already observed, Neu-VWF was cleaved slower than 
Ctrl-VWF and PNG-VWF cleaved faster. Neu/PNG-VWF was cleaved at a similar rate 
to PNG-VWF. However, the removal of sialic acid residues appeared to a slight 
protective effect, with the collagen binding activity of the Neu/PNG-VWF being 
slightly higher (-5%) at all time points, although this failed to reach significance. 
(Error bars represent the mean and standard deviation of 3 separate experiments) 
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5.5.3 Cleavage of PNG-VWF in the Absence of Urea 
Since PNG-VWF was more susceptible to cleavage by ADAMTS13, it was 
hypothesised that this may be due to the ability of the molecule to adopt a confirmation 
permissive for ADAMTS13 cleavage to occur. Thus, VWF devoid of N-linked glycans 
may take on a confirmation that would allow ADAMTS13 cleavage in the absence of 
any denaturants. To test this hypothesis, ADAMTS13 cleavage of Ctrl-VWF and 
PNG-VWF was repeated in the absence of urea and the extent of proteolysis determined 
using CBA. 
In the absence of urea no cleavage of Ctrl-VWF was observed (Figure 5.12) 
demonstrated by no reduction in collagen binding activity over the time course. 
However, PNG-VWF was cleaved in the absence of urea (Figure 5.12) demonstrated by 
a reduction in collagen binding activity. A control reaction of PNG-VWF incubated for 
the duration of the time course without ADAMTS13, did not show any reduction in 
collagen binding, indicating that the PNG-VWF was stable and the reduction in 
collagen binding observed was solely due to cleavage by ADAMTS13 (Figure 5.12). 
Also shown on the figure is PNG-VWF cleaved in the presence of urea for comparison. 
Although PNG-VWF is cleaved faster in the presence of urea, it is still highly 
significant that cleavage can still occur in its absence. 
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Figure 5.12 Cleavage of PNG-VWF in the absence of urea 
ADAMTS 13 cleavage of control and PNG-VWF was performed in the absence of urea 
and analysed by CBA. No proteolysis of Ctrl-VWF was observed (black), demonstrated 
by no reduction in collagen binding over the time course. PNG-VWF was cleaved in the 
absence of urea (blue) shown by the reduction in collagen binding. A control reaction, 
where PNG-VWF was incubated without ADAMTS 13 for the duration of reaction, was 
also analysed (green). No reduction in collagen binding was observed, indicating that 
PNG-VWF is stable and the observed cleavage of PNG- VWF is solely due to 
ADAMTS 13. Also shown on the graph for comparison, is cleavage of PNG-VWF in the 
presence of 1.5M urea (red). (Error bars represent the mean and standard deviation of 4 
separate experiments performed in duplicate). 
176 
5.6 Effect of VWF Glycan Modification on Binding of ADAMTS13 to VWF 
The evidence obtained thus far demonstrates that the glycan moiety of VWF affects the 
susceptibility of the molecule to proteolysis by ADAMTS13. How this effect is 
mediated is not clear. Alteration of VWF glycan structure by the removal of terminal 
sialic acid residues or the removal of whole N-linked glycan chains may alter the 
conformation of the molecule making it less or more prone to ADAMTS 13 proteolysis. 
Alteration of the glycan structure may also influence binding of ADAMTS13 to VWF, 
once again through altering the conformation of the molecule or by altering any steric 
effect that the glycans chains convey. Indeed, as discussed in Chapter 4, the two N- 
linked glycan sites N 1515 and N 15 74 are located close to the ADAMTS 13 cleavage site 
and close to other residues within the A2 domain shown to be important for 
ADAMTS13 binding. 
In a previous study by Majerus et al a plate binding assay was developed to examine the 
binding of ADAMTS13 to VW . 
222 The assay operated on the basis that when bound to 
surfaces, VWF takes on its "unwound" confirmation and enables the binding of 
ADAMTS13. The authors of the study showed that soluble, globular VWF bound 
ADAMTS13 with low affinity, where as plate bound VWF bound ADAMTS13 with 
high affinity; KD'"-': 14nM. 222 
To further investigate the effect of VWF glycan modification on the interaction with 
ADAMTS13, a plate binding assay was optimised based on the study of Majerus et al 
and used to examine the binding of ADAMTS 13 to Neu- and PNG-VWF. 
5.6.1 Optimisation of VWF: ADAMTS13 Plate Binding Assay 
To determine the optimal plate coating concentration of VWF, purified VWF was 
diluted to final concentrations of 0-15[tg/ml in PBS and used to coat MaxiSorp plates 
overnight at 40C. After removal of unbound protein and blocking with 2%BSA-PBS- 
Tween, bound VWF was detected with anti-VWF-HRP as described in materials and 
methods. At a VWF concentration of -7.5ýtg/ml the wells were saturated (Figure 5.13) 
and thus for all subsequent experiments a VWF coating concentration of 7.5gg/ml was 
used. In all binding assays performed, duplicate wells of each VWF preparation were 
analysed with anti-VWF-HRP to ensure that equal amounts of protein were bound to the 
wells. 
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In initial experiments, VWF coated plates were incubated with 0-125nM ADAMTS13 
in the presence and absence of lOmM EDTA and the obtained data fitted to the 
equation: 
B= Bmax x [LCI 
KD + [X] 
(where B is the binding expressed in absorbance unit, B.. is the maximal binding when 
saturation is reached, [XI is the ligand (ADAMTS13) concentration and KD is the 
equilibrium dissociation constant) 
Binding of ADAMTS13 to VWF in the presence of EDTA was determined to be 
KD = 4nM and in the absence of EDTA, KD = l4nM (Figure 5.14). 
The reduced binding in the absence of EDTA suggested that, although the ADAMTS13 
had not been activated with divalent ions, some residual enzymatic activity was present 
and the VWF substrate could be proteolysed. This was further supported by the use of 
an ADAMTS13 mutant that had its catalytic site mutated and thus was unable to cleave 
VWF. * The ADAMTS13 active site mutant bound to immobilised VWF with 
KD = 5.2nM, similar to wild type ADAMTS13 in the presence of EDTA (Figure 5.15) 
implying that EDTA does not have a conformational effect on ADAMTS13. All 
subsequent binding experiments were performed using wild type ADAMTS13 in the 
presence of I OmM EDTA. 
The ADAMTS 13 active site mutant was kindly provided by Mr Jonathon Lam 
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Figure 5.13 Optimal VWF plate coating concentration 
The wells of MaxiSorp plates were incubated with 0-151Lg/ml VWF diluted in PBS and 
binding of VWF detected with anti-VWF-HRP. Wells were saturated with VWF at a 
concentration of -7.5[tghnl. This concentration of VWF was used to coat plates in all 
further VWFADAMTS 13 binding assays. 
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Figure 5.14 Binding of ADAMTS13 to VWF +/- EDTA 
In the presence of EDTA, ADAMTS13 binds to VWF with KD 4nM. In the absence of 
EDTA binding is decreased, KD 14nM, suggesting that in the absence of EDTA some 
residual ADAMTS13 enzymaiic activity occurs. (Error bars represent ýhe mean and 
standard devialign of 3 separate experiments) 
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Figure 5.15 Binding of ADAMITS13 active site mutant to VWF 
An ADAMTS13 active site mutant that was unable to cleave VWF was bound to 
immobilised VWF as described. The active site mutant bound to VWF with similar 
affinity to wild type ADAMTS13 +lOmM EDTA, KD = 5.2nM. (Error bars represent 
the mean and standard deviation of 3 separate experiments) 
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5.6.2 Binding of ADAMTS13 to Neu and PNG-VWF 
To investigate the binding of ADAMTS13 to Neu- and PNG-VWF, MaxiSorp plates 
were coated with 7.5jtg/mI of control, Neu- or PNG-WF and the binding of 
ADAMTS13 in the presence of EDTA established as described. In all binding assays, 
wells were probed with anti-VWF-HRP to ensure that an equal amount each VWF 
preparation was bound to the plate. Neu-VWF bound ADAMTS 13 with similar affinity 
to Ctrl-VWF; KD 4.2nM: LO. 5 for Ctrl-VWF and KD 4.6riM±0.6 for Neu-VWF. 
PNG-VWF bound ADAMTS13 with significantly greater affinity (-4 fold), p= <0.001, 
with a of KD InM±O. I (Figure 5.16). 
Figure 5.16 Binding of ADAMTS13 to immobilised VWF 
Immobilised Ctrl-VWF and Neu-VWF bound ADAMTS13 with similar affinity, KD 
4-2nM and 4.6nM respectively. PNG-VWF bound ADAMTS13 with significantly 
ýigher affinity, (p=<0.001), KD In. M. (Error bars represent the mean and standard 
deviation of 8 separate experimelits) 
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5.6.3 Binding of ADAMTS13 to Globular VWF 
As observed, ADAMTS13 is able to cleave PNG-VWF in the absence of urea, 
suggesting it is able to interact with PNG-VWF whilst in a globular form. To further 
investigate this, the VWF: ADAMTS13 binding assay was modified to examine the 
interaction of ADAMTS 13 with globular VWF. 
Firstly, MaxiSorp plates were coated with an anti-VWF monoclonal antibody directed 
against the C-terminus of the molecule and this was used to capture globular VWF, 
which could then be incubated with increasing concentrations of ADAMTS13. 
Secondly, collagen plates were used to capture VWF, so that the binding of 
ADAMTS13 to collagen-bound VWF could be determined. Previous studies have 
shown that collagen bound VWF remains in a globular conformation, 368 however little 
is known about the interaction of ADAMTS 13 with collagen-bound VWF. 
When captured with the monoclonal anti-VWF antibody, Ctrl-VWF bound 
ADAMTS13 with low affinity, KD 92rM±11, as did Neu-VWF, KD 90nM±6.2- 
However, PNG-VWF still bound ADAMTS13 with high affinity, KD 3.8nM±0.6 
(Figure 5.17). Interestingly, collagen captured VWF bound ADAMTS13 with high 
affinity. As before no difference was observed between Ctrl-VWF and Neu-VWF; KD 
l2nM±l. I and lOnM±0.6 respectively, but once again PNG-VWF bound ADAMTS13 
with higher affinity, KD 3riM±0.2 (Figure 5.18) 
To ensure that collagen did not bind ADAMTS13, collagen coated plates were 
incubated with O-IgM ADAMTS13. No binding of ADAMTS13 to collagen was 
observed. 
182 
Figure 5.17 Binding of ADAMTS13 to globular VWF 
VWF was captured by a monoclonal antibody directed against the C-terminus of the 
molecule to investigate binding of ADAMTS 13 to globular VWF. Both Ctrl- and Neu- 
VWF bound ADAMTS13 with low affinity, KD 92nM and 90nM respectively, 
indicating that the VWF was in a globular conformation not apt for ADAMTS 13 
binding. PNG-VWF was able to bind ADAMTS13 with high affinity, KD 3.8nM 
suggesting that its confirmation was permissive for ADAMTS 13 binding or the removal 
of the N-linked glycans prevented steric hindrance between ADAMTS13 and VWF- 
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Figure 5.18 Binding of ADAMTS13 to collagen bound VWF 
Collagen coated plates were used to capture VWF and binding of ADAMTS13 to 
collagen bound VWF analysed. Both Ctrl- and Neu-VWF bound ADAMTS 13 with high 
affinity, KD l2nM and lOnM respectively, indicating that collagen bound VWF was 
permissive to ADAMTS13 binding. As in the previous binding assays, PNG-VWF 
bound ADAMTS13 with higher affinity than control VWF, (KD 3nM Vs 12nM). f4o-' 
binding of ADAMTS13 to collagen was observed. (Error bars represent the mean and 
standard deviation of 4 separate experiments) 
.e 
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5.7 DISCUSSION 
Various studies have the reported the functional effects of VWF glycan modification, 
sometimes with conflicting results. However the naturally occurring effect of ABO 
blood group on VWF levels and susceptibility to ADAMTS13 cleavage gives a strong 
indication of their importance. The results presented in this chapter provide the first in 
vitro analysis of the effect of VWF glycan modification on the interaction of VWF with 
ADAMTS13. 
5.7.1 Modifleation of VWF Glycan Structure 
Modification of VWF glycan structure was performed by digestion of VWF with 
exo/endo-glycosidases to remove specific sugar residues or structures. In keeping with 
previous reports, >95% of VWF terminal sialic acid could be removed by digestion with 
a-2(3,6,8,9) neuraminidase as demonstrated by abolition of EBL binding to 
VW. 261,262,264,270 EBL is a lectin specific for terminal sialic residues, preferentially 
binding sialic acid in an a2-6 linkage, but also recognising sialic acid in a2-(3,8,9) 
linkages. 369 The majority of human VWF sialic acid is either a2-3 or a2-6 linked. 
In keeping with previous studies, digestion of VWF with P-galactosidase resulted in the 
removal of only -20% of galactose residues, 264 as demonstrated by a drop in RCA-I 
binding. RCA-I is a lectin specific for terminal galactose resides. 370 Digestion of Neu- 
VWF with P-galactosidase resulted in the removal of -47% of VWF galactose, once 
again in-keeping with previous studies. 261,264 It is not known why complete removal of 
VWF galactose cannot be achieved. A possible explanation is that some of the galactose 
resides are inaccessible to the P-galactosidase enzyme, although this seems unlikely in 
view of the observation that >90% of the N-linked glycans chains can be removed by 
PNGase F. 
To remove whole N-linked glycan chains, VWF was treated with Peptide-N-glycosidase 
F (PNGase F) that cleaves high mannose, hybrid and complex N-linked glycan 
structures deaminating the asparagine residue to aspartic acid. 371,372 Removal of N- 
linked glycans was detected by analysis with Concanavalin A (Con A) lectin that 
recognises a-linked mannose residues in high mannose, hybrid and complex N-linked 
glycans-373 Significantly, digestion of VWF with PNGase F resulted in the removal of 
>90% of the N-linked glycan chains. There have been conflicting reports concerning the 
effect of removal of VWF N-linked glycans from VWF. Federici et al (1984) 
demonstrated that treatment of VWF with endo-o-N-acetyl-glucosaminidase (endo F) 
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removed -69% of the total carbohydrate content of V, %T. 262 Endo F cleaves after the 
second GlcNAc residue in the basic GlcMan3GIcNAC2 core of high mannose, hybrid 
and complex N-linked glycans, thus leaving a single G1cNAc residue attached to the 
asparagine residue. 374 Since -70% of the total VWF carbohydrate is N-linked glycan, 
69% reduction in total sugar would reflect almost total removal of the N-linked glycan 
moiety. Surprisingly, a study by Fischer et al (1997) using recombinant VWF suggested 
that quantitative removal of glycans from rVWF could only be achieved after 
denaturation of the molecule. 375 Although not consistent with Federici et al's 
observation this might have indicated that some of the N-linked glycans are buried 
within the three-dimensional VWF protein structure and are not accessible to PNGase F 
digestion. 
To further investigate this the method used to analyse N-linked glycan chain removal 
was modified to examine VWF in its "uncoiled" conformation. In the lectin ELISA 
method, VWF is captured by anti-VWF antibodies and can be assumed to remain in a 
globular state. Thus Con A may only bind to those glycans accessible on the protein 
surface, and the reduction in Con A binding observed with PNGase F treated VWF may 
represent the removal of only the accessible glycans. Other non-accessible N-linked 
chains may still be present within the folded VWF molecule but are unable to bind Con 
A. To detect any potential non-accessible N-linked glycans, VWF was bound directly to 
a MaxiSorp plate. As will be discussed later, this causes the molecule to uncoil into its 
elongated conformation and therefore should expose any buried glycan sites. However, 
the binding of Con A to PNGase F digested VWF using this system was still <10%, as 
observed with the lectin ELISA, demonstrating that VWF N-linked glycans are 
accessible to PNGase F while the molecule is in a globular conformation. Furthermore, 
VWF was denatured and subjected to PNGase F digestion and the extent of N-linked 
glycan removal compared to a no PNGase F control sample and non-denatured VWF 
digested with PNGase F as before. Under reducing SDS-PAGE in 3-8% gels the 
PNGase F digested samples migrate further than Ctrl-VWF, consistent with a reduction 
in molecular weight, however both the non-denatured and denatured VWF samples 
migrate at the same rate. Thus prior denaturation is not required for removal of VWF N- 
linked glycans. Therefore, in conclusion, PNGase F is capable of removing almost all 
the N-linked glycan chains from VWF. 
Since it was possible to produce VWF almost devoid of N-linked glycans (PNG-VWF), 
the sialic acid content of PNG-VWF was analysed. PNG-VWF demonstrated 65% 
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binding to EBL compared to Ctrl-VWF, indicating that 35% of VWF sialic acid is 
presented on the N-linked glycan chains. This is consistent with the preliminary mass 
spectrometry analysis suggesting that 50% of VWF N-linked glycans present sialic acid. 
5.7.2 Functional Analysis of Glycan Modified VWF 
Conflicting evidence has been previously presented regarding the effect of VWF glycan 
modification on multimeric structure and collagen binding. Some studies have reported 
that removal of galactose or sialic acid and galactose affects multimer structure. 263-265 
However, Federici et al reported no effect on VWF multimer structure following sialic 
acid and galactose removal, and furthermore removal of 83% of total VWF 
carbohydrate with neuraminidase, P-galactosidase and endo F did not alter multimeric 
structure. 262 Multimer analysis of glycan modified VWF in this study demonstrated that 
removal of VWF sugars had no effect on multimer structure. The only difference 
observed was a distinct band shift with PNG-VWF; however this is due to the decrease 
in molecular weight of the PNGase F digested molecule. 
Analysis of collagen binding demonstrated that all the glycan modified VWF 
preparations had a similar affinity for collagen, KD 1.3-1.8nM. The value for the KD was 
calculated based on a VWF monomeric weight of 25OkDa, and was in keeping with 
previously published values. 156 
5.7.3 Effect of Sialic Acid Removal on the Interaction with ADAMTS13 
The sialic acid moiety of VWF has previously been shown to protect the molecule from 
proteolytic degradation, with AsVWF being more prone to digestion by plasmin, trypsin 
261,262 
and chymotrypsin. Furthermore the sialic component of other proteins has been 
376,377 shown to protect against proteolytic attack. It was therefore hypothesised that Neu 
VWF would be more susceptible to ADAMTS13 proteolysis compared to Ctrl-VWF. 
Furthermore in view of my previous observation with blood group specific VWF, that 
reduction in N-linked glycan length increased the rate of ADAMTS13 cleavage, it was 
expected that reducing the glycan chain by removal of sialic acid would also increase 
susceptibility to ADAMTS13 proteolysis. However, as was shown by CBA and 
multimer analysis, Neu-VWF is cleaved slower by ADAMTS13 than Ctrl-VWF. To 
further this observation, blood group specific VWF was digested with neuraminidase 
and then O-VWF, AB-VWF, Neu-0-VWF and Neu-AB-VWF were subjected to 
ADAMTS13 cleavage. The CBA showed that O-VWF VWF was cleaved faster than 
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AB-VWF VWF (as previously observed), both Neu-0-VWF and Neu-AB-VWF VWF 
were cleaved slower than the wild types, but the ABO effect on cleavage was lost, with 
both asialo preparations cleaved at the same rate. The loss of the ABO effect implies 
that either: 
1) The sialic acid effect is dominant over the ABO effect, or 
2) The ABO effect is mediated by its effect on the number of sialic acid residues 
presented on VWF glycans. 
The blood group transferases and sialyltransferase enzymes are located in the post- 
Gol gi22,378 and may compete with each other for the glycan substrate. AB VWF may 
present more A and B structures and hence less sialic acid. However this seems highly 
unlikely; firstly the rate limiting step in the formation of A or B antigens is the 
formation of the H antigen. Thus any competition would be between the H transferase 
and the sialyltransferases and there is no evidence for increased H transferase 
expression in blood group A or B individuals. Potentially the formation of A or B 
structures may make it more difficult to sialylate the other branch(es) of an N-linked 
glycan chain. However the preliminary mass spectrometry analysis of VWF N-linked 
glycans did present a biantennary glycan with one branch terminated by the A antigen 
and the other branch terminated by sialic acid (see Chapter 4, figure 4.7). Finally, a 
study by de Romeuf et al demonstrated that ABO blood group had no effect on levels of 
VWF sialic acid or 01-4 linked galactose. 379 
Sialic acid imparts a negative charge to glycoproteins due its carboxyl group 
dissociating a proton at physiological pH. 380 The removal of VWF sialic acid may 
decrease the overall charge on the protein and this may affect the ability of ADAMTS 13 
to interact with VWF. However, analysis of ADAMTS13 binding to VWF (to be 
discussed in detail shortly) showed that Neu-VWF bound ADAMTS13 with similar 
affinity to wild type. The mechanism by which sialic acid removal from VWF affects 
susceptibility to ADAMTS13 proteolysis requires further investigation. 
VWF sialic acid has been shown to be decreased in patients with primary pulmonary 
hypertension (PPH). 381,382 In a study by Collados et al patients with PPH presented 
increased VWF levels and decreased VWF sialic acid levels. Based on the patients' 
response to a vasodilator, the patients were grouped as either responders or non- 
responders. Interestingly, the "responders" group presented -50% less sialic acid 
compared to control patients and lacked the highest molecular weight VWF multimers. 
The non-responders group presented -70% less sialic acid than the control group, but 
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multimer analysis showed the presence of ultra large VVvT mulitimers. 381 The authors 
concluded that the presence of the lower molecular weight multimers in the responders 
group may have represented increased consumption of VWF due to increased platelet 
binding and/or increased cleavage of VWF, (based on the previous observation that 
AsVWF is more prone to proteolytic degradation261), similar to a VWD type 2B 
phenotype. The presence of UL-VWF multimers was largely unexplained, although this 
is consistent with the observation made in this study that Neu-VWF is less susceptible 
to ADAMTS13 cleavage. The lower level of sialic acid in the non-responders group 
may represent a critical level of VWF sialic acid content, below which ADAMTS13 
proteolysis is inhibited, however this is only a speculative suggestion. 
5.7.4 Effect of N-linked Glycan Removal on the Interaction with ADAMTS13 
In contrast to Neu-VWF, CBA analysis of ADAMTS13 cleavage assays showed that 
PNG-VWF was proteolysed significantly faster than Ctrl-VWF. This was expected 
since the N-linked glycans of other glycoproteins have been shown to protect against 
proteolytic cleavage. For example, non-glycosylated fibronectin is more susceptible to 
proteolysis than the glycosylated form and glycosylation of single-chain tissue-type 
plasminogen activator (tPA) at a specific site modulates proteolysis of the molecule by 
plasmin. 281,383 
The observation that PNG-VWF was cleaved faster by ADAMTS13 was extended by 
subjecting the modified molecule to ADAMTS13 cleavage in the absence of urea. 
Previous work has shown that VWF is not proteolysed in vitro by ADAMTS13 in the 
absence of denaturants159,161 
CBA analysis showed that Ctrl-VWF was not proteolysed and also PNG-VWF 
incubated in the absence of urea and ADAMTS13 did not lose any collagen binding 
activity, demonstrating that PNG-VWF was stable for the duration of the reaction. 
Significantly, PNG-VWF was cleaved by ADAMTS13 in the absence of urea, 
indicating that removal of the N-linked glycans affects either the conformation of the 
VWF molecule or the accessibility of the ADAMTS 13 cleavage site. 
The binding of ADAMTS13 to VWF was investigated using a plate based assay taking 
advantage of the fact that VWF takes on its elongated conformation when bound to the 
plate surface. 384 Using this assay the KD for ADAMTS13 binding to Ctrl-VWF was 
detennined to be 4.2nM. This is close to a previous estimate by Majerus et al of 14nM 
222 using a Similar assay. The difference in the KD is most likely explained by the 
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antibody used to detect bound ADAMTS13; Majerus et al detected ADAMTS13 with 
the anti-V5 epitope antibody where as I used a polyclonal anti-ADAMTS13 antibody 
which is likely to be more sensitive. Significantly, PNG-VWF bound ADAMTS13 with 
increased affinity, KD I nM. 
Since PNG-VWF was cleaved in the absence of urea, the binding of ADAMTS13 to 
globular VWF was investigated. The binding assay was modified to capture VWF on to 
the plate via a monoclonal antibody directed against the C-terminal portion of the 
molecule. This antibody was shown not to inhibit ADAMTS13 cleavage of VWF or 
binding (data not shown). In this assay ADAMTS 13 bound Ctrl-VWF with low affinity, 
KD 90nM, reflecting the globular nature of VWF. Significantly, PNG-VWF bound 
ADAMTS13 with high affinity, KD 3.8nM, thus consistent with the observation that 
PNG-VWF could be cleaved by ADAMTS 13 in the absence of a denaturant. 
Finally, the binding of ADAMTS 13 to collagen bound VWF was investigated. Analysis 
of the morphology of collagen-bound VWF by atomic force microscopy demonstrated 
that it remained in a globular state with no apparent elongation. 368 ADAMTS13 bound 
to collagen-bound control and PNG-VWF with high affinity, but once again the affinity 
was greater for PNG-VWF, (KD IOnM and 3nM respectively). The observation that 
ADAMTS13 can bind with high affinity to collagen bound VWF is significant itself, 
suggesting that the binding of VWF to collagen causes a conformational change that 
enables binding of ADAMTS 13. 
The exact mechanism by which the N-linked glycans of VWF mediate/facilitate the 
VWF: ADAMTS13 interaction is not yet resolved. The effect may be due to steric 
hindrance by the glycans affecting the interaction between the molecules. If the glycan- 
protein linkage is flexible the glycan may be able to cover a portion of the protein 
surface and protect it from proteolytic attack. 383 In the case of VWF, the most likely 
candidate glycans would be N1515 or N1574. Potentially one or both of these glycans 
may define access to the ADAMTS 13 cleavage site. Equally, ADAMTS 13 binding sites 
or sites of access to the cleavage site could theoretically be masked by the presence of 
an N-linked glycan chain. This might explain why ADAMTS 13 can bind with increased 
affinity to PNG-VWF, particularly when VWF is in a globular conformation. Steric 
hindrance may also provide a suitable explanation for the observation that PNG-VWF is 
cleaved by ADAMTS13 in the absence of urea, with the cleavage site protected by N- 
linked glycosylation and removal of glycans allowing ADAMTS 13 to access the 
cleavage site. However, although PNG-VWF is cleaved without urea, the rate of 
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proteolysis is increased in its presence, implying that the molecule still needs to undergo 
a conformational change to allow efficient ADAMTS 13 cleavage. Therefore removal of 
VWF N-linked glycans may affect the conformation of the molecule, making it more 
permissive to ADAMTS 13 binding and cleavage. 
In conclusion this Chapter represents the first analysis of VWF glycan modification on 
susceptibility to ADAMTS13 cleavage, demonstrating that removal of terminal sialic 
acid residues reducing the rate of cleavage, while the removal of whole N-linked glycan 
chains enhances ADAMTS13 cleavage and binding. These results however, do not 
indicate whether this is a global effect of glycan modification, or if modification of 
specific VWF glycan sites results in the altered cleavage patterns observed. Although it 
is not possible to prevent sialylation at specific sites, N-linked glycosylation at specific 
sites can be prevented and this forms the basis for the next chapter. 
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CHAPTER 6 
6. EXPRESSION AND CHARACTERISATION OF VWF A2 
DOMAIN GLYCOSYLATION MUTANTS 
6.1 INTRODUCTION 
From the results obtained in the previous chapter it is apparent that the N-linked glycans; 
of VWF affect the VWF-ADAMTS13 interaction. Removal of the N-linked glycans 
from VWF increases the rate at which the molecule is cleaved by ADAMTS13 and 
increases the affinity with which ADAMTS 13 can bind to VWF. The removal of the N- 
linked glycans with PNGase F is non-specific however, and it maybe the case that only 
certain N-linked sites affect the interaction of ADAMTS 13 with VWF. The most likely 
candidates are hypothesised to be the two A2 domain N-linked glycans, located at sites 
N1515 and N1574, that occur in the vicinity of the ADAMTS13 cleavage site at 
Y1605MI606. As demonstrated in Chapter 4, both these potential glycosylation sites 
are occupied and therefore may play an important role in mediating the effect of N- 
linked glycosylation on the interaction of VWF with ADAMTS 13. 
To further investigate this, the full length VWF (FL-VWF) cDNA was prepared in a 
mammalian expression vector and the N1515 and N1574 glycan sites were mutated 
individually and as a pair. Recombinant VWF (rVWF) was then expressed in HEK293T 
cells and its functional activity and glycan content analysed. Finally mutated VWF was 
cleaved by ADAMTS13 and the extent of cleavage compared to that of wild type 
rVWF. 
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6.2 Construction of a Full Length VWF Expression Vector and Mutagenesis of 
N1515 and N1574 
The mammalian expression vector pSVhVWF, containing the full length VWF cDNA, 
was a kind gift from Dr Said Enyayt, (Birmingham's Children's Hospital). Sequencing 
of the VWF clone provided showed the sequence to be 8676bp long, with the first 
234bp comprising part of the 5'UTR. The sequence has been numbered relative to the 
ATG start codon, thus bases -234 to 0 represent the 5'UTR. An EcoRl site was located 
at bases -234 to -229. 
To facilitate efficient mutagenesis of the VWF gene, a smaller fragment of the cDNA 
sequence was generate by restriction digest and cloned into the pGEM cloning vector. 
Full length VWF cDNA was then cloned into the pBS cloning vector (that had been 
mutated to remove the KpnI restriction site), using a number of steps and then cloned 
into the mammalian expression vector pcDNA3.1 for expression in HEK293T cells. 
Figure 6.1 shows a diagrammatic representation of the VWF cDNA with selected 
restriction sites and the restrictions fragments used to prepare the VWF construct. 
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Figure 6.1 VWF restriction sites and digestion fragments 
The VWF cDNA contained in pSVhVWF is -8.7kb with the first 234bp comprising part 
of the 5"UTR. Base number I is taken from the start codon. Shown on the figure are the 
restriction fragments used to prepare the final VWF construct. The 3' Agel site was 
introduced by PCR of the 3' end of the sequence described in section 6.1.2. 
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6.2.1 Mutagenesis of pBlueScript to remove the KpnI restriction site 
The 3kb cloning vector, pBlueScript (pBS), was mutated to remove the KpnI restriction 
sequence from the multiple cloning site. As will be seen later, this step was necessary to 
allow the insertion of a 2.4kb fragment of VWF cDNA containing the desired 
mutations. 
The Stratagene site directed mutagenesis kit was used into introduce the desired 
mutation. The primers used are listed in Appendix II. Following PCF, the mutagenesis 
reaction was digested with DpnI to remove the parental methylated DNA and 
transformed into XL-10 gold ultra competent cells. Following plasmid extraction from 
selected colonies, clones were analysed by restriction digestion with KpnI and Xmnl. 
Positive colonies that successfully had the KpnI site mutated appeared as a linearised 
3kb band on a 1% agarose gel (Figure 6.2, lanes 2-4), whereas non-mutated clones were 
cut by both enzymes and appeared as two bands of -1 and 2kb (Figure 6.2, lane 1). 
Clones were further verified by DNA sequencing and positive clones were labelled 
pBS-Kpnl. 
6.2.2 PCR of VWF 3' end 
Sequencing of the pSVhVWF vector demonstrated that a number of useful restriction 
sites were located after the VWF cDNA sequence, and as such it would be impossible to 
remove an appropriate size fragment of VWF cDNA for mutagenesis and then replace it 
again. Therefore, PCR was used to generate a fragment of VWF cDNA comprising the 
final 955bp pairs, beginning at base 7487 of the sequence, encompassing the Sphl site 
(see figure 6.1) and including the stop codon. As described in materials and methods, 
the PCR primers were designed to introduce at the 3' end an unique Agel restriction site 
immediately after the stop codon, a SacI site immediately after the Agel site, and 7 
other bases pair to aid efficient restriction digest of the PCR product. At the 5' end of 
the PCR product the primers were designed to introduce an Xbal site flanked by 7 bases 
to aid restriction digestion. Following PCR, the reaction was digested with Xbal and 
Sacl, then visualised on a 1.2% agarose gel. The resulting band of -900bp, was 
consistent with the size of fragment expected (Figure 63A). Following purification 
from the gel, the fragment was cloned into the pBS-Kpnl cloning vector, that had been 
digested with Xbal and Sacl and treated with calf intestinal alkaline phosphatase 
(CIAP). Following transformation into DH5a cells and culture of obtained colonies, 
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clones were analysed by restriction digestion with Xmnl - present in the vector only, 
and Sphl - present in the insert only. Non-positive clones appeared as a linearised 3kb 
band on agarose gel electrophoresis (Figure 6.3B lane 1); positive clones were digested 
to two fragments of 2.6kb and 1.3kb (Figure 6.3B, lane 2). The presence of the insert 
was confin-ned by DNA sequencing and the construct designated pBS-kP"'VWF3' 
3kb 
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Figure 6.2 Restriction enzyme analysis of mutagenesis of pBS 
Site directed mutagenesis was used to mutate the KpnI restriction site in the pBS 
cloning vector. Following digestion with XmnI and Kpnl, clones containing the mutated 
site were only digested with Xmnl and appeared as a linearised -3kb band (lanes 2-4). 
Negative clones could be digested with both enzymes and appeared as two bands of 
-I kb and 2kb (lane I). 
196 
Lad 
lkb 
R 
3kb 
2kb 
1 kb 
Lad 
I 
iýý 
r-- 
I 2 
10 
Figure 6.3 PCR and generation of VWF 3' end 
PCR was used to generate a 3' end fragment of VWF spanning the final 955bp of the 
cDNA encompassing the Sphl site. The PCR primers were designed to introduce an 
unique Agel site immediately after the stop codon. The PCR product of -900bp was 
consistent with the size of band expected (Panel A). Following cloning into pBS-'P"' and 
plasmid isolation, clones were analysed for the presence of the insert by digestion with 
Xmnl and Sphl. Clones without the insert were only digested with XmnI and appeared 
as a linearised 3kb band (Panel B, lane 1). Positive clones contained both restriction 
sites and appeared as two bands of -2.6kb and -1.3kb (Panel B, lane 2). All positive 
clones were further confirmed by DNA sequencing and the construct named pBS- 
KpnI VWF3'. 
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6.2.3 Further generation of VWF construct 
Following the construction of pBS-VWF3', a number of VWF cDNA fragments were 
generated by restriction digestion and used to assemble the full length VWF construct 
and generate a smaller fragment of VWF cDNA for mutagenesis. Digestion of 
pSVhVWF with the appropriate restriction enzymes generated the following fragments: 
a BamHl - SphI fragment of -5kb, a XhoI - KpnI fragment of -2.4kb, and a EcoRl - 
BamHI fragment of - 3kb (Figure 6.4 and also see figure 6.1). 
The BarnHI - SphI fragment was cloned into pB S-VWF3' and clones were analysed for 
the presence of the insert by digestion with EcoRI, followed by visualisation on 1% 
agarose gels. Negative clones appeared as a -4kb linearised bands and positive clones 
as -8.6kb bands. Positive clones were sequenced to confirm the presence of the insert 
and to ensure that no random mutations were introduced. This construct was designated 
pBS-KpnlVVYT(BamHI-Agel). 
The Xhol - KpnI fragment was cloned into pGEM and the presence of the insert 
confirmed by DNA sequencing and named pGEM-VWF(Xhol-KpnI). 
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Figure 6.4 VWF restriction fragments and analysis of 
pBS-Kpn'VWF(BamHI-Agel) 
To further clone VWF three restriction fragments were generated by digestion of 
pSVhVWF: a -5kb BamHI-Sphl fragment (Panel A, lane 1), an -2.4kb Xhol-Kpnl 
fragment (Panel A, lane 2), and an -3kb EcoRl-BamHI fragment (Panel A, lane 3). 
(Also refer to Figure 6.1). The BamHI-Sphl fragment was cloned into pB S-Kp,, IV WFY 
and the presence of the insert confirmed by restriction digestion with EcoRl. Clones 
without the insert appeared as a linearised band of -4kb consistent with the size of pBS- 
KpnI VWF3'. Positive clones appeared as a linearised band of -8.6kb demonstrating the 
presence of the 5kb insert. Positive clones were further verified by DNA sequencing and 
named pBS-Kpn[VWF(BamHI-Agel). 
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6.2.4 Generation of VWF glycan mutants 
The pGEM-VWF(XhoI-KpnI) construct contained the VWF cDNA sequence from 
bases 2356-4752, and encompassed the codons for N1515 and N1574. To prevent 
glycosylation at these sites the VWF cDNA sequence was mutated using site-directed 
mutagenesis to change the asparagine residues to glutarnic acid residues individually 
(NI515Q or N1574Q) and together as a double mutant (DM). Using the primers listed 
in Appendix 11, the asparagine codon, AAC, was mutated to CAA, encoding for 
glutamic acid. Following the mutagenesis PCR reaction, digestion with DpnI and 
subsequent cloning into XL-10 gold cells, obtained colonies were cultured and DNA 
isolated as described. The presence of the mutation(s) were confirmed by DNA 
sequencing. 
Clones that contained the desired mutation(s) were digested from pGEM-VWF(Xhol- 
KpnI) with BamHI and KpnI and cloned into pBS-KpnlVWF(BamHI-Agel) and then re- 
sequenced to confirm the presence of the newly inserted fragment and the mutation. 
6.2.5 Completion of FL-VWF construct and cloning into pcDNA3.1 
To complete the FL-VWF construct, the -3kb EcoRI-BamHI fragment described in 
section 6.1.3, comprising the 5' end of VWF (also see Figure 6.1), was cloned into pBS' 
KpnIV)W(BamHI-Agel) containing wtVWF or mutated VWF. Clones were analysed by 
restriction analysis with EcoRI; where positive clones migrated as an -1 1.6kb band 
(Figure 6.5, lane 1) and negative clones migrated as an -8.6kb band (Figure 6.5, lane 2). 
Furthermore, digestion of positive clones with KpnI demonstrated two bands of -4.4kb 
and -7.2kb, consistent with the presence of a second KpnI site within the EcoRI-BamHI 
fragment (Figure 6.5, lane3). This construct was named pBS-Kpn'FL-VWF 
Finally, to complete the construct, the FL-VWF cDNA was digested from pBS-Kpn'FL- 
VWF with EcoRl and AgeI and cloned into pcDNA3.1 and named pcDNA3.1-wtVWF 
or pcDNA3.1-NI515Q/NI574Q/DM-VWF depending on the mutation present. Clones 
were then sequenced to confirm that no random mutations had been introduced. 
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Figure 6.5 Analysis of pBS-Kpn'FL-VWF 
The 3kb EcoRl-BamHl fragment comprising the 5' end of VWF was cloned into pBS- 
KpnJ VWF(BamHI-Agel) and analysed by restriction digest with EcoRl. Positive clones 
appeared as an -1 1.6kb band consistent with the expected size for the full length VWF 
cDNA and pBS vector (Lane I). Clones without the insert appeared as an -8-6kb band 
(lane 2). Positive clones were also digested with Kpnl and appeared as two bands of 
-4.4kb and -7.2kb consistent with the presence of two Kpnl sites in the full length 
VWF CDNA (Lane 3). The FL-VWF was digested from pBS with EcoRl and Agel then 
cloned into pcDNA3.1 and re-sequenced to confirm that no random mutations had been 
introduced. 
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6.3 EXPRESSION OF RECOMBINANT VWF 
Expression of rVWF was performed as described (materials and methods section 2.14) 
by transfecting HEK293T cells with 33gg DNA per 10cm2 dish using lOmM 
polyethylenimine (PEI) as the transfection reagent. Following 2 days incubation, 
conditioned media was collected and concentrated 10-fold as described and VWF 
concentration determined by VWF: Ag ELISA. No difference was seen in the level of 
expression between wtVWF, N1515Q, N1574Q and the DM, with -20gg/ml of each 
concentrated sample being obtained (Figure 6.6). Four separate transfections were 
performed, each with a similar level of VWF expression (-20gg/ml concentrated), 
indicating the reproducibility of this transfection method and demonstrating that all the 
mutants could be synthesised and secreted as efficiently as wild type. In all transfection 
experiments control cells were transfected with empty pcDNA3.1 plasmid, and no VWF 
expression was observed (Figure 6.6) 
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Figure 6.6 Expression of rVWF in HEK293T cells 
Recombinant VWF was expressed in HEK293T cells using lOmM PEI as transfection 
reagent. Conditioned media was concentrated 10 fold and analysed for VWF content. 
No difference was observed in the amount of VWF expressed between wt, N1515Q, 
NI 574Q and the DM. No VWF expression was observed when cells were transfected 
with empty pcDNA3.1 vector (control). 
(Error bars are the mean and standard deviation of the VWF concentration obtained 
from 4 separate transfections) 
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6.4 ANALYSIS OF INTRACELLULAR STORAGE OF VWF 
One function of N-linked glycans is to aid protein folding within the cell. Since the 
VWF mutants had N-glycosylation sites mutated, it was possible that this may affect the 
folding of the molecule or result in abnormal storage of VWF within the cell. 
Expression of VWF in HEK293T cells induces the formation of Weibel-Palade body 
like organelles that store VWF in the cell. To investigate the possibility of the glycan 
mutations affecting WP body formation parallel transfections were preformed on 13MM 
glass coverslips and the cells stained for VWF and visualised under a fluorescence 
microscope. 
WP body formation was observed with wt and mutant VWF, with no apparent 
difference between wt and mutants (Figure 6.7). Some of the structures have the classic 
cigar shape, however due to the highly spherical nature of the HEK293T cells, many of 
the WP bodies have a more rounded appearance. No WP bodies were observed in 
control cells transfected with empty pcDNA3.1 vector 
This, in conjunction with the similar expression levels between wt and mutant VWF, 
indicates that the N-linked glycans at sites NI 515 and N1574, do not influence secretion 
or storage of VWF. 
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Figure 6.7 Analysis of intracellular storage of VWF 
Transfected and non-transfected control cells were stained with anti-VWF antibodies 
and visualised under a fluorescence microscope. WP body formation was seen with 
wtVWF and mutant VWF, with no observable differences. No WP body formation was 
seen in the control cells. 
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6.5 CHARACTERISATION OF VWF GLYCAN MUTANTS 
Wild type VWF and the VWF glycan mutants were analysed by reducing SDS-PAGE in 
3-8% gels to determine subunit composition and by CBA and multimer gel analysis to 
determine the multimeric structure of the recombinant VWF (Figure 6.8A) 
Under reducing SDS-PAGE a major 250kDa band was observed consistent with 
monomeric VWF. A faint larger band of -35OkDa was also present, representing 
unprocessed proVWF. The doublet band that runs below the 250kDa band was also 
present. As discussed before this may represent an altered glycosylation pattern. 
Furthermore a number of smaller bands are also present at 176kDa, 140kDa and 
I OOkDa. The I OOkDa most likely represents the propeptide, however the appearance of 
the 176kDa and 140kDa is unexplained since these correspond the ADAMTS13 
cleavage product bands. Either they represent naturally occurring by-products of VWF 
synthesis or HEK293T cells possess some ADAMTS13 expression and activity. As 
expected there is also a slight difference in the rate of migration between the bands, with 
N1515Q and N1574Q further than wild type, due to the absence of one glycan chain 
and the DM migrating further than N1515Q and N1574Q, due the absence of two 
glycan chains. 
Multimer analysis demonstrated that wild type rVWF presented a full range of VWF 
multimers and was comparable to normal plasma (Figure 6.8B) Furthermore, no 
difference in multimeric structure was observed between wt VWF and mutant VWF, 
demonstrating that mutation of VWF A2 domain glycans does not affect multimeric 
composition. Finally, all the mutants bound collagen with similar affinity to wt rVWF, 
KD = 2.5nM (Figure 6.9). 
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Figure 6.8 Characterisation of VWF glycan mutants 
A) Analysis of rVWF by SDS-PAGE in 3-8% gels demonstrated the presence of a 
major 250kDa band consistent with monomeric VWF. As expected there is also a slight 
difference in the rate of migration between the bands, with N1515Q and N1574Q 
further than wild type, due to the absence of one glycan chain and the DM migrating 
further than N1515Q and N1574Q, due the absence of two glycan chains. A 350kDa 
band was also present, representing un-cleaved pro-VWF. A number of lower molecular 
weight bands are also present. The IOOkDa band most likely represents the propeptide. 
however the origin of the other bands is not known. Interestingly they roughly 
correspond to the ADAMTS 13 cleavage fragments of 176kDa and 140kDa. 
B) Multimeric analysis of rVWF demonstrated that wt rVWF presented a multimer 
pattern comparable to normal plasma (NP). Furthermore no difference could be 
observed between the multimeric structure of the glycan mutants compared to wtVWF. 
It is possible to see that N1515Q and N1574Q have migrated slighter further than 
wtVWF and the DM has migrated slight further than NI 515Q and NI 574Q, consistent 
with the removal of specific glycan sites! 
The difference in migration between wtVWF and the glycan mutants is more apparent on the multimer 
gel presented in Figure 6.12 
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Figure 6.9 Collagen binding analysis of rVWF 
The affinity of recombinant VWF for collagen was assessed using CBA. The VWF 
glycan mutants all bound collagen with similar affinity to wtVWF and plasma derived 
VWF- Confirming the observation with multimer gel analysis that mutation of N-linked 
sites N1515 and N1574 does not affect the multimeric structure of VWF. 
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6.6 ANALYSIS OF rVWF GLYCAN STRUCTURE 
The glycan structure of HEK293T cell expressed rVWF was assessed using lectin 
ELISA. Plasma derived control VWF and rVWF samples were standardised for VWF 
antigen and captured on to a MaxiSorp plate by polyclonal anti-VWF antibodies. 
EBL was used to detect terminal sialic acid residues, RCA-1 was used to detected 
galactose residues and Ulex europaeus was used to detect H antigen expression. 
Analysis with EBL demonstrated that rVWF presents up to 50% less terminal sialic acid 
than plasma derived VWF (Figure 6.9) and analysis with RCA-1 demonstrated that 
rVWF presented -20% more terminal galactose than plasma derived VWF. This is most 
likely due to the decreased amount of sialic acid leaving more galactose residues 
exposed. The presence of terminal sialic and galactose residues also shows that 
HEK293T are able to form complex N-linked glycan structures. Finally, as expected, no 
H-antigen could be detected on the rVWF samples. 
Figure 6.10 Lectin analysis of rVWF glycan structure 
Compared to plasma derived VWF, rVWF presented up to 50% less sialic acid and 
-20% more terminal galactose residues as demonstrated by binding to EBL and RCA-I 
lectins respectively. As expected, no H-antigen was detected on rVWF. 
(Error bars are the mean and standard deviation of 4 recombinant VWF preparations 
compared to pooled normal plasma) 
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6.7 CLEAVAGE OF VWF GLYCAN MUTANTS BY ADAMTS13 
The effect of mutating the A2 domain glycans on susceptibility to ADAMTS13 
proteolysis was investigated by incubating mutant and wild type rVWF with 
ADAMTS13 in the presence of 1.5M urea and analysing the extent of proteolysis by 
CBA and multimer analysis. 
The CBA demonstrated that at time points 60mins and 120mins N1574Q and the DM 
had been cleaved significantly (p<0.000 1) faster then wtVWF or N 15 15Q (Figure 
6.10), with both N1574Q and the DM mutant demonstrating only minimal collagen 
binding activity after 60mins incubation with ADAMTS13. A slight difference is also 
observed in the rate of cleavage between wtVWF and N1515Q, with wtVWF being 
proteolysed slightly faster as demonstrated by a greater reduction in CBA at time points 
60mins and 120mins. Although this did not reach significance (p=O. 1) (Figure 6.10). 
This observation was also confirmed by low resolution multimer gel analysis. At time 
point zero the four VWF preparations have a similar multimer pattern; however it is 
apparent that after 60mins incubation with ADAMST13, the N1574Q and DM samples 
have been reduced to monomers and dimers, while the wt and N1515Q samples still 
contain medium weight multimers (Figure 6.11). Is it also apparent that the N IS 15 Q 
sample contains slightly higher molecular weight multimers then the wtVWF sample. 
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Figure 6.11 Collagen binding assay of ADAMST13 cleavage of VWF glycan 
mutants 
Wild type and mutated rVWF was incubated with ADAMTS13 in the presence of urea 
and the extent of proteolysis analysed by CBA. N1574Q and the DM are more 
susceptible to ADAMTS13 proteolysis than wt. or N1515Q as demonstrated by a 
significantly greater reduction in collagen binding activity after time 60mins and 
120mins. The N1515Q mutant is cleaved slight slower by ADAMTS13 than wtVWF, 
demonstrated by slightly higher collagen binding activity at time 60mins and 120mins 
compared to wtVWF. (Error bars are the mean and standard deviation of 3 separate 
assay performed in duplicate, with rVWF from three separate transfections). 
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Figure 6.12 Multimer gel analysis of ADAMST13 cleavage of VWF glycan mutants 
At time Omins the multimer profile of wt and mutant VWF is similar. After 60mins 
incubation it is apparent that both the N1574Q mutant and the DM have been 
proteolysed faster by ADAMTS13 than the wt or N1515Q mutant. with only the 
presence of monomeric and dimeric VWF. It is also observable that the NI 515Q mutant 
has been proteolysed slightly slower than wtVWF. Thus the multimer gel analysis 
confirms the results obtained with the CBA. 
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6.8 CLEAVAGE OF VWF GLYCAN MUTANTS IN THE ABSENCE OF UREA 
As demonstrated in the previous chapter, PNGase F treated VWF was more susceptible 
to ADAMTS 13 proteolysis than control VWF and was also cleaved by ADAMTS 13 in 
the absence of urea. Since the N1574Q and DM were cleaved rapidly by ADAMTS13 
compared to wtVWF, ADAMTS 13 digestion of the mutants was repeated in the absence 
of urea and analysed by CBA. 
No cleavage of wtVWF or the N1515Q mutants was observed in the absence of urea, 
however both NI 574Q and the DM were cleaved by ADAMTS 13 without the need of 
urea (Figure 6.12). This is similar to the behaviour of plasma derived VWF treated with 
PNGase F. Furthermore, in the absence of ADAMTS13 none of the VWF preparations 
lose collagen binding activity over the duration of the reaction, indicating that they are 
all stable and no other proteases are present (Figure 6.12). 
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Figure 6.13 Collagen binding assay of ADAMTS13 cleavage of VWF glycan 
mutants in the absence of urea 
VWF glycan mutants were subjected to ADAMTS13 cleavage in the absence of urea 
and extent of proteolysis analysed by CBA. In the absence of 1.5M urea wtVWF and 
N1515Q were not cleaved by ADAMTS13 and ftuthermore none of the samples lost 
collagen binding activity when incubated in 1.5M urea in the absence of ADAMTS 13. 
For clarity this is shown as a single line on the graph (light blue). Both NI 574Q and 
DM were proteolysed by ADAMTS13 in the absence of urea although the extent of 
proteolysis is greater in the presence of urea. 
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6.9 BINDING OF ADAMTS13 TO VWF N1574Q 
A preliminary analysis of the binding of ADAMTS13 to recombinant wtVWF and 
N1574Q was investigated using the plate based binding assay as described previously. 
ADAMTS13 bound wild type rVWF with KD = 7.5nM±0.5nM and bound to N1574Q 
with -2-fold increased affinity, KD = 3.5nM±0.6nM (Figure 6.14). The -2-fold 
difference in the KD was consistently observed in all repeats of the binding experiments 
and was deemed significant with p= <0.05. 
Figure 6.14 Binding of ADAMTS13 to recombinant VWF 
ADAMTS13 bound to immobilised wild type rVWF with KD = 7.5n. M. ADAMTS13 
bound to N1574Q with -2-fold increased affinity, ýCD = 3-5nM. In all experiments an 
-2-fold difference was observe4 between the affinity of ADAMTS 13 for 'AIVWF and 
N1574Q. (p = <Q. 05) 
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6.10 DISCUSSION 
6.10.1 Expression of Recombinant VMT 
The results presented in the previous chapter clearly demonstrate that the removal of 
VWF N-linked glycans increases the susceptibility of the molecule to ADAMTS13 
cleavage, and allows ADAMTS13 to bind to VWF with increased affinity. However, 
since digestion of VWF with PNGase F results in the removal of virtually all the N- 
linked glycan chains, it is not known if the effect on the interaction with ADAMTS 13 is 
due to the general removal of all the glycan structures or if only specific glycan sites are 
involved. If the effect of VWF N-linked glycosylation is mediate by specific sites, the 
most likely glycans to be implicated are the two A2 domains glycans, N1515 and 
N1574. As established in chapter 4, both these sites are occupied and both sites 
potentially present the blood group antigens and sialic acid. To specifically investigate 
the role of N-linked sites N1515 and N1574 in mediating the susceptibility of VWF to 
ADAMTS13 cleavage, FL-rVWF was produced in HEK293T cells with both sites 
mutated individually and as a pair, to prevent glycosylation. 
The FL-VWF cDNA (a kind gift from Dr Said Enyayt) was provided in the mammalian 
expression vector pSV7d. 385 Since little information could be obtained about the pSV7d 
vector and its properties, the VWF cDNA was cloned into a high level mammalian 
expression vector, pcDNA3.1. This was achieved through a series of cloning steps, 
including the introduction of an unique AgeI restriction site at the 3' end of the 
sequence and the generation of 2.4kb fragment that encompassed the coding region for 
sites N1515 and N1574. Site directed mutagenesis was used to mutate the codons for 
the asparagine residues to glutamic acid, thus preventing the addition of an N-linked 
glYcan at those sites. 
The resulting VWF constructs, wt, N1515Q, N1574Q and the DM were transfected into 
HEK293T cells using polyethylenimine (PEI), which has been to shown to be a highly 
effective transfection reagent and is also extremely cost effective. 386 
A crucial role of N-linked glycosylation is mediating protein folding, often via the 
calnexin-calreticulin cycle. 387,388 For example; HIV type I glycoprotein 120, does not 
fold into its active state* in the absence of glycosylation. 389 Glycosylation at specific 
sites has also been shown to be important in mediating protein folding. Addition of a 
N-glycan chain at Asn 30 of human chorionic gonadotropin P-subunit is crucial for 
In its active state, HIV type I glycoprotein 120 binds to CD4 expressed on T helper cells, regulatory T 
cells, monocytes, macrophages, and dendritic cells. 
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efficient folding, whereas glycosylation at Asn 18 is not so important. 390 In light of this 
is was possible that the VWF glycan mutants would not be secreted or would be 
secreted, but at a reduced level. Moreover, N-linked glycosylation has been shown to 
essential for dimerisation of VWF monomers. 18 The observation that all the mutants 
were expressed at levels similar to wild type indicated that N-linked glycosylation at 
sites N1515 and N1574 is not required for dimerisation and furthermore does not appear 
to play an important role in the folding process of the molecule. It has also been 
previously observed that expression of VWF in HEK293T cells induces the formation 
of pseudo Weibel-Palade body type structures. 56 To investigate this, transfected 
HEK293T cells were stained with anti-VWF antibodies and visualised under a 
fluorescence microscope. Pseudo WP bodies were observed in all transfected cells, with 
no apparent differences in the size and number of WP bodies between wt and mutants. 
No WP bodies were seen in control cells that had been transfected with empty 
pcDNA3.1 vector, demonstrating that HEK293T cells do not express any endogenous 
VWF and the induction of the WP bodies is solely due to transfection of the cells with 
VWF CDNA. Due to the highly spherical nature of the HEK293T cells, many of the WP 
bodies appear as more spherical structures compared to the more classical "cigar 
shape. " Thus N1515 and N1574 are not critical for WP body formation. 
Analysis of wild type and mutant VWF demonstrated a normal multimer pattern, with 
the recombinant material exhibiting a full range of multimers, similar to normal plasma. 
In addition the collagen binding activity of the wild type and mutant VWF was similar 
to that of plasma derived VWF. Therefore, mutation of N1515, N1574 and both sites 
does not affect VWF multimeric structure or collagen binding. Analysis of the 
recombinant VWF samples in 3-8% gels under reducing conditions showed a major 
band of -250kDa, and smaller less intense bands at -176kDa, -140kDa and IOOkDa. 
The I OOkDa band possibly represents the propeptide, however the nature of the 176kDa 
and 140kDa bands are unknown. Interestingly they appear to correspond to the 
ADAMTS13 cleavage products seen in normal plasma. This would suggest that 
HEK293T express a small quantity of ADAMTS13 that is able to process VWF- 
However multimer analysis of rVWF did not show the characteristic satellite bands 
indicative of ADAMTS13 proteolysis. Since the bands are too small to represent altered 
glYCOfOrms they may be naturally occurring by-products of rVWF synthesis. A larger 
band of -350kDa was also present, consistent with pro-VWF. Since the major species 
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present is the 250kDa band, HEK293T cells must possess furin activity to process 
VWF. 
6.10.2 Analysis of Recombinant VWF Glycan Structure 
A basic view of the glycan structure of rVWF was determined by lectin analysis with 
EBL and RCA-I. Since wtVWF migrated with the same apparent molecule weight as 
plasma derived VWF (pdVWF) it was assumed that all the N-linked glycan sites were 
occupied. This was interesting itself, since transient transfections often overwhelm the 
cells' processing capacity resulting in heterogeneously glycosylated products, 386 
although it has been shown that all the potential N-linked sites of a protein can be 
glycosylated when transiently expressed. For example Rat CD39 contains seven 
potential N-linked sites, which have been shown to all be glycosylated when expressed 
in COS7 cells. 391 Mammalian cells lines have been shown to synthesize complex 
glycans 392 and this was confirmed by the ability of rVWF to bind EBL and RCA-I, 
highlighting the presence of sialic acid and terminal galactose residues that are 
indicative of complex glycan formation. As demonstrated by analysis with EBL, rVWF 
presented up to 50% less sialic acid than pdVWF. A possible explanation for this is the 
absence of a2-6 linked sialic acid residues. Analysis of rVWF expressed in Chinese 
Hamster Ovary (CHO) cells showed a total absence of a2-6 linked sialic acid . 
375 This 
has also been demonstrated for recombinant EPO expressed in CHO cells. 393 
Furthermore, analysis of the glycan structures produced by Baby Hamster Kidney cells 
demonstrated a lack of a2-6 sialic acid. 394 The galactose content of rVWF was shown 
by RCA-1 binding to be -20% higher than pdVWF, this is probably due to increased 
exposure of terminal galactose residues resulting from the decreased sialic acid content, 
rather than an increased total galactose content. 
Although the presence of sialic acid and galactose indicate the synthesis of complex N- 
linked glycans, it is not known to what extent these complex structures are branched. 
From Matsui et al's study the majority of VWF N-linked glycans (70%) are of the bi- 
antennary type. 23 However tri-antennary and tetra-antennary glycans comprise 12.3% 
and 2.3% respectively of the total N-linked chains. It is not known if HEK293T cells are 
capable of forming tri- and tetra-antennary N-linked glycans, although EPO expressed 
in CHO cells has been shown to present tri- and tetra-antennary structures, so based on 
this it may be possible. 393 Finally, as expected, no H-antigen presentation was detected 
on rVWF. 
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6.10.3 ADAMTS13 Cleavage of VWF Glycan Mutants 
In view of the observation made in the last chapter that PNG-VWF was proteolysed 
significantly faster than Ctrl-VWF, it was hypothesised that mutation of one or both of 
the A2 domain N-linked glycan sites would affect the susceptibility of VWF to 
proteolysis by ADAMTS13. Cleavage of wt and mutant rVWF in the presence of urea, 
followed by collagen binding and multimer analysis demonstrated that wtVWF and 
N1515Q were cleaved at a similar rate, although the N1515Q mutation did offer some 
slight protection against ADAMTS13 cleavage. Significantly N1574Q and the DM were 
proteolysed significantly faster than wtVWF. After 60mins incubation with 
ADAMTS13, N1574Q and the DM exhibited only minimal collagen binding activity. 
This was confirmed by multimer analysis that showed only the presence of monomers 
and dimers after 60mins incubation. The observation that N1515Q was cleaved at a 
comparable rate to wtVWF, implies that the critical glycan site is N1574. To further 
examine this ADAMTS 13 cleavage assays were repeated in the absence of urea. 
In the absence of urea no cleavage of wtVWF or N1515Q was observed, additionally all 
four samples (wt, N1515, N1574 and DM) all retained 100% collagen binding when 
incubated without ADAMTS13, indicating that the four preparations were stable over 
the duration of the reaction and that no other contaminating proteases were present. 
Significantly, NI 574Q and the DM were proteolysed by ADAMTS 13 in the absence of 
urea, similar to the observation made with PNG-VWF. 
How the N-linked glycan at site N1574 affects cleavage is unknown. Once again it 
could be due to steric hindrance or a conformation effect. Specific N-linked sites have 
previously been shown to affect proteolysis. The addition of an N-linked glycan chain at 
Asn184 on tissue plasminogen activator reduces the rate at which the molecule is 
383 cleaved by plasmin. The exact mechanism for this is undetermined, although 
evidence suggests it is due to the glycan covering a region of the protein surface 
preventing efficient proteolySiS. 383 Also, the N-linked glycan at Asn281 in bovine 
lactoferrin, has been shown to protect the molecule against trypsin cleavage at the 
adjacent amino acid, Lys282, almost certainly via a direct steric hindrance effeCt. 395 
From the predicted model of the VWF A2 domain the N1574 site is predicted to occur 
on a loop region. Interestingly, the N1574 site occurs in fairly close proximity to some 
residues shown to be important for ADAMTS13 binding: D1587, D1614, E1615, 
K1617 and E1638. These residues are predicted to occur on the surface of the A2 
domain and forin a potential docking site for ADAMTS 13.216 Although only 
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speculative, the glycan at N1574 could limit access of ADAMTS13 to this region by 
masking the protein surface. The N1515 site is predicted to occur on the opposite side to 
this region and this may account for the mutation having no effect on susceptibility to 
ADAMTS13 cleavage. 
Although the effect may be mediated by steric hindrance, the favoured hypothesis is 
altered conformation of the VWF molecule. Like PNG-VWF, N1574Q is cleaved in the 
absence of the urea but the rate of cleavage is increased in its presence. As with PNG- 
VWF, this suggests that the molecule is permissive to ADAMTS13 cleavage, but still 
needs to undergo a further conformational change to allow more efficient proteolysis. 
Analysis of the binding of ADAMTS13 to immobilised wtVWF and N1574Q 
demonstrated that ADAMTS13 could bind with -2-fold increased affinity to N1574Q, 
whereas ADAMTS13 could bind to PNG-VWF with -4-fold increased affinity. This 
suggests that another glycan(s) site is involved in modulating binding of ADAMTS 13 to 
VWF. The nearest other N-linked sites, N1231 and N2223 are probably located too far 
from the site of ADAMTS13 interaction to exert a steric effect. It is not clear if the 
N 1574 glycan exerts a conformation effect on the A2 domain alone or has a more long 
range effect on the stability of the molecule. An increasing body of experimental 
evidence suggests that N-linked glycosylation has a long range effect on the backbone 
flexibility of folded proteins, 396,397 therefore removal on the glycan at site N1574 may 
increase the flexibility of the VWF molecule, de-stabilising the multimeric structure. 
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CHAPTER 7 
7. DISCUSSION, CONCLUSIONS & FUTURE DIRECTIONS 
7.1 DISCUSSION AND CONCLUSIONS 
VWF is a large multimeric plasma glycoprotein that plays an essential role in 
haemostasis by mediating the adhesion of platelets to thrombogenic surfaces under 
conditions of high shear stress. 2 Its multimeric structure is critical for its adhesive 
function of adhering to collagen and capturing platelets. Within the circulation it is the 
largest VWF multimers that the most efficient in this function. 77 The adhesive 
properties of VWF are regulated by ADAMTS13, which cleaves VWF within its A2 
domain (Y1605-MI606) reducing its multimeric size and its ability to recruit platelets at 
sites of vessel injury. 159 ADAMTS13 cleavage of VWF may also affect the removal of 
VWF from plasma, although this relationship remains poorly understood. 
A significant portion (-20%) of the VWF molecule is comprised of carbohydrate in the 
form of N- and 0-linked glycan chains. 16 From the primary amino acid sequence and an 
initial study by Titani et al, VWF was predicted to contain 12 N-linked sites and 10 0- 
linked sites. 16 Interestingly the N-linked glycans of VWF have been shown to present 
the ABO blood group sugarS23 and an indication of the importance of VWF 
glycosylation came from the observation that a major determinant of plasma VWF 
levels is ABO blood group, with individuals of blood group 0 having -30% less 
circulating VWF compared to non-0 blood groups. 309,312,316-32 
1 The mechanism by 
which ABO blood group has an effect on VWF levels is not understood, but linkage 
analysis suggests that the effect is due to a direct functional effect of the ABO locus 
rather than a linkage disequilibrium. 320 Current data suggest that the effect is not due to 
an influence on the rate of synthesis and/or secretion, thus the effect may be mediated 
by altered rates of clearance which in turn may be dependent on proteolysis. 350-352 
A recent study by Bowen (2003) demonstrated that ABO blood group mediates 
susceptibility of VVVT to ADAMTS13 proteolysis. 324 This study showed that blood 
group 0 VWF was cleaved faster by ADAMTS13 than blood group A or AB VWF- 
(Interestingly, blood group B VWF was proteolysed at a similar rate to 0 VWF despite 
the difference in plasma levels). 324 This was the first demonstration of a functional 
alteration of VWF resulting from a natural variation in glycan structure. Initially, the 
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aim of this thesis was to further investigate this observation using Bombay VWF- As 
described previously, the Bombay blood group is a rare blood group that results from 
failure to express the H-transferase, thus no H-antigen is formed and no A or B antigens 
can be formed. 339 The result of this natural model is that a further sugar residue is 
missing from some of the N-linked glycan chains. Thus Bombay VWF presents one less 
sugar than 0 VWF and two less sugars than A or B VWF. Analysis of plasma VWF 
levels demonstrated that Bombay individuals have significantly less VWF than non-0 
blood groups. I also observed that Bombay VWF levels were lower than group 0 VWF, 
however this result failed to reach a significant p value. I then proceeded to confirm 
Bowen's observation that 0 VWF was cleaved faster than AB VWF by ADAMTS13, 
and extended this to demonstrate that Bombay VWF is cleaved faster than 0 VWF. 
These observations clearly indicate that the terminal blood group sugars uniquely 
presented on VWF significantly affect ADAMTS13 proteolysis. How this relates to 
VWF levels is not yet resolved, however an indirect relationship does appear to exist 
between N-linked glycan chain length, susceptibility to ADAMTS13 proteolysis and 
plasma VWF levels. With decreasing glycan chain length, the susceptibility to 
ADAMTS 13 cleavage is increased and VWF levels are decreased. It seems unlikely that 
proteolysis alone accounts for the variation in VWIF levels observed between ABO 
blood groups and implies that there is relationship between VWF proteolysis and 
clearance. 
The interconnection between VWF proteolysis and clearance has not yet been 
established. Animal models used to investigate the clearance of VWF have returned 
conflicting results. Although it has been established that VWF is cleared in a biphasic 
pattern,, 269,282,283 the evidence regarding the effect of VWF multimer size on rate of 
clearance is not conclusive. In a murine model, using the VWF knock-out mouse, 
multimer size has no effect on clearance, 283 whereas HMW-multimers were cleared 
faster than LMW multimers in Sprague Dawley Rats and Kookier dog modelS. 282,284 
Although useful, these studies do not take into account proteolysis of VWF. The human 
plasma derived VWF or human recombinant VWF used in these studies was not 
proteolysed by murine, canine or rat ADAMTS 13, therefore any effects of ADAMTS 13 
proteolysis would not have been observed. 
Two recent studies have estimated the half-life of VWF within the circulation using the 
. 
321,363 VV plasma VWF propeptide to VWF: Ag ratio (VWFpp-VWF: Ag) VT is secreted 
in equimolar amounts with its propeptide, which has a shorter half-life and has been 
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shown not to present ABO sugars and whose levels do not vary with ABO blood group 
VWF propeptide can therefore be used as a measure of VWF secretion and the 
VWF: VWFpp ratio allows estimation of VWF half-life. Both these studies concluded 
that the half-life for 0 VWF was significantly shorter than the half-life for non-0 blood 
groups (10 hours vs. 12 hours respectively) . 
32 1,363 Although these studies do not address 
ADAMTS13 cleavage of VWF, they do provide evidence that 0 VWF is cleared from 
the circulation faster than non-0 VWF. However it seems a plausible conjecture that the 
haemostatic system would function to retain the lager, more biologically active VWF 
multimers and remove the less functional LMW species. At the same time, the 
multimeric size of VWF is controlled by ADAMTS13 preventing excess accumulation 
of HMW-VWF. Thus a balance is created between VWF synthesis and secretion, 
proteolysis and clearance. The rate of synthesis and secretion is not altered between 
blood groups; but it is hypothesised that as the rate of proteolysis increases, the rate of 
clearance increases, explaining the differences in VWF levels between blood groups. 
In normal individuals the multimer distribution reflects the relationship between 
proteolysis and clearance. This explains my observation that although Bombay VWF 
was proteolysed significantly faster than 0 or AB VWF, a normal multimer pattern was 
presented comparable to normal plasma. 
In individuals with some type 2A VWD mutations, the rate of cleavage increases 
relative to clearance so only LMW-multimers are present in the circulation. In a type of 
VWD called VWD Vicenza, patients have decreased VWF: Ag but multimer analysis 
demonstrates the presence of UL-VWF multimers. A proposed model for this 
observation is that the rate of clearance increases relative to proteolysis and the 
distribution of VWF multimers, is forced the opposite way to a type 2A phenotype with 
the accumulation of HMW-multimers. 398 
The key unknown factor in this area is the relationship between VWF proteolysis and 
clearance which requires further investigation. Whether proteolysis influences clearance 
or vice versa is not clear. If it assumed that the proposed model for VWF Vicenza is 
correct, increased clearance in group 0 would lead to accumulation of HMW- 
multimers. However, if the increased clearance is the result of increased cleavage the 
two effects would cancel each other out, and the multimer distribution would remain 
normal. The observation that ABO sugars can affect susceptibility to ADAMTS13 
proteolysis and that cleavage may determine clearance, offers a possible explanation for 
the effect of ABO/Bombay blood group on plasma VWF levels. Much further 
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investigation is need to determine if VWF proteolysis and clearance are related and the 
argument is only likely to be resolved by using an in vivo model system where multimer 
size and proteolysis can be manipulated independently. Establishing such a system 
forms part of the future work resulting from this thesis. 
How the ABO sugars modulate susceptibility to ADAMTS13 proteolysis is also not 
fully determined, however the results presented in this thesis allow hypotheses to be 
proposed that may account for the differences observed. The ABO and Bombay data 
imply a simple relationship, in which the rate of cleavage correlates with glycan chain 
length. How this might affect the VWF molecule was investigated further by subjecting 
blood group specific VWF to ADAMTS13 proteolysis with varying urea 
concentrations. With increasing urea concentration the overall rate of cleavage was 
increased, but the differences seen between blood groups was decreased. This implies 
that the ABO sugars have an effect on the conformation of the VWF molecule, with 
reduction in glycan length increasing the permissiveness of the molecule to 
ADAMTS13 proteolysis, but as the rate of unfolding of the molecule increases with 
increasing urea concentration, the ABO effect is lost. 
In this "conformational" hypothesis a contribution from both local and distant N-linked 
glycosylation sites might be expected. However local effects on the A2 domain itself are 
likely to predominate. A second hypothesis for my observations might be termed the 
"steric" hypothesis. In this model, N-linked glycosylation affects ADAMTS13 cleavage 
by physically blocking access to the ADAMTS13 cleavage site or to the ADAMTS13 
binding site. This effect would be restricted to local glycosylation within the A2 
domain. Both models are likely to affect ADAMTS 13 cleavage and binding to VWF. 
VWF has a large number of glycan chains and it is not known what structures are 
present at specific sites. From the effects of ABO/Bombay blood group and increasing 
urea concentrations it is not clear whether these effects are mediated by all the N-linked 
glycans of VWF and thus represent an overall structural effect; or by a single chain, 
presumably in the A2 domain, affecting local structure or forming an obstruction to the 
ADAMTS13 binding and cleavage sites. It may therefore be interesting, that two N- 
linked sites, N1515 and N1574 are predicted to occur in close proximity to the 
ADAMST13 cleavage site at Y1605MI606. 
As I have shown, sites N1515 and N1574 were both predicted to be occupied by the 
NetNglyc prediction algorithm and are both highly conserved through out the A2 
domain sequences of the 59 species analysed. To experimentally determine if these sites 
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were occupied by N-linked glycan chains, I isolated a tryptic fragment of VWF 
spanning the A2 and A3 domains, encompassing N1515 and N1574. As I demonstrated, 
both sites are occupied by complex N-linked glycan chains, and significantly, at least 
one of the sites is decorated with the H-antigen. 
The observation that both sites are highly conserved, implies that they may have an 
important function. Consultation of the VWF mutation database (available from 
http: //www. raiztimedesign. com/vwf/mutationo shows that there are no known mutations 
of either the specific N1515 and N1574 sites, or any mutations that would affect 
glycosylation at these sites. This may in part be explained by the observation that loss of 
glycosylation mutations are relatively rare. 399 Certainly this, and the highly conserved 
nature of the two sites, and the observation that at least one of them presents ABO 
antigens suggests that they have a crucial role for the VWF molecule. 
To further explore the role of VWF glycosylation more general and specific 
manipulations of VWF glycans were required. Therefore, as well as the effect of the 
ABO sugars on susceptibility to ADAMTS13 cleavage, I also investigated the effect of 
modifying other VWF glycan structures. The observation that Neu-VWF was cleaved at 
a slower rate by ADAMTS13 was slightly unexpected. Previous studies had shown that 
AsVWF is more prone to proteolytic degradation 261,262 and the results obtained with 
blood group specific VWF suggested that with reduction in N-linked glycan length, the 
rate of ADAMTS13 cleavage increased. I also showed that removal of terminal sialic 
acid from blood group specific VWF not only reduced the rate of cleavage, but also 
prevented the ABO effect, with both neuraminidase treated 0 and AB-VWF being 
proteolysed at the same rate. As previously discussed, this implies that the sialic acid 
effect is dominant over the ABO effect, or the ABO effect is mediated by modifying the 
number of sialic acid residues present on VWF glycans. The latter may be unlikely 
since sialic acid levels do not appear to vary between blood groups, however, this may 
require further investigation. 379 My findings also do not take into account that sialic acid 
is present on both N- and O-linked glycans. Therefore it may be that sialic acid residues 
on either specifically the N or O-linked glycan chains mediate the effect. However, 
specifically removing sialic acid residues from only N or O-linked chains is not yet 
possible. A recent study has suggested that variations in O-linked glycosylation of 
VWF affects plasma levels. '00 Using Peanut Agglutinin (PNA) to detected de-sialylated 
O-linked glycans, van Schooten et al demonstrated an inverse relationship between 
PNA binding and VWF levels. The majority of O-linked glycans present on VWF are 
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the disialyated core I type 257* and therefore reduction in PNA binding may represent a 
reduction in O-linked glycosylation, which in turn would result in reduced sialic acid 
presentation. (Although this seems at odds with previous findings that VWF sialic acid 
levels do not vary over the population, hence further investigation is required. ) From 
van Schooten et al's study it is not clear how altered O-linked glycosylation would 
affect VWF levels. Although I only propose this as a tentative suggestion, a possible 
mechanism could be related to the rate of proteolysis. Decreased O-linked glycosylation 
resulting in decreased VWF sialic acid content may result in decreased ADAMTS13 
proteolysis. If ADAMTS13 proteolysis of VWF is related to VWF clearance the 
reduction in proteolysis would result in increased levels. This is however highly 
speculative, and does not account for the variation seen between ABO blood groups. 
Interestingly, I have recently obtained data to suggest that VWF devoid of O-linked 
glycans is proteolysed slower than wtVWF, implying that the O-linked glycans do play 
a role in mediating susceptibility of VWF to ADAMTS 13 proteolysis and will form part 
of future investigation. 
In contrast to the removal of sialic acid, removal of the N-linked glycans of VWF 
significantly increased the susceptibility of the molecule to ADAMTS13 proteolysis, 
even allowing cleavage by ADAMTS13 in the absence of urea. To investigate the 
mechanisms involved, binding studies were performed to determine the effect of glycan 
modification on the affinity of the VWF-ADAMTS13 interaction. The binding of 
ADAMTS13 to PNG-VWF was altered, with PNG-VWF binding ADAMTS13 with 
increased affinity compared to Ctrl-VWF. Interestingly, collagen bound VWF was 
capable of binding ADAMTS13 with high affinity, (KD 12nM). Implying that binding 
of VWF to collagen causes a conformation change in the molecule, exposing the 
ADAMTS13 binding site. Collagen bound VWF has been shown by AFM to remain in 
a globular conformation, 368 so the conformational change required to expose the 
ADAMTS13 binding site may be relatively small. Binding of VWF to type III collagen 
has been proposed to induce a conformational change to expose the collagen binding 
site within the Al domain. 153 This may also alter the conformation of the A2 domain, 
allowing ADAMTS 13 access to its binding site. 
Since the treatment of VWF with PNGase F resulted in the non-specific removal of N- 
linked glycan chains, it was not possible to determine if the effect on the interaction 
* Also known as the T-antigen 
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with ADAMTS13 was due to general removal of the glycans or the removal of specific 
sites. To further investigate this, I mutated the two N-linked sites, N1515 and N1574 
within the A2 domain. The results from the cleavage analysis showed that the N1574Q 
site represents a critical N-linked chain, since removal of this glycan results in a greatly 
increased rate of ADAMTS13 proteolysis. Interestingly, mutation of N1515 did not 
have any significant effect on ADAMTS 13 proteolysis, suggesting that glycosylation at 
this site is not important in modulating the interaction with ADAMTS13. From the 
results presented in Chapter 4 it is evident that the site is occupied, but from the results I 
have obtained it does not appear that the site has any functional relevance. NI 574Q also 
bound ADAMTS13 with increased affinity, but only -2-fold, compared to the -4-fold 
difference seen with PNG-VWF. This suggests other glycan site(s) may be involved in 
mediating the VWF-ADAMTS 13 interaction. 
It does however appear that the N1574Q mutation accounts for the majority of the effect 
on ADAMTS 13 cleavage observed with PNG-VWF. The mechanism by which removal 
of VWF N-linked glycans or mutation of N1574 renders VWF more susceptible to 
ADAMTS13 proteolysis and binding is not fully clear, however the effect is likely to be 
either due to steric hindrance or a conformational effect, or possibly both. 
As mentioned earlier, the glycan moiety of other glycoproteins can protect the molecule 
from proteolytic attack by covering a portion of the protein surface. 383 This is dependent 
on the protein-glycan linkage being flexible rather than fixed. From the predicted model 
N1574 occurs in close proximity to several residues on the surface of the A2 domain 
that have been shown to form part of the ADAMTS13 docking site within the domain: 
Arg1583, AspI587, Asp1614, Glul6l5 and Lys1617.216 From the predicted model, 
these residues are in close enough proximity to be shielded by the N-linked chain at 
N1574 (Figure 7.1). The average length of a complex biantennary glycan chain is 
predicted to be 3-4mn. 401 The furthest residue from N1574 is AspI587, predicted to 
occur -24A (2.4nm) away from N1574, is therefore close enough to be potentially 
shielded by the N 1574 glycan chain. The presence of a glycan at N 1574 may therefore 
define ADAMTS 13 access to its docking site suggesting a local effect of removing 
N1574. A large majority of the effect observed with PNG-VWF may therefore represent 
the removal of the N1574 site. Although, since N1574Q bound ADAMTS13 with 
decreased affinity compared to PNG-VWF, other glycan sites appear to be involved in 
modulating binding of ADAMTS13 to VWF. 
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Previously it has been shown that recombinant A2 domain expressed in both E coli 
(non-glycosylated) and Sf9 insect cells (glycosylated) required the presence of urea for 
ADAMTS 13 cleavage to occur. 216,218,402 Although it is very difficult to draw a 
comparison between the non-glycosylated and glycosylated A2 domain, since they have 
been used in separate studies with different ADAMTS13 preparations and are expressed 
in different systems, the observation that both require urea for cleavage does suggest 
that they behave in similar ways. Interestingly, recent data obtained in our laboratory 
demonstrates that a recombinant VWF A2 domain expressed in Ecoli is able to inhibit 
the binding of ADAMTS13 to immobilised VWF. It will be important to see if 
glycosylated A2 domain also inhibits binding of ADAMTS13 to immobilised VWF. If 
glycosylated A2 domain cannot inhibit ADAMTS13 binding, or is less efficient at 
inhibiting binding, this will provide evidence that the N-linked glycan at N1574 does 
indeed shield the ADAMTS13 docking site within the A2 domain. Expression of a 
glycosylated A2 domain is currently in progress and forms part of the future work 
relating to this thesis. 
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Figure 7.1 Distances between N1574 and A2 domain surface residues important for 
ADAMTS13 binding 
The distances between Asn1574 and the residues shown to forrn the ADAMTS13 
docking site in the A2 domain are shown in A (O. Inm). The furthest residue from 
N1574 is Asp1587, predicted to occur -24A (2.4nm) away from the Asn1574 sites. 
Since the average length of a complex glycan chain is 3-4nm, the glycan at N 1574 could 
potentially shield the ADAMTS 13 docking site. 
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Although steric hindrance is an attractive hypothesis to explain my observations, there 
is evidence to suggest it may not be the most dominant factor. A number of monoclonal 
antibodies directed against the VWF A2 domain have been produced and significantly, 
a number of these recognise the region of the A2 domain where the ADAMTS13 
binding site is predicted to occur. Antibody RAb7745 is directed against residues 1606- 
1620; 403 antibody RG69 is directed against residues 1493-1606; 261 antibody M19 is 
directed against residues 1607-1710; 261 and antibody VP-1 is directed against residues 
1591-1605.404 The fact that these antibodies can interact with the ADAMTS13 binding 
site region implies that the region is not concealed by a glycan chain. As shown in 
Chapter 4, the glycan at N1574 is likely to be of the complex type. This demonstrates 
that the glycan site is accessible to the enzymes required to convert the glycan from a 
high mannose to a complex structure and may imply that rather than interacting with the 
surface of the domain, the glycan may extend away from it. If the glycan at N 1574 did 
interact with the domain surface, it may be shielded from complex glycan processing 
enzymes present in the Golgi and post-Golgi. Furthermore, it has been previously 
observed that N-linked glycans that occur on loop regions are extensively processed due 
to their relative accessibility! 01 Also from the predicted model the N1574 sites appears 
to occur on a more convex region of the domain, in this case the glycan chain is 
unlikely to make contact with the domain and will project away from the A2 domain. 365 
However further investigation is required to predict the nature of linkage between the 
glYcan chain and N1574 to conform this. Extension of the glycan chain away from the 
domain would favour a conformational effect rather than a steric one. 
A major function of N-linked glycans is to aid protein folding and to maintain protein 
conformation. 405 Often N-linked glycans act as molecular chaperones, aiding the folding 
of the protein within the cell but whose removal once the protein is fully folded does not 
affect its biological activity. 406,407 In other cases, N-linked glycans may act to stabilise 
the conformation of the molecule, often through interaction of the glycan with specific 
regions of the molecule. For example: Immunoglobulin G (IgG) contains a conserved 
N-linked glycosylation site at residue N297 . 
408 Evidence suggest that interactions 
between the glycan at site N297 and surrounding amino acids stabilize the 
conformational integrity of the protein. 409 Glycosylation of RNase B has been shown to 
increase the overall dynamic stability of the protein by reducing solvent access to many 
regions of the peptide backbone both close to and remote from the glycosylation site 
suggesting that it reduces fluctuations of the backbone, 410 and the N-linked glycans of 
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Quercetin 2,3-dioxygenase have been shown to play an active role in maintaining the 
dimeric structure of the protein. 41 1A general phenomenon observed with proteins is that 
the glycosylated version is more stable than the non-glycosylated form, with the 
stabilisation being due to largely entropic effects, rather than enthalpic effects. 
412 The 
human chorionic gonadotropin hormone (hCG) is stabilised by N-linked glycosylation 
413 at Asn78. Evidence suggests that this glycan chains shields a hydrophobic core on the 
molecule via interaction of the glycan with the protein. 413 Moreover, the N-linked 
glycans of Human Erythropoietin (EPO) have been shown to stabilise the protein 
conformation by interacting with hydrophobic areas of the protein surface. 414 SPR 
analysis demonstrated that E. coll produced EPO (therefore without glycans) could bind 
to purified bi, tri and tetra-antennary N-linked glycans and this binding was enhanced in 
the presence of high-salt conditions, indicative of a hydrophobic interaction. 4 15 Glycans 
are able to generate areas of hydrophobicity, the extent of which depends on the CH- 
dense surface area, degrees of polymerization and branching, and molecular 
planarity. 416 It was therefore concluded that complex N-linked glycans exhibit 
extensively stretched hydrophobic planes and stabilize the protein conformation through 
hydrophobic interactions with the hydrophobic protein surface. 415 The size of the 
hydrophobic surface produced by the glycan is increased with the degree of branching 
of the glycan chain, thus complex glycans produce more extensive hydrophobic regions 
than high mannose glycans. 417 Molecular modelling of N-acetyllactosamine units, 
present in complex N-linked glycans but not high mannose structures, showed that they 
have an amphiphilic structure and greatly contribute to the formation of extensive 
hydrophobic surfaces. 417 Therefore, the N-linked glycans of VWF may interact with 
hydrophobic regions of the molecule, adding stability to the multimeric structure. 
Specifically this effect could be mediated by N1574 either stabilising the A2 domain 
itself or by interactions with other domains of the VWF molecule, particularly the Al 
and A3 domains. 
Furthermore, as well as hydrophobic interactions between glycan and protein, the 
removal of VWF N-linked glycans or specifically N1574 may also confer long range 
effects on the VWF molecule. N-linked glycans have been shown to impart a long-range 
decrease in the backbone flexibility of folded proteins and impart long range stabilising 
effects on tertiary and quaternary structures remote from specific sites of 
glycosylation. 397,412 N-linked glycosylation also has short range effects on proteins by 
adding rigidity to the surrounding region. 397,412 Thus the N1574 site in VWF may be 
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critical for stabilising the A2 domain itself and the general structure of the fully folded 
monomer and multimer structures. 
In summary, removal of the VWF N-linked chains or mutation of N 1574 does not alter 
the conformation of the molecule per se, but may "relax" firstly, the conformation of 
each monomer and secondly, the conformation of the multimer. Thus, in the absence of 
urea, the PNG-VWF or N1574Q molecule is in a conformation already permissive 
enough for ADAMTS13 cleavage to occur. Upon the addition of urea, PNG-VWF or 
N1574Q can therefore more readily adopt a conformation fully apt for ADAMTS13 
cleavage. 
The observation that ADAMTS13 can bind to PNG-VWF with increased affinity may 
also reflect the conformation of the molecule. When PNG-VWF is bound to the plate, 
its more "relaxed" structure can readily adopt an elongated structure akin to normal 
VWF under shear stress conditions. Likewise, when captured via the monoclonal anti- 
VWF antibody, PNG-VWF may present a less tightly packed globular structure than 
normal VWF, allowing binding of ADAMTS13. As previously mentioned, the 
observation that ADAMTS13 can bind with high affinity to collagen-bound VWF 
indicates that binding of VVvT to collagen induces a conformational change to allow 
ADAMTS13 to bind to VWF. This change in conformation is thus likely to be 
potentiated with PNG-VWF, allowing increased binding of ADAMTS 13. 
From the preliminary binding assays perforined with N1574Q it was observed that 
N1574Q could bind ADAMTS13 with -2-fold increased affinity rather the -4-fold 
increased affinity seen with PNG-VWF. This probably reflects the involvement of 
another, remote, glycan site in maintaining VWF conformation. 
The hypothesis that VWF N-linked glycans affect the conformation of the molecule 
through hydrophobic interactions with the protein also provides an explanation of the 
ABO effect on VWF cleavage by ADAMTS13. The addition of a galactose or GaINAc 
residue (A or B antigen respectively) to the complex glycan may increase the 
hydrophobic surface of the glycan and strengthen the hydrophobic interactions between 
glycan and protein. Moreover, this hypothesis may present a reason for the observation 
that Neu-VWF is proteolysed at a significantly reduced rate by ADAMTS 13. Sialic acid 
carries a negative charge and is likely to be hydrophilic, removal of the negative charge 
may serve to increase the hydrophobic nature of the N-linked glycan and in turn 
increase the hydrophobic interaction of the glycan with the protein making the protein 
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more stable. The complex glycan at site N1574 may therefore specifically function to 
maintain the globular structure of VWF and protect against ADAMTS 13 cleavage. 
In conclusion, the glycan structure of VWF plays an important role in mediating the 
interaction of the molecule with ADAMTS13. Subtle, natural alterations in glycan 
structure, observed with VWF from different blood groups, alter the susceptibility of the 
molecule to proteolysis by ADAMTS13. More dramatic changes induced by enzymatic 
and mutational modifications also alter the interaction of VWF with ADAMTS13. 
Removal of terminal sialic acids residues do not alter the affinity of ADAMTS13 for 
VWF, but do decrease the rate of ADAMTS13 proteolysis. In contrast, removal of the 
N-linked glycans of VWF increases the affinity of ADAMTS13 for VWF and also 
increases the susceptibility of VWF to ADAMTS13 proteolysis; to the extent that 
multimeric VWF lacking N-linked glycans can be cleaved in the absence of urea. 
Specifically, site N1574, which is occupied and presents the blood group antigens, is a 
critical N-linked glycan site in VWF, with mutation of this site increasing susceptibility 
to ADAMTS13 cleavage. Analysis of the sugar structures of VWF therefore gives 
valuable insight into the structure function relationship of the molecule. 
7.2 FUTURE DIRECTIONS 
The data presented in this thesis has clearly demonstrated that naturally occurring and 
in vitro alterations to the glycan structures of VWF have an effect on the interaction of 
the molecule with ADAMTS13. It has also raised a number of questions that require 
further investigation. Some of the future directions that this work could take are 
discussed below. 
7.2.1 Role of VWF N-linked glycosylation in Determining VWF Structure and 
Function 
As shown, the N-linked glycan structure of VWF has an effect on the interaction of 
VWF with ADAMTS13, with the N1574 site being a crucial glycan in the interaction. 
However the results also indicate that other glycan sites may also affect the 
susceptibility of VWF to ADAMTS 13 proteolysis. Moreover, the VWF glycan structure 
may also have an effect on other functional aspects of the VWF molecule. To further 
investigate this, a series of VWF N-linked glycan mutants will be produced and 
analysed for their effects on various functional aspects of the VWF molecule, including; 
storage and release, multimeric structure, susceptibility to ADAMTS13 cleavage and 
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binding, FVII1 binding, GPIIbIIIa binding, GPIba binding, collagen binding and VWF 
dimerisation/multimerisation and intracellular transport. 
Currently the N-linked glycan sites predicted to occur at N857, Ni 147 and N1231 have 
been prepared are will be expressed, as described, in HEK293T cells. It is anticipated 
that since these mutations occur in the D'D3 region of the molecule they may effect the 
multimerisation of the VWF molecule. If these molecules are fully multimerised I plan 
to investigate the affect these glycan mutations have on the interaction of VWF with 
FVIII and P-Selectin. 
To determine the role of the VWF the glycans I have also prepared mutations of the N- 
linked sites predicted to occur in the propeptide: N99, N157, N21 1, N666. Further to 
this, I have obtained a monoclonal antibody directed against the VWF propeptide (a 
kind gift from Dr Jan Voorberg) and this will be used to capture the propeptide from 
plasma followed by lectin analysis to give a preliminary analysis of the glycan 
structures presented on the propeptide. 
A mutation has also been made of the N-linked site predicted to occur at N2790 with the 
CK domain. Recent studies have suggested that N-linked glycans present in the cysteine 
knot domains of dimeric proteins are required for efficient dimerisation. It is therefore 
likely that this site will be critical for the formation of VWF dimers. 
7.2.2 Producing a Comprehensive Glycan Map of VWF 
As discussed, little experimental evidence exists confirming which predicted N and 0- 
linked glycosylation sites are occupied by glycans, structures and indeed what specific 
structures occur at specific sites. It is now known from the data I have presented, that 
the two predicted A2 domain glycosylation sites are occupied by complex glycan 
chains, and certainly one, if not both chains present ABO(H) antigens. To further this, 
the glycan structures present on the 55kDa VWF fragment will be sequenced in detail 
using a mass spectroscopy approach. Using a similar strategy of generating VWF 
fragments encompassing specific glycan sites, followed by detailed sequencing of the 
glycans by mass spectroscopy, it will be possible to build a comprehensive glycan map 
of VWF. This will provide detail of the glycosylation status of specific sites and provide 
sequence analysis of the glycan structures present. From this it will be possible to 
determine what sites present the ABO(H) antigens and to investigate if certain glycan 
structures are unique to specific sites. This body of work has been accepted for a British 
Heart Foundation PhD studentship grant. 
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7.2.3 Role of VWF O-linked Glycosylation 
Previous studies have demonstrated that VWF expressed lacking O-linked glycans 
forms normal multimers and exhibits normal collagen binding, but causes increased 
ristocetin mediated platelet aggregation. To investigate this further, rVWF lacking 0- 
linked glycosylation will be expressed and analysed for its affinity to bind platelet 
GPlba using a previously described GPlba plate based binding assay that is reported to 
be more sensitive than the ristocetin cofactor assay. I have recently established a clone 
of the N-terminal of GPIba and will express the protein in HEK293T cells. Moreover, 
from preliminary results that I have obtained, O-less VWF is proteolysed slower than 
wtVWF- To investigate this, individual and multiple mutations will be made of the 
predicted O-linked glycosylation sites to determine what O-linked sites mediate this 
effect. 
7.2.4 Relationship between VWF Proteolysis and Clearance 
As discussed, the relationship between VWF proteolysis and clearance has not yet been 
determined. This will be investigated using the VWF knock out mouse model in 
collaboration with Dr Cecile Denis. In these experiments we plan to inject mice with 
purified blood group specific VWF with and without purified human recombinant 
ADAMTS13 to determine the effect of, firstly, ABO blood group on VWF clearance 
and secondly, the effect of ADAMTS 13 proteolysis on VWF clearance. 
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Appendices 
Appendix I- Restriction enzymes and buffers 
Digest NEB Buffer BSA 100pg/ml 
Xmnl & Kpnl I yes 
Xbal & Sad 4 yes 
Xmnl & Sphl I no 
BamHl & SphI BarnHI Buffer yes 
Xhol & KpnI I yes 
EcoRI & BamHl 4 yes 
EcoRl EcoRl Buffer no 
Kpnl I yes 
BamHl & Agel 4 yes 
NEB Buffer I 
10 mM Bis-Tris-Propane-HCI 
10 MM M9CI2 
I mM Dithiothreitol 
pH 7.0 @ 2511C 
NEB Buffer 4 
20mM Tris-acetate 
50mM Potassium acetate 
I OmM Magnesium acetate 
I mM Dithiothreitol 
pH 7.9 @ 25T 
NEB Buffer BamHl 
I OmM Tris-HCI 
ISOmMNaCl 
I OMM MgC12 
I mM Dithiothreitol 
pH 7.9 @ 250C 
NEB Buffer EcoRl 
I OOmM Tris-IICI 
5OmM NaCl 
I omm m9cl2 
0.025% TritonX-100 
pH 7.5 @25'C 
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Appendix 11 - Oligonucleotide primers 
Primer Sequence (5' --+ 3') 
VWF3'fwd ACGTTAGAGCTCGAATTCTCACTTGCTGCACTTCCTG 
VWF3'rev ACGTTATGAGCTCACCGGTTCACTTGCTGCACTTCCTG 
pBS KpnI fwd GCGAATTGGGTATTGGGCCCCCCCTCG 
pBS KpnI rev CGAGGGGGGGCCCAATACCCAATTCGC 
N1515Q fwd GGTGAAGCCGACTTCCAAAGGAGCAAGGAGTTC 
N1515Q rev GAACTCCTTGCTCCTTTGGAAGTCGGCTTCAC 
N1574Q fwd CCGCTACCAGGGCGGCCAAAGGACCAACACTGGGC 
N1574Q rev GCCCAGTGTTGGTCCTTTGGCCGCCCTGGTAGCGG 
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Appendix III - Buffers and solutions 
10 X DNA loading buffer 
0.125% (w/v) xilene cyanol, 0.125% (w/v) bromophenol blue, 0.625% SDS (w/v), 20% (v/v) 
glycerol 
10 X TBE buffer 
0.89 M Tris-borate (pH 8.3), 20 mM EDTA. Prior to use, this was diluted to 1x TBE buffer witb 
purified water. 
TE buffer 
10 mM Tris (pH 8.0), 1 mM EDTA 
SDS-PAGE Electrophoresis buffer 
25 mM Tris-HCI (pH 8.3) 192 mM glycine and 0.1% (w/v) SDS 
2x Protein Loading buffer 
150 mM Tris-HCI (pH 6.8), 20% (v/v) glycerol, 4% (W/V) SDS, 0.125% (w/v) bromophenol 
blue 
Transfer buffer 
25 mM Tris-HCI (pH 8.3), 192 mM glycine, 20% (v/v) methanol 
PBS buffer 
Dissolve 5 PBS tablets (Sigma) to I litre of distilled H20 
LB (Luria-Bertani) broth 
1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% (w/v) NaCl 
LB agar 
1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% (w/v) NaCl, 1.5% bacto-agar 
(The components of each medium are dissolved in ultra-pure water and autoclaved) 
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